

CITATION REPORT

List of articles citing

C-reactive protein and other markers of inflammation
in the prediction of cardiovascular disease in women

DOI: 10.1056/nejm200003233421202

New England Journal of Medicine, 2000, 342, 836-43.

Source: <https://exaly.com/paper-pdf/32282784/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2272	Analysis of Carotid color ultrasonography and high sensitive C-reactive protein in patients with atherosclerotic cerebral infarction. 2016 , 32, 931-4		4
2271	Antagonist EMG temporal patterns during rapid voluntary movement. 1980 , 30, 36-41		9
2270	Biology of arterial atheroma. 2000 , 10 Suppl 5, 1-8		24
2269	Reduced concentrations of soluble adhesion molecules after antioxidant supplementation in postmenopausal women with high cardiovascular risk profiles--a randomized double-blind study. 2000 , 94, 227-32		20
2268	Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection?. 2000 , 31, 2127-33		77
2267	The ERA trial: findings and implications for the future. 2000 , 3, 227-32		14
2266	In search of the underlying mechanisms of frailty. 2000 , 55, M706-8		64
2265	The past, the present and the future of oestrogen and progestogen therapy for cardiovascular disease in postmenopausal women. 2000 , 6, 9-14		
2264	Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto. 2000 , 15 Suppl 5, 69-80		74
2263	Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. 2000 , 15, 1624-30		140
2262	High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. 2000 , 33, 601-10		67
2261	C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. 2000 , 248, 406-14		33
2260	Are statins anti-inflammatory?. 2000 , 1, 161-165		69
2259	CRP : un paramètre biologique prédictif des événements cardio-vasculaires futurs. 2000 , 2000, 9		
2258	FORUM: oxidation and atherosclerosis. 2000 , 28, 1681-2		17
2257	High sensitivity C-reactive protein: can it predict cardiovascular risk in postmenopausal women?. 2000 , 15, 152-3		
2256	Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. 2000 , 887, 80-9		246

2255 Estrogen and atherothrombosis. **2000**, 86, 482-3

2254 Statin therapy and plasma C-reactive protein levels in primary prevention. **2000**, 14, 699-700

1

2253 Global risk assessment for lipid therapy to prevent coronary heart disease. **2000**, 2, 424-32

2252 Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. **2000**, 2, 269-73

15

2251 The role of C-reactive protein in cardiovascular disease risk. **2000**, 2, 274-9

27

2250 Hormone replacement therapy and cardiovascular risk. **2000**, 2, 288-92

3

2249 A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. **2000**, 78, 562-8

26

2248 Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. **2000**, 394-408

23

2247 Images in cardiology. Saddle pulmonary embolism: diagnosis by spiral computed tomography. **2000**, 84, 10

2246 Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. **2000**, 2000, 394-408

6

2245 Direct proinflammatory effect of C-reactive protein on human endothelial cells. **2000**, 102, 2165-8

1539

2244 Clinical and research challenges in risk factors for cardiovascular diseases. **2000**, 21, 1917-21

5

2243 C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. **2000**, 21, 1598-606

42

2242 Inflammatory markers of coronary risk. *New England Journal of Medicine*, **2000**, 343, 1179-82

59.2 198

2241 Activated polymorphonuclear leukocytes and monocytes in the peripheral blood of patients with ischemic heart and brain conditions correspond to the presence of multiple risk factors for atherothrombosis. **2000**, 94, 19-25

27

2240 C-reactive protein in the prediction of cardiovascular disease. *New England Journal of Medicine*, **2000**, 343, 512-3

59.2 14

2239 Quality of care for patients with rheumatoid arthritis. **2000**, 284, 984-92

163

2238 Understanding cytokines. Part II: Implications for nursing research and practice. **2000**, 2, 41-8

14

2237	Brugada syndrome: an electrocardiographic diagnosis not to be missed. 2000 , 84, 1-2		10
2236	Albumin, fibrinogen, von Willebrand factor, factor VIII activity, and leukocyte count are significant nontraditional risk factors for CHD in patients with diabetes. 2000 , 4, 89-91		
2235	Cardiac marker testing: where should we focus?. 2000 , 140, 351-3		4
2234	Genetics, genomics, proteomics: what is a cardiologist to do?. 2000 , 140, S48-50		1
2233	A short catalytic enantioselective synthesis of the vascular antiinflammatory eicosanoid (11R,12S)-oxidoarachidonic acid. 2000 , 2, 3437-8		11
2232	Immunological Aspects of Ischaemic Stroke. 2000 , 14, 213-228		1
2231	Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. <i>New England Journal of Medicine</i> , 2000 , 343, 522-9	59.2	1029
2230	Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. 2000 , 321, 199-204		1106
2229	Periodontal infections contribute to elevated systemic C-reactive protein level. 2001 , 72, 1221-7		480
2228	Helicobacter pylori and myocardial infarction: one final push for the truth?. 2001 , 5, 165-166		
2227	The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease--baseline findings of the PAIS project. 2001 , 156, 451-6		89
2226	C-Reactive protein and electron beam computed tomography: a perfect match?. 2001 , 37, 971-2		
2225	The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. 2001 , 37, 1266-70		86
2224	A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. 2001 , 38, 1302-6		186
2223	[C-reactive protein as a coronary risk factor]. 2001 , 117, 303-8		4
2222	[Inflammation and infection in stable coronary disease and acute coronary syndrome]. 2001 , 54, 453-9		5
2221	Acute-phase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics. 2001 , 32, 753-60		83
2220	Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. 2001 , 111, 607-13		430

2219	Early rheumatoid arthritis: a medical emergency?. 2001 , 111, 498-500	24
2218	Generation of C-reactive protein and complement components in atherosclerotic plaques. 2001 , 158, 1039-51	465
2217	Coronary artery disease in systemic lupus erythematosus: A review of the literature. 2001 , 30, 436-43	59
2216	A leukocyte and erythrocyte adhesiveness/aggregation test to reveal the presence of smoldering inflammation and risk factors for atherosclerosis. 2001 , 57, 207-9	11
2215	The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. 2001 , 141, 893-8	45
2214	PRINCE's prospects: statins, inflammation, and coronary risk. 2001 , 141, 881-3	20
2213	The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. 2001 , 22, 843-8	78
2212	Human C-reactive protein: expression, structure, and function. 2001 , 38, 189-97	628
2211	The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. 2001 , 22, 2243-52	281
2210	Current concepts of the pathogenesis of the acute coronary syndromes. 2001 , 104, 365-72	1205
2209	High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. 2001 , 103, 1813-8	1051
2208	Endothelial dysfunction in endocrine disease. 2001 , 12, 257-65	52
2207	Focal enhancement of expression of c-Met/hepatocyte growth factor receptor in the myocardium in human myocardial infarction. 2001 , 10, 235-40	22
2206	C-reactive protein and primary prevention of ischemic heart disease. 2001 , 311, 45-8	10
2205	Therapeutic implications of inflammation in atherosclerotic cardiovascular disease. 2001 , 71, 2066-74	26
2204	Obesity and preeclampsia: the potential role of inflammation. 2001 , 98, 757-62	114
2203	Diagnosis and risk stratification in patients with acute coronary syndromes according to ESC guidelines. 2001 , 103 Suppl 1, S57-61	2
2202	Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. 2001 , 358, 971-6	324

2201	Role of inflammatory biomarkers in prediction of coronary heart disease. 2001 , 358, 946-8	108
2200	Interleukin 6 and C-reactive protein levels in patients with acute allergic reactions: an emergency department-based study. 2001 , 87, 412-6	35
2199	Systemic and Cardiovascular Effects of Airway Injury and Inflammation: Ultrafine Particle Exposure in Humans. 2001 , 109, 529	34
2198	Assessing the role of oestrogen in the prevention of cardiovascular disease. 2001 , 33, 305-12	5
2197	Opportunities for the treatment of inflammation in cardiovascular disease. 2001 , 2, 1751-63	1
2196	Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. 2001 , 164, 396-402	666
2195	Low grade chronic inflammation in women with polycystic ovarian syndrome. 2001 , 86, 2453-5	450
2194	Long-term health consequences of polycystic ovary syndrome. 2001 , 81-101	1
2193	Postmenopausal hormone therapy and cardiovascular disease. 2001 , 135, 1092-3; author reply 1093-4	1
2192	Anti-GPIIb/IIIa Drugs: Current Strategies and Future Directions. 2001 , 86, 427-443	165
2191	Lack of Association of Increased C-Reactive Protein and Total Plasma Homocysteine. 2001 , 104,	4
2190	Role of inflammation in stable angina patients without hypercholesterolemia. 2001 , 31, 620	2
2189	Sex differences in long-term mortality after myocardial infarction. 2001 , 135, 1090; author reply 1090-1	
2188	Impact of Coronary Heart Disease on World Leaders. 2001 , 135, 1095	
2187	Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. 2001 , 161, 2474-80	100
2186	Systemic and cardiovascular effects of airway injury and inflammation: ultrafine particle exposure in humans. 2001 , 109 Suppl 4, 529-32	100
2185	High-Sensitivity C-Reactive Protein: A Novel and Promising Marker of Coronary Heart Disease. 2001 , 47, 403-411	394
2184	Absence of Diurnal Variation of C-Reactive Protein Concentrations in Healthy Human Subjects. 2001 , 47, 426-430	284

2183	Proposed Cardiovascular Risk Assessment Algorithm Using High-Sensitivity C-Reactive Protein and Lipid Screening. 2001 , 47, 28-30	151
2182	Evaluation of Nine Automated High-Sensitivity C-Reactive Protein Methods: Implications for Clinical and Epidemiological Applications. Part 2. 2001 , 47, 418-425	406
2181	Variability and Classification Accuracy of Serial High-Sensitivity C-Reactive Protein Measurements in Healthy Adults. 2001 , 47, 444-450	323
2180	5?-Nucleotidase in the Detection of Increased Activity of the Liver Form of Alkaline Phosphatase in Serum. 2001 , 47, 2046-2048	11
2179	Effects of Oral and Transdermal Estrogen Replacement Therapy on Markers of Coagulation, Fibrinolysis, Inflammation and Serum Lipids and Lipoproteins in Postmenopausal Women. 2001 , 85, 619-625	208
2178	Late occurrence of chronic renal failure in familial mediterranean fever after 20 years of colchicine treatment. 2001 , 135, 1096	1
2177	Hereditary hemochromatosis. 2001 , 135, 1091	
2176	Effects of Fluvastatin and Bezafibrate Combination on Plasma Fibrinogen, t-Plasminogen Activator Inhibitor and C Reactive Protein Levels in Coronary Artery Disease Patients with Mixed Hyperlipidaemia (FACT Study) 2001 , 85, 189-189	2
2175	Dying Patients in the Intensive Care Unit. 2001 , 135, 1092	2
2174	Impact of coronary heart disease on world leaders. 2001 , 135, 1094-5	
2173	C-Reactive Protein and Cardiovascular Risk: Has the Time Come for Screening the General Population?. 2001 , 47, 9-10	24
2172	Evaluation of Turbidimetric High-Sensitivity C-Reactive Protein Assays for Cardiovascular Risk Estimation. 2001 , 47, 2044-2046	25
2171	Targeting the central nervous system inflammatory response in ischemic stroke. 2001 , 14, 349-53	58
2170	Relationship between cytokine levels and coronary artery disease in women. 2001 , 3, 80-4	12
2169	Is C-reactive protein an independent risk factor for essential hypertension?. 2001 , 19, 857-61	203
2168	Dietary carbohydrates, physical inactivity, obesity, and the 'metabolic syndrome' as predictors of coronary heart disease. 2001 , 12, 395-404	106
2167	Hyperlipidaemia and cardiovascular disease. 2001 , 12, 359-62	
2166	Amyloid precursors and amyloidosis in inflammatory arthritis. 2001 , 13, 67-73	65

2165	Obesity and Preeclampsia. 2001 , 98, 757-762	82
2164	Inflammation and coronary heart disease: an overview. 2001 , 9, 31-5	87
2163	Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. 2001 , 3, 326-32	41
2162	Broadsheet: Biochemical markers of coronary heart disease. 2001 , 33, 329-37	6
2161	Inflammatory and atherosclerotic interactions in the depleted uremic patient. 2001 , 19, 53-61	168
2160	Hormone Replacement Therapy in Primary and Secondary Prevention of Coronary Artery Disease: Cardiologist and Geriatric Specialist Perspectives. 2001 , 23, 409-416	
2159	The coagulation-fibrinolysis system in patients with leukoaraiosis and Binswanger disease. 2001 , 58, 1620-5	23
2158	Acute mental stress elicits delayed increases in circulating inflammatory cytokine levels. 2001 , 101, 185-192	200
2157	Acute mental stress elicits delayed increases in circulating inflammatory cytokine levels. 2001 , 101, 185	123
2156	Postmenopausal Hormone Therapy and Cardiovascular Disease. 2001 , 135, 1093	
2155	An association between an antibody against Chlamydia pneumoniae and common carotid atherosclerosis. 2001 , 40, 208-13	10
2154	Intercessory prayer. 2001 , 135, 1094	2
2153	Some considerations regarding geriatric syndromes. 2001 , 135, 1095	5
2152	Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. 2001 , 116 Suppl, S108-15	32
2151	Cell Adhesion Molecules in Cardiovascular Pathology [A Glance into the Future?]. 2001 , 1, 225-235	2
2150	Blood donations and risk of coronary heart disease in men. 2001 , 103, 52-7	143
2149	Heterogeneity affecting outcome from acute stroke therapy: making reperfusion worse. 2001 , 32, 2318-27	71
2148	Current world literature. 2001 , 14, 93-125	

2147 Current World Literature. **2001**, 12, 439-454

2146 Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. **2001**, 103, 346-7

22

2145 Detection of Helicobacter pylori in human carotid atherosclerotic plaques. **2001**, 32, 385-91

146

2144 [Cardiovascular changes in obesity]. **2001**, 26, 194-201

2143 The Hordaland Homocysteine Studies. **2001**, 36 Suppl, S33-9

46

2142 The renin angiotensin system as a risk factor for coronary artery disease. **2001**, 3, 117-24

33

2141 New developments in the detection of vulnerable plaque. **2001**, 3, 125-35

58

2140 CRP en het risico op hart- en vaatziekten. **2001**, 44, 779-779

2139 End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?. **2001**, 59, 407-14

272

2138 Transcription factor-kappa B (NF-kappa B) and renal disease. **2001**, 59, 415-24

374

2137 Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. **2001**, 59, 1960-6

154

2136 Sudden cardiac death: exploring the limits of our knowledge. **2001**, 12, 369-81

203

2135 Primary stroke prevention. **2001**, 8, 1-15

23

2134 Vasculoprotective effects of oestrogens. **2001**, 28, 1032-4

10

2133 Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women. **2001**, 250, 508-15

30

2132 Chlamydia pneumoniae and chronic skin wounds: a focused review. **2001**, 6, 233-7

6

2131 Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. **2001**, 44, 1170-6

50

2130 Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. **2001**, 34, 309-15

32

2129	Soluble CD40L and cardiovascular risk in women. 2001 , 104, 2266-8	396
2128	Novel clinical markers of vascular wall inflammation. 2001 , 89, 763-71	592
2127	C-reactive protein and coronary heart disease: diagnostic and therapeutic implications for primary prevention. 2001 , 1, 153-7	13
2126	C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. 2001 , 25, 1416-20	143
2125	The relation of body fat mass and distribution to markers of chronic inflammation. 2001 , 25, 1407-15	486
2124	Cardiovascular monitoring and therapy for HIV-infected patients. 2001 , 946, 236-73	14
2123	Muscle-derived interleukin-6: possible biological effects. 2001 , 536, 329-37	356
2122	Association of C-reactive protein with markers of prevalent atherosclerotic disease. 2001 , 88, 112-7	195
2121	C-reactive protein and coronary heart disease in western Turkey. 2001 , 88, 601-7	43
2120	Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. 2001 , 88, 825-8	70
2119	What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?. 2001 , 88, 7J-16J	15
2118	Inflammatory pathways in atherosclerosis and acute coronary syndromes. 2001 , 88, 10K-15K	181
2117	Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. 2001 , 88, 1125-8	148
2116	Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. 2001 , 88, 1306-7	167
2115	The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease. 2001 , 26, 734-64	4
2114	Pathophysiology of oxidative stress in diabetes mellitus. 2001 , 15, 203-10	175
2113	What about estrogens now?. 2001 , 10, 24-28	2
2112	Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. 2001 , 38, 1271-6	27

2111	Is obesity an inflammatory condition?. 2001 , 17, 953-66	594
2110	Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. 2001 , 285, 2481-5	909
2109	Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. 2001 , 21, 961-7	442
2108	Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. 2001 , 21, 968-70	251
2107	Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. 2001 , 104, 25-31	223
2106	Markers of the acute phase response in cardiovascular disease: an update. 2001 , 39, 1054-64	10
2105	The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. 2001 , 50, 2384-9	473
2104	Atherosclerosis: Is it time for a new name?. 2001 , 104, E38	2
2103	C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. 2001 , 104, 63-7	161
2102	Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. 2001 , 104, 921-7	315
2101	High sensitivity C-reactive protein (CRP) reference intervals in the elderly. 2001 , 39, 1169-70	10
2100	Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. 2001 , 183, 995-9	44
2099	Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. 2001 , 103, 947-53	361
2098	Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. 2001 , 22, 2135-7	37
2097	Dietary fats in the prevention of coronary heart disease: the need for more clinical trials. 2001 , 3, D79-D84	2
2096	Coagulation and thrombosis in cardiovascular disease: plausible contributions of infectious agents. 2001 , 6, 16-9	8
2095	High sensitivity C-reactive protein for predicting cardiovascular disease: an inflammatory hypothesis. 2001 , 22, 349-52	46
2094	Patients, families and populations at high risk for coronary heart disease. 2001 , 22, 1682-90	7

2093	Particulate air pollution, C-reactive protein, and cardiac risk. 2001 , 22, 1149-50	27
2092	Cell adhesion molecules and inflammation in acute coronary syndromes: markers and emerging risk factors. 2001 , 22, 1155-9	8
2091	Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. 2001 , 104, 992-7	202
2090	Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. 2001 , 286, 2107-13	395
2089	Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. 2001 , 19, 143-51	119
2088	Current approaches to therapy for vascular injury. 2001 , 2, 753-64	
2087	Risk factors for cardiovascular disease in systemic lupus erythematosus. 2001 , 104, 1887-93	397
2086	Blood pressure and inflammation in apparently healthy men. 2001 , 38, 399-403	521
2085	C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. 2001 , 104, 145-50	323
2084	Risk factors for coronary disease: the time for a paradigm shift?. 2001 , 39, 907-19	7
2083	Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. 2001 , 153, 1094-101	85
2082	High sensitivity immunoassays for C-reactive protein: promises and pitfalls. 2001 , 39, 1171-6	42
2081	Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. 2001 , 21, 1458-63	354
2080	Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. 2001 , 103, 2236-41	82
2079	Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. 2001 , 24, 956-7	55
2078	Statins for stroke: the second story?. 2001 , 103, 348-50	16
2077	Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. 2001 , 21, 1712-9	1066
2076	Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. 2001 , 103, 1191-3	355

2075	C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. 2001 , 286, 327-34	2927
2074	Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. 2001 , 103, 2788-91	202
2073	Increased endothelial expression of HLA-DQ and interleukin 1alpha in extra-articular rheumatoid arthritis. Results from immunohistochemical studies of skeletal muscle. 2001 , 40, 1346-54	27
2072	Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. 2001 , 135, 939-53	498
2071	Soluble P-selectin and the risk of future cardiovascular events. 2001 , 103, 491-5	453
2070	C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. 2001 , 104, 2886-91	1089
2069	Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. 2001 , 6, 145-9	28
2068	Bacterial lipopolysaccharide and tumor necrosis factor alpha synergistically increase expression of human endothelial adhesion molecules through activation of NF-kappaB and p38 mitogen-activated protein kinase signaling pathways. 2001 , 69, 1273-9	89
2067	Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity. 2001 , 103, 1390-5	56
2066	Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. 2001 , 21, 1962-8	105
2065	Ecology in evolution. <i>New England Journal of Medicine</i> , 2001 , 344, 2018-20	59.2 6
2064	Statins and the acute-phase response. <i>New England Journal of Medicine</i> , 2001 , 344, 2016-8	59.2 121
2063	Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. 2001 , 32, 2575-9	668
2062	Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. <i>New England Journal of Medicine</i> , 2001 , 344, 1959-65	59.2 1298
2061	Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. 2002 , 51, 2596-603	60
2060	Hemostatic and inflammatory markers as risk factors for coronary disease in the elderly. 2002 , 11, 93-100, 107	16
2059	Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?. 2002 , 325, 157-60	544
2058	Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. 2002 , 25, 1371-7	113

2057	Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. 2002 , 16, 1335-47	631
2056	Ethnic variation in C-reactive protein: UK resident Indo-Asians compared with Caucasians. 2002 , 9, 139-41	4
2055	Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. 2002 , 106, 1447-52	301
2054	Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. 2002 , 25, 2016-21	395
2053	Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. <i>New England Journal of Medicine</i> , 2002 , 347, 1557-65	59.2 2812
2052	High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment. 2002 , 39, 459-97	44
2051	Periodontal disease and cardiovascular disease: epidemiology and possible mechanisms. 2002 , 133 Suppl, 14S-22S	184
2050	Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response. 2002 , 99, 12515-7	36
2049	Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. 2002 , 33, 862-75	166
2048	Prospective study of effect of androgens on serum inflammatory markers in men. 2002 , 22, 1136-41	61
2047	Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition?. 2002 , 105, 11-4	43
2046	Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. 2002 , 168, 5792-7	77
2045	Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. 2002 , 22, 1662-7	193
2044	Effect of ciprofibrate on C-reactive protein and fibrinogen levels. 2002 , 53, 273-7	45
2043	What is C-reactive protein telling us about coronary artery disease?. 2002 , 162, 389-92	19
2042	Inflammation in acute coronary syndromes. 2002 , 4, B8-B13	7
2041	Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. 2002 , 105, 1890-6	507
2040	Need to test the arterial inflammation hypothesis. 2002 , 106, 136-40	106

2039	Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. 2002 , 106, 679-84	757
2038	Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. 2002 , 106, 403-6	139
2037	Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. 2002 , 106, 820-5	174
2036	Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. 2002 , 87, 252-5	69
2035	Tumour necrosis factor-alpha, inflammatory biomarkers, and atherogenesis. 2002 , 23, 345-7	17
2034	Short-term effects of atorvastatin on C-reactive protein. 2002 , 23, 794-9	60
2033	The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. 2002 , 23, 960-6	38
2032	Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques. 2002 , 23, 1664-9	55
2031	Is time the overriding factor in thrombolytic therapy?. 2002 , 23, 347-9	
2030	Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. 2002 , 17, 435-41	134
2029	Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. 2002 , 53, 1029-34	206
2028	Use of statins and aspirin to reduce risks of cardiovascular disease. 2002 , 7, 77-80	15
2027	C-reactive protein--to screen or not to screen?. <i>New England Journal of Medicine</i> , 2002 , 347, 1615-7	59.2 106
2026	Diabetes and atherothrombotic disease: linked through inflammation?. 2002 , 2, 67-73	4
2025	Inflammation and cholesterol. 2002 , 4, A18-A25	1
2024	Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. 2002 , 87, 1692-9	82
2023	Diabetes, insulin resistance and vascular disease among Indian Asians and Europeans. 2002 , 2, 199-214	18
2022	Importance of periodontal disease in the kidney patient. 2002 , 20, 113-9	41

2021	Associations between cardiorespiratory fitness and C-reactive protein in men. 2002 , 22, 1869-76	272
2020	Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis. 2002 , 89, 163-171	67
2019	Women and Coronary Heart Disease Risk Factors. 2002 , 9, 315-322	8
2018	C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. 2002 , 22, 1512-3	38
2017	Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. 2002 , 106, 1224-8	101
2016	Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. 2002 , 22, 656-61	98
2015	Invited commentary: Height-cardiovascular disease relation: where to go from here?. 2002 , 155, 688-9	8
2014	Soluble adhesion molecules and the search for biomarkers for atherosclerosis. 2002 , 106, 766-7	50
2013	Insulin resistance but not inflammation is associated with gestational hypertension. 2002 , 40, 886-91	40
2012	Chronology versus biology: telomeres, essential hypertension, and vascular aging. 2002 , 40, 229-32	61
2011	Body mass index and the risk of stroke in men. 2002 , 162, 2557-62	336
2010	Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. 2002 , 106, 2073-7	173
2009	Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. 2002 , 105, 2600-4	139
2008	In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. 2002 , 22, 2066-71	213
2007	C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. 2002 , 303, 1007-13	65
2006	Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. 2002 , 105, 800-3	111
2005	Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. 2002 , 105, 2632-7	157
2004	Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. 2002 , 106, 1930-7	315

2003	Weight loss reduces C-reactive protein levels in obese postmenopausal women. 2002 , 105, 564-9	422
2002	Association between pulse pressure and C-reactive protein among apparently healthy US adults. 2002 , 39, 197-202	114
2001	Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. 2002 , 106, 24-30	470
2000	Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. 2002 , 105, 2583-5	47
1999	Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. 2002 , 288, 980-7	487
1998	Coronary atherogenic risk factors in women. 2002 , 23, 1738-52	57
1997	Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). 2002 , 105, 2962-7	192
1996	Role of inflammation and its treatment in ESRD patients. 2002 , 20, 70-80	36
1995	C-reactive protein and prognosis after percutaneous coronary intervention. 2002 , 23, 923-5	13
1994	White blood cell count as a risk factor for hypertension; a study of Japanese male office workers. 2002 , 20, 851-7	36
1993	Time course of plasma adhesion molecules in acute coronary syndromes. 2002 , 13, 215-21	3
1992	Relation of insulin resistance to blood pressure in childhood. 2002 , 20, 509-17	51
1991	. 2002 , 9, 139-141	16
1990	Insulin resistance: what is its role in the polycystic ovary syndrome?. 2002 , 9, 444-450	7
1989	High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. 2002 , 17, 325-31	36
1988	Cardiovascular Disease and the Maturing Woman. 2002 , 4, 71-88	3
1987	Hyperlipidaemia and cardiovascular disease: C-reactive protein and atherosclerosis--new dimensions. 2002 , 13, 101-3	2
1986	Inflammatory markers and coronary heart disease. 2002 , 13, 383-9	78

1985	Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial. 2002 , 17, 2748-53	18
1984	C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. 2002 , 17 Suppl 8, 29-32; discussion 39-40	93
1983	Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine. 2002 , 98, 6-12	12
1982	Serum markers of inflammation and cardiovascular risk. 2002 , 345-354	
1981	Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. 2002 , 75, 492-8	445
1980	Glycemic index: overview of implications in health and disease. 2002 , 76, 266S-273S	601
1979	Cytokines in the Pathogenesis of Atherosclerosis. 2002 , 88, 554-567	203
1978	Diagnostic value of CRP and Lp(a) in coronary heart disease. 2002 , 57, 197-204	36
1977	Is metabolic syndrome X an inflammatory condition?. 2002 , 227, 989-97	106
1976	Estrogen increases iNOS expression in the ovine coronary artery. 2002 , 283, H1169-80	31
1975	Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. 2002 , 162, 1286-92	327
1974	. 2002 , 9, 315-322	18
1973	Fibrates and coronary heart disease reduction in diabetes. 2002 , 9, 312-322	8
1972	Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology?. 2002 , 33, 2141-3	34
1971	Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. 2002 , 23, 831-4	149
1970	Changes in proinflammatory cytokine activity after menopause. 2002 , 23, 90-119	647
1969	Diabetes and cardiovascular disease. 2002 , 53, 245-67	111
1968	Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. 2002 , 113, 188-93	141

1967	Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. 2002 , 113, 331-4	28
1966	C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. 2002 , 5, 42-6	13
1965	A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. 2002 , 106, 913-9	821
1964	Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. 2002 , 19, 193-200	36
1963	C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. 2002 , 39, 632-7	179
1962	Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. 2002 , 39, 1133-8	75
1961	Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. 2002 , 40, 49-55	35
1960	Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. 2002 , 40, 1723-30	245
1959	Adolescent Caucasian mothers have reduced adult hip bone density. 2002 , 77, 136-40	19
1958	Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. 2002 , 77, 128-35	109
1957	A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. 2002 , 77, 945-51	64
1956	C-reactive protein predicts death in patients with previous premature myocardial infarction--a 10 year follow-up study. 2002 , 160, 433-40	70
1955	Parameters of inflammation and infection in a community based case-control study of coronary heart disease. 2002 , 160, 457-63	34
1954	Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. 2002 , 160, 471-6	49
1953	Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. 2002 , 162, 179-85	91
1952	Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. 2002 , 162, 187-91	28
1951	Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. 2002 , 162, 217-9	182
1950	Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. 2002 , 162, 245-51	37

1949	Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients. 2002 , 165, 159-66	19
1948	Relationship of serum ferritin with cardiovascular risk factors and inflammation in young men and women. 2002 , 165, 179-84	125
1947	The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. 2002 , 165, 301-7	85
1946	Statins and menopause. 2002 , 62, 2421-31	5
1945	Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. 2002 , 22, 1668-73	337
1944	Predictors of fatigue in healthy young adults: moderating effects of cigarette smoking and gender. 2002 , 3, 222-33	47
1943	Factors associated with oxidative stress in human populations. 2002 , 156, 274-85	326
1942	Elevated homocysteine serum level is associated with low enrichment of homocysteine in coronary arteries of patients with coronary artery disease. 2002 , 107, 189-96	6
1941	Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. 2002 , 359, 118-23	278
1940	Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. 2002 , 359, 2159-63	198
1939	C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. 2002 , 360, 1462-7	99
1938	C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. 2002 , 317, 1-15	115
1937	Charting the course of medical laboratories in a changing environment. 2002 , 319, 87-100	46
1936	Development of ELISA on microplate for serum C-reactive protein and establishment of age-dependent normal reference range. 2002 , 322, 163-8	75
1935	High-sensitivity C-reactive protein as pretransplant marker for acute rejection and cardiovascular morbidity. 2002 , 34, 392-3	6
1934	Stress, inflammation and cardiovascular disease. 2002 , 52, 1-23	533
1933	Effects of high- and low-isoflavone (phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women. 2002 , 51, 919-24	126
1932	Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease. 2002 , 143, 349-55	56

1931	Aspirin: redundant in users of nonaspirin, nonsteroidal antiinflammatory agents?. 2002 , 143, 381-2	1
1930	C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. 2002 , 144, 233-8	173
1929	High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. 2002 , 144, 449-55	52
1928	Racial and ethnic disparities in coronary heart disease in women: prevention, treatment, and needed interventions. 2002 , 12, 252-71	15
1927	Inflammatory cytokines, socioeconomic status, and acute stress responsivity. 2002 , 16, 774-84	140
1926	Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. 2002 , 55, 882-7	115
1925	C-reactive protein: history and revival. 2002 , 13, 412	112
1924	Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus. 2002 , 58, 37-44	42
1923	Different associations of C-reactive protein, fibrinogen and C3 with traditional risk factors in middle-aged men. 2002 , 83, 63-71	22
1922	Beyond lipid lowering: the role of statins in vascular protection. 2002 , 86, 5-18	205
1921	Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women. 2002 , 43, 49-53	23
1920	Inflammation in atherosclerosis and acute coronary syndromes. 2002 , 1229, 95-102	1
1919	Inflammation and atherosclerosis. 2002 , 105, 1135-43	5212
1918	C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. 2002 , 51, 1596-600	598
1917	[Prevention and treatment of ischemic heart disease in patients with diabetes mellitus]. 2002 , 55, 975-86	8
1916	Pharmacologic therapy for peripheral arterial disease and claudication. 2002 , 36, 1283-91	62
1915	[Eptifibatide blocks the increase in C-reactive protein concentration after coronary angioplasty]. 2002 , 55, 186-9	6
1914	Reproductive hormones and cardiovascular disease mechanism of action and clinical implications. 2002 , 29, 475-93	19

1913	Inflamaci3n, hemostasia y enfermedad coronaria. La prote3na C reactiva y el d3mero D como marcadores del proceso de la arteriosclerosis. 2002 , 14, 242-257	
1912	Valores altos de apolipoprote3na B, valores bajos de apolipoprote3na A-I y mejora de la predicci3n del infarto de miocardio fatal (estudio AMORIS): estudio prospectivo. 2002 , 14, 109-111	
1911	Determinaci3n de la prote3na C reactiva para indicar el tratamiento con estatinas en la prevenci3n primaria de los acontecimientos coronarios agudos. 2002 , 14, 108-109	
1910	Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. 2002 , 105, 2595-9	418
1909	Impact of the Third Cholesterol Report from the Adult Treatment Panel of the National Cholesterol Education Program on the Clinical Laboratory. 2002 , 48, 11-17	38
1908	Stability of Novel Plasma Markers Associated with Cardiovascular Disease: Processing within 36 Hours of Specimen Collection. 2002 , 48, 1781-1784	78
1907	Effect of Analytical Error on the Assessment of Cardiac Risk by the High-Sensitivity C-Reactive Protein and Lipid Screening Model. 2002 , 48, 1955-1962	5
1906	Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity. 2002 , 48, 877-883	118
1905	Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort. 2002 , 33, 2182-6	60
1904	Elevated C-reactive protein is associated with an increased intima to media thickness of the common carotid artery. 2002 , 13, 57-63	45
1903	Comparison between adventitial and intimal inflammation of ruptured and nonruptured atherosclerotic plaques in human coronary arteries. 2002 , 79, 20-4	43
1902	Inflammation, blood pressure, and stroke: an opportunity to target primary prevention?. 2002 , 33, 2732-3	5
1901	Neopterin as a marker for immune system activation. 2002 , 3, 175-87	515
1900	The Change of Cholesterol Level and IL-6, CRP in Unstable Angina Patients with Hypercholesterolemia after Low Dose Simvastatin Therapy. 2002 , 32, 981	1
1899	Predictive Value of C-Reactive Protein for Cardiac Events after Coronary Stenting. 2002 , 32, 766	
1898	Prediction of cardiovascular risk using soluble cell adhesion molecules. 2002 , 23, 1569-74	66
1897	On Evolutionary Biology, Inflammation, Infection, and the Causes of Atherosclerosis. 2002 , 105, 2-4	112
1896	Atherosclerosis or atheroscleritis: what's in a name?. 2002 , 98, 111-2	2

1895	Association between electrocardiographic pattern and level of C-reactive protein in patients with first anterior wall acute myocardial infarction. 2002 , 97, 122-6	2
1894	A Prospective Evaluation of the Heat Shock Protein 70 Gene Polymorphisms and the Risk of Stroke. 2002 , 87, 622-625	9
1893	Is C-reactive protein specific for vascular disease in women?. 2002 , 136, 529-33	59
1892	Effects of Transdermal and Oral Oestrogen Replacement Therapy on C-Reactive Protein Levels in Postmenopausal Women: A Randomised, Placebo-Controlled Trial. 2002 , 88, 605-610	41
1891	Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice. 2002 , 17, 174-85	15
1890	Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. 2002 , 89, 145-9	144
1889	Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. 2002 , 89, 468-9	8
1888	Relative risk of cardiovascular events in patients with rheumatoid arthritis. 2002 , 89, 33D-38D	72
1887	Association of systemic inflammatory state with troponin I elevation after elective uncomplicated percutaneous coronary intervention. 2002 , 89, 981-3	37
1886	Relation between markers of systemic vascular inflammation and smoking in women. 2002 , 89, 1117-9	291
1885	Effect of cocaine usage on C-reactive protein, von Willebrand factor, and fibrinogen. 2002 , 89, 1133-5	51
1884	Cardiovascular disease in postmenopausal women: myths and reality. 2002 , 89, 5E-10E; discussion 10E-11E	16
1883	Risk factors for coronary artery disease in women. 2002 , 89, 28E-34E; discussion 34E-35E	62
1882	Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. 2002 , 90, 7F-10F	36
1881	Relation of plasma total homocysteine to cardiovascular mortality in a French population. 2002 , 90, 591-5	23
1880	Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. 2002 , 90, 942-6	31
1879	Clinical depression and inflammatory risk markers for coronary heart disease. 2002 , 90, 1279-83	345
1878	[Cardiovascular manifestations in inflammatory rheumatic diseases]. 2002 , 152, 220-2	2

1877	Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. 2002 , 39, 1096-101	37
1876	Association of serum albumin and atherosclerosis in chronic hemodialysis patients. 2002 , 40, 721-7	93
1875	Serum markers of periodontal disease status and inflammation in hemodialysis patients. 2002 , 40, 983-9	82
1874	C-reactive protein is elevated in symptomatic compared with asymptomatic patients with carotid artery disease. 2002 , 23, 505-9	21
1873	Obesity, metabolic syndrome X, and inflammation. 2002 , 18, 430-2	82
1872	Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. 2002 , 52, 168-74	557
1871	Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. 2002 , 46, 862-73	493
1870	Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. 2002 , 46, 2010-9	295
1869	Statins and inflammatory markers. 2002 , 4, 42-7	17
1868	Postmenopausal hormone replacement therapy as antiatherosclerotic therapy. 2002 , 4, 52-8	9
1867	The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease. 2002 , 4, 278-88	37
1866	Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes. 2002 , 2, 396-402	16
1865	Statins: the new aspirin?. 2002 , 59, 1771-86	72
1864	[Acute coronary syndrome--better risk stratification by determination of inflammatory parameters?]. 2002 , 97, 63-9	
1863	Pleiotropic effects of HMG-CoA reductase inhibitors. 2002 , 97, 105-16	161
1862	Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis. 2002 , 89, 163-71	38
1861	Inflammatory bio-markers and cardiovascular risk prediction. 2002 , 252, 283-94	498
1860	Impact of renal failure on the risk of myocardial infarction and death. 2002 , 62, 1776-83	65

1859	Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. 2002 , 62, 2208-15	62
1858	Scientific gaps in the prediction and prevention of sudden cardiac death. 2002 , 13, 709-23	98
1857	Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atherosclerosis. 2002 , 1, 3	70
1856	Why is soluble intercellular adhesion molecule-1 related to cardiovascular mortality?. 2002 , 32, 1-8	44
1855	The effect of the Interleukin-6-174G > C promoter gene polymorphism on endothelial function in healthy volunteers. 2002 , 32, 153-7	33
1854	Roles of oxidized low-density lipoprotein and its receptors in the pathogenesis of atherosclerotic diseases. 2002 , 2, 172-178	1
1853	Cardiovascular effects of raloxifene: the potential for cardiovascular protection in women. 2002 , 4, 166-76	11
1852	Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes. 2002 , 19, 847-52	56
1851	Atherogenic progression of carotid stenosis associates selectively with monocyte fraction in circulating leukocytes. 2002 , 9, 307-10	11
1850	Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. 2002 , 56, 1130-6	173
1849	Levels of C-reactive protein in pregnant women who subsequently develop pre-eclampsia. 2002 , 109, 297-301	48
1848	Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia. 2002 , 109, 759-64	59
1847	Local neuroinflammation and the progression of Alzheimer's disease. 2002 , 8, 529-38	204
1846	Hormone therapies and vascular outcomes: who is at risk?. 2003 , 16, 87-90	5
1845	Association between coronary endothelial dysfunction and local inflammation of atherosclerotic coronary arteries. 2003 , 249, 67-73	8
1844	Breast cancer prevention trials using retinoids. 2003 , 8, 19-30	24
1843	Cynical hostility, depressive symptoms, and the expression of inflammatory risk markers for coronary heart disease. 2003 , 26, 501-15	55
1842	Coronary artery disease, inflammation and the ghost of John Hunter. 2003 , 11, 195-201	

1841	Soluble adhesion molecules: surrogate markers of cardiovascular disease?. 2003 , 61, 63-8	17
1840	Connecting the role of C-reactive protein and statins in cardiovascular disease. 2003 , 26, III39-44	39
1839	The relation between serum cytokine levels and common laboratory tests in healthy Japanese males. 2003 , 8, 6-12	2
1838	Hypercholesterolemia and Dyslipidemia: Issues for the Clinician. 2003 , 5, 35-50	5
1837	Gender, hyperlipidemia, and coronary artery disease. 2003 , 29, 7-17	2
1836	C-reactive protein and risk of cardiovascular disease: evidence and clinical application. 2003 , 5, 341-9	80
1835	Isoprenoid metabolism and the pleiotropic effects of statins. 2003 , 5, 372-8	73
1834	C-Reactive Protein and Cardiovascular Diseases. 2003 , 12, 1-12	17
1833	Atherosclerosis as an inflammatory arterial disease <i>Årjvud</i> . 2003 , 12, 23-25	1
1832	C-reaktives Protein in der Risikovorhersage und Intervention bei kardiovaskulären Erkrankungen. 2003 , 27, 100-112	
1831	A comparison of acute phase proteins and traditional risk factors as markers of combined plaque and intima-media thickness and plaque density in carotid and femoral arteries. 2003 , 26, 81-7	10
1830	Estrogen increases inducible nitric oxide synthase gene expression. 2003 , 188, 1208-10	5
1829	C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. 2003 , 126, 1886-91	73
1828	Coronary heart disease: the female heart is vulnerable. 2003 , 46, 199-229	105
1827	Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. 2003 , 23, 1141-52	29
1826	[Value and role of lipid lowering therapy for cardiovascular prevention in the elderly]. 2003 , 52, 246-53	1
1825	Role of C-reactive protein in the assessment of cardiovascular risk. 2003 , 91, 200-2	37
1824	Effect of plasma C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense, low-density lipoproteins in men (The Quebec Cardiovascular Study). 2003 , 91, 555-8	21

1823	Why did green tea not protect against coronary artery disease but protect against myocardial infarction?. 2003 , 91, 1290-1	4
1822	Utility of inflammatory markers in the management of coronary artery disease. 2003 , 92, 10i-8i	64
1821	A practical approach to risk assessment to prevent coronary artery disease and its complications. 2003 , 92, 19i-26i	62
1820	Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women. 2003 , 92, 212-4	22
1819	Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. 2003 , 92, 236-9	29
1818	Insulin resistance, inflammation, and the prediabetic state. 2003 , 92, 18J-26J	176
1817	The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. 2003 , 92, 34J-41J	59
1816	Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines. 2003 , 92, 515-21	88
1815	Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). 2003 , 92, 522-8	228
1814	C-reactive protein and depressed mood in a sub-group of smokers during nicotine abstinence. 2003 , 18, 329-37	9
1813	C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. 2003 , 41, 21-5	29
1812	Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. 2003 , 15, 91-100	37
1811	Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. 2003 , 48, 3159-67	271
1810	Radiation-associated cardiovascular disease. 2003 , 45, 55-75	393
1809	Possible beneficial role of exercise in modulating low-grade inflammation in the elderly. 2003 , 13, 56-62	80
1808	Calciophylaxis in chronic, non-dialysis-dependent renal disease. 2003 , 4, 8	12
1807	The molecular genetics of cardiovascular disease: clinical implications. 2003 , 253, 120-7	73
1806	Prognostic value of plasma C-reactive protein and fibrinogen determinations in patients with acute myocardial infarction treated with thrombolysis. 2003 , 254, 244-50	10

1805	Update on C-reactive protein as a risk marker in cardiovascular disease. 2003 , S58-61	28
1804	Uremia-related metabolic cardiac risk factors in chronic kidney disease. 2003 , 16, 148-56	30
1803	Rheopheresis in patients with ischemic diabetic foot syndrome: results of an open label prospective pilot trial. 2003 , 7, 444-55	33
1802	The genetics of atherothrombotic disorders: a clinician's view. 2003 , 1, 1381-90	31
1801	Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. 2003 , 1, 1195-201	27
1800	Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women. 2003 , 1, 2149-52	22
1799	Cellular adhesion molecules and cardiovascular disease. Part I. Their expression and role in atherogenesis. 2003 , 33, 380-6	59
1798	Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. 2003 , 33, 450-62	66
1797	Activation of the innate immune system as a predictor of cardiovascular mortality in Type 2 diabetes mellitus. 2003 , 20, 723-6	29
1796	Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. 2003 , 20, 743-5	50
1795	Increased Interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness. 2003 , 59, 242-50	33
1794	Immune activation and degradation of tryptophan in coronary heart disease. 2003 , 33, 550-4	122
1793	Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. 2003 , 11, 1055-64	162
1792	Obesity, fasting plasma insulin, and C-reactive protein levels in healthy children. 2003 , 11, 95-103	45
1791	Effect of family history of type 2 diabetes on white blood cell count in adult women. 2003 , 11, 1232-7	9
1790	Relation of waist circumference and glycemic status to C-reactive protein in the Sandy Lake Oji-Cree. 2003 , 27, 347-54	44
1789	Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. 2003 , 17, 223-30	144
1788	Soluble integrin adhesion receptors and atherosclerosis: much heat and a little light?. 2003 , 17, 449-53	7

1787	Clinical biomarkers in drug discovery and development. 2003 , 2, 566-80	583
1786	Mechanisms, challenges and opportunities in stroke. 2003 , 4, 399-415	1363
1785	Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. 2003 , 14, 513-21	108
1784	Comprehensive evaluation of the older woman. 2003 , 78, 1157-85	18
1783	Polimorfismo genético en el paciente crítico. Parte II: aplicaciones especiales de los polimorfismos genéticos. Farmacogenética y terapia génica. 2003 , 27, 181-187	3
1782	Insulin sensitizers. 2003 , 78, 471-9	26
1781	Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. 2003 , 15, 171-173	
1780	Relationship of destructive periodontal disease to the acute-phase response. 2003 , 74, 1007-16	171
1779	Coxibs and the endothelium. 2003 , 42, 1754-6	6
1778	Value of the micropig model of menopause in the assessment of benefits and risks of postmenopausal therapies for cardiovascular and reproductive tissues. 2003 , 79 Suppl 1, 779-88	7
1777	Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women. 2003 , 80, 541-5	10
1776	Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings. 2003 , 166, 203-12	29
1775	Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. 2003 , 166, 129-35	132
1774	Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. 2003 , 166, 379-86	176
1773	Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. 2003 , 167, 73-9	186
1772	Circulating markers of inflammation and atherosclerosis. 2003 , 169, 203-14	314
1771	Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. 2003 , 168, 123-9	62
1770	Adhesion molecules and atherosclerosis. 2003 , 170, 191-203	823

1769	Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. 2003 , 169, 283-91	75
1768	C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups. 2003 , 170, 79-86	55
1767	Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. 2003 , 170, 169-76	127
1766	IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. 2003 , 170, 223-8	38
1765	Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. 2003 , 170, 315-23	115
1764	Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men. 2003 , 41, 333-9	13
1763	C-reactive protein and other inflammatory risk markers in acute coronary syndromes. 2003 , 41, 37S-42S	255
1762	Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. 2003 , 41, 916-24	187
1761	Atherothrombosis, inflammation, and diabetes. 2003 , 41, 1071-7	190
1760	Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. 2003 , 41, 1358-63	123
1759	34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap?. 2003 , 41, 1863-74	147
1758	Through the looking glass: an angioscopic view of the effect of statin therapy on coronary artery plaques. 2003 , 42, 687-9	7
1757	Physical fitness and C-reactive protein level in children and young adults: the Columbia University BioMarkers Study. 2003 , 111, 332-8	93
1756	Association between alveolar bone loss and elevated serum C-reactive protein in Japanese men. 2003 , 74, 1741-6	73
1755	Elevated concentrations of C-reactive protein in subjects with type 2 diabetes mellitus are moderately influenced by glycemic control. 2003 , 26, 216-21	17
1754	Relation of inflammation and benefit of statins after percutaneous coronary interventions. 2003 , 107, 1750-6	166
1753	Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. 2003 , 115, 695-701	88
1752	The prognostic value of markers of inflammation in patients with troponin T-negative chest pain before discharge from the emergency department. 2003 , 115, 521-8	16

1751	Reduction of C-reactive protein levels through use of a multivitamin. 2003 , 115, 702-7	47
1750	Hyperglycemia as a cardiovascular risk factor. 2003 , 115 Suppl 8A, 6S-11S	84
1749	Endothelial function, inflammation, and prognosis in cardiovascular disease. 2003 , 115 Suppl 8A, 99S-106S	189
1748	Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. 2003 , 146, 62-8	147
1747	Inflammation in atherosclerosis: causal or casual? The need for randomized trials. 2003 , 146, 199-202	2
1746	Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. 2003 , 146, 591-604	100
1745	Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. 2003 , 146, 1052-9	25
1744	Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. 2003 , 114, 180-7	282
1743	Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. 2003 , 114, 283-7	83
1742	Inflammation and coagulation: direct mediators of physical function in the elderly?. 2003 , 114, 235-6	4
1741	Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. 2003 , 114, 485-94	40
1740	C-reactive protein activates complement in infarcted human myocardium. 2003 , 163, 269-75	81
1739	Endothelial function testing as a biomarker of vascular disease. 2003 , 108, 2054-9	427
1738	Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. 2003 , 171, 359-67	87
1737	Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. 2003 , 108, 2317-22	742
1736	Clinical application of C-reactive protein for cardiovascular disease detection and prevention. 2003 , 107, 363-9	1772
1735	C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. 2003 , 107, 391-7	1881
1734	IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. 2003 , 170, 277-83	123

1733	Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. 2003 , 107, 499-511	4541
1732	Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. 2003 , 35, 417-9	45
1731	Cytokine signatures in atherosclerotic claudicants. 2003 , 111, 215-21	37
1730	The role of estrogen in cardiovascular disease. 2003 , 115, 325-44	120
1729	Acute myocardial infarction. 2003 , 361, 847-58	246
1728	Seroprevalence of antibodies to Chlamydia pneumoniae in women with preeclampsia. 2003 , 101, 221-6	35
1727	The evaluation of C-reactive protein, homocysteine and vitamin B6 concentrations in Behçet and rheumatoid arthritis disease. 2003 , 329, 143-5	8
1726	Marked reduction in serum high-density lipoprotein cholesterol concentrations in a woman with acute inflammation due to diabetic gangrene. 2003 , 335, 33-8	6
1725	The hypertriglyceridemic waist phenotype among women. 2003 , 171, 123-30	86
1724	Natural killer cell and proinflammatory cytokine responses to mental stress: associations with heart rate and heart rate variability. 2003 , 63, 101-15	46
1723	Pre-diabetes, insulin resistance, inflammation and CVD risk. 2003 , 61 Suppl 1, S9-S18	101
1722	Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. 2003 , 46, 245-53	29
1721	Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway. 2003 , 60, 634-9	12
1720	Plasma C-reactive protein in subjects with hypo/hyperalphalipoproteinemias. 2003 , 52, 432-6	24
1719	Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. 2003 , 145, 248-53	67
1718	Effect of atorvastatin and pravastatin on serum C-reactive protein. 2003 , 145, e8	29
1717	Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. 2003 , 95, 559-69	320
1716	The prognostic value of high-sensitive C-reactive protein and cardiac troponin T in young and middle-aged patients with chest pain without ECG changes. 2003 , 14, 310-314	5

1715	Relationship of total and abdominal adiposity with CRP and IL-6 in women. 2003 , 13, 674-82	189
1714	Growth hormone and cardiovascular risk markers. 2003 , 13 Suppl A, S109-15	12
1713	Inflammation, infection, and atherosclerosis. 2003 , 17, 238-44	22
1712	Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. 2003 , 17, 276-85	198
1711	Socioeconomic status, C-reactive protein, immune factors, and responses to acute mental stress. 2003 , 17, 286-95	135
1710	Plasma interleukin-6 is associated with psychological coronary risk factors: moderation by use of multivitamin supplements. 2003 , 17, 296-303	30
1709	Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. 2003 , 29, 65-71	27
1708	Acute-phase proteins among patients with type 1 diabetes. 2003 , 29, 405-11	48
1707	[Hormonal replacement therapy and cardiovascular risk: contra-indication or non-indication?]. 2003 , 31, 657-66	
1706	Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. 2003 , 108, 2292-7	355
1705	Minireview: adiposity, inflammation, and atherogenesis. 2003 , 144, 2195-200	610
1704	The cardiovascular burden of lupus: a complex challenge. 2003 , 163, 1507-10	41
1703	La proteína C reactiva como marcador del riesgo cardiovascular. 2003 , 20, 74-81	
1702	[The SIESTA study. One more step in the knowledge of acute coronary syndromes]. 2003 , 56, 335-7	1
1701	High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. 2003 , 38, 1018-24	89
1700	Inflammation Protocols. 2003 ,	22
1699	PPARgamma agonists and vascular risk factors: potential effects on cardiovascular disease. 2003 , 1, 23-32	3
1698	Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. 2003 , 107, 87-92	611

1697	Coming of age of C-reactive protein: using inflammation markers in cardiology. 2003 , 107, 370-1	309
1696	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. 2003 , 108, 1772-8	886
1695	The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study. 2003 , 10, 11-18	
1694	Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003 , 42, 1206-52	10207
1693	New markers of inflammation and endothelial cell activation: Part I. 2003 , 108, 1917-23	547
1692	Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. 2003 , 289, 1799-804	1087
1691	Diagnostic implications of C-reactive protein. 2003 , 138, 220-4	62
1690	Alcohol consumption and plasma concentration of C-reactive protein. 2003 , 107, 443-7	264
1689	Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. 2003 , 49, 666-9	149
1688	Interleukin-6 promoter polymorphism modulates the effects of heavy alcohol consumption on early carotid artery atherosclerosis: the Carotid Atherosclerosis Progression Study (CAPS). 2003 , 34, 402-7	69
1687	Blood pressure, C-reactive protein, and risk of future cardiovascular events. 2003 , 108, 2993-9	259
1686	Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. 2003 , 158, 844-51	78
1685	High-sensitivity analysis of serum C-reactive protein in young patients with lumbar disc herniation. 2003 , 85, 1151-4	22
1684	A novel role for calpains in the endothelial dysfunction of hyperglycemia. 2003 , 17, 1511-3	70
1683	Inflammatory markers and cognition in well-functioning African-American and white elders. 2003 , 61, 76-80	553
1682	C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. 2003 , 107, 1783-90	433
1681	The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. 2003 , 54, 391-9	29
1680	Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. 2003 , 100, 4736-41	563

1679	Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. 2003 , 88, 4649-54	193
1678	Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. 2003 , 88, 627-36	180
1677	Infections and the Cardiovascular System: New Perspectives. 2003 ,	5
1676	Repression of farnesoid X receptor during the acute phase response. 2003 , 278, 8988-95	125
1675	Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). 2003 , 108, 2453-9	273
1674	C-reactive protein and lesion morphology in patients with acute myocardial infarction. 2003 , 108, 282-5	117
1673	Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. 2003 , 107, 671-4	657
1672	Effects of postmenopausal hormone replacement therapy on HbA(1c) levels. 2003 , 26, 1088-92	10
1671	Evidence of a lack of effect of a phytoestrogen regimen on the levels of C-reactive protein, E-selectin, and nitrate in postmenopausal women. 2003 , 88, 5180-5	63
1670	Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. 2003 , 26, 2622-7	91
1669	Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. 2003 , 107, 2416-21	198
1668	Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. 2003 , 108, e81-5	261
1667	Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. 2003 , 108, 2323-8	77
1666	Hormone replacement therapy and inflammation: interactions in cardiovascular disease. 2003 , 42, 657-63	59
1665	Why cardiologists should be interested in air pollution. 2003 , 89, 1383-8	38
1664	Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy. 2003 , 42, 1055-61	20
1663	HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?. 2003 , 10, 169-79	26
1662	Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. 2003 , 14, 3233-8	88

1661	Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. 2003 , 108, 161-5	207
1660	Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. 2003 , 108, 512-5	245
1659	Cytokines and Mental Health. 2003 ,	1
1658	Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. 2003 , 26, 2493-9	258
1657	C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. 2003 , 108, 166-70	267
1656	Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. 2003 , 289, 2673-84	818
1655	C-reactive protein and coronary artery calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA). 2003 , 23, 1851-6	84
1654	Elevated carotid artery intima-media thickness levels in individuals who subsequently develop type 2 diabetes. 2003 , 23, 1845-50	54
1653	High sensitivity C-reactive protein in clinical practice. 2003 , 1, 207-11	23
1652	Inflammation and its relationship to insulin resistance, type 2 diabetes mellitus, and endothelial dysfunction. 2003 , 1, 55-67	15
1651	C-reactive protein and gestational diabetes: the central role of maternal obesity. 2003 , 88, 3507-12	175
1650	Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status. 2003 , 57, 730-3	98
1649	Association between blood pressure and C-reactive protein levels in acute ischemic stroke. 2003 , 42, 1117-23	31
1648	Pulmonary artery sarcoma. 2003 , 89, 1388	5
1647	Sophisticated tests for susceptibility to atherosclerosis: an added value for heart hospitals. 2003 , 1, 135-40	
1646	Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. 2003 , 49, 611-6	59
1645	Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. 2003 , 49, 1258-71	165
1644	Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. 2003 , 49, 1347-52	44

1643	C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. 2003 , 34, 2463-8	144
1642	Evaluation of two new high-sensitivity methods for C-reactive protein. 2003 , 40, 398-405	17
1641	C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study. 2003 , 107, 245-50	57
1640	Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy. 2003 , 23, 111-6	54
1639	C-reaktives Protein in der Risikovorhersage und Intervention bei kardiovaskulären Erkrankungen/C-Reactive Protein for Risk Prediction and Intervention in Cardiovascular Disease. 2003 , 27, 100-112	
1638	Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. 2003 , 23, 1116-21	105
1637	Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine. 2003 , 41, 1266-78	27
1636	Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. 2003 , 23, 1042-7	307
1635	C-reactive protein and cardiovascular disease: new insights from an old molecule. 2003 , 96, 793-807	173
1634	New definitions in cardiovascular risk management: is it time for angiotensin II receptor blockers to become first-line medication?. 2003 , 5, F3-F11	1
1633	Women--a neglected risk group for atherosclerosis and vascular disease. 2003 , 37, 3-12	10
1632	C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. 2003 , 18, 1039-41	11
1631	Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. 2003 , 23, 695-701	96
1630	Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. 2003 , 108, 1428-31	132
1629	Editorial comment--C-reactive protein and vascular risk in stroke patients: potential use for the future. 2003 , 34, 2468-70	3
1628	Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. 2003 , 34, 2922-9	96
1627	A Look at Infectious Agents as a Possible Causative Factor in Cardiovascular Disease: Part I. 2003 , 34, 203-212	6
1626	Why is coronary heart disease of uraemic patients so frequent and so devastating?. 2003 , 18, 631-40	36

1625	[Cardiovascular risk factors in women]. 2003 , 128, 1659-64	2
1624	CD40 ligand--assessing risk instead of damage?. <i>New England Journal of Medicine</i> , 2003 , 348, 1163-5	59.2 34
1623	Novel Biomedical Risk Markers for Cardiovascular Disease. 2003 , 10, 41-55	2
1622	Laboratory assessment of the acute phase response: using CRP as a model. 2003 , 225, 343-52	2
1621	Platelet activation, inflammatory mediators and hypercholesterolemia. 2003 , 1, 157-69	57
1620	Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques: the Copenhagen City Heart Study. 2003 , 24, 567-76	52
1619	Risk assessment in cardiovascular disease: from traditional risk factors to genomics. 2003 , 5, F48-F55	0
1618	Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". 2003 , 76, 891-9	125
1617	C-reactive protein: a novel marker of cardiovascular risk. 2003 , 11, 169-79	43
1616	Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. 2003 , 21, 1841-6	106
1615	Lipid metabolism: inflammatory-immune responses in atherosclerosis. 2003 , 14, 337-9	4
1614	n-3 Polyunsaturated fatty acids, inflammation and obesity-related disease. 2003 , 62, 447-53	89
1613	Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. 2003 , 163, 33-40	114
1612	C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. 2003 , 32, 210-4	69
1611	Obesity and heart failure. 2003 , 18, 360-6; quiz 367-8	19
1610	. 2003 , 10, 41-55	10
1609	Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. 2003 , 18, 471-8	68
1608	. 2003 , 10, 169-179	49

1607	Inflammatory biomarkers of the patient with myocardial insufficiency. 2003 , 9, 369-74	8
1606	Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. 2003 , 17 Suppl 1, S96-122	25
1605	Seroprevalence of Antibodies to Chlamydia pneumoniae in Women With Preeclampsia. 2003 , 101, 221-226	21
1604	Joint effect of hostility and severity of depressive symptoms on plasma interleukin-6 concentration. 2003 , 65, 523-7	93
1603	hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation. 2003 , 5, 2-7	40
1602	What price support? Ventricular assist device induced systemic response. 2003 , 49, 518-26	19
1601	C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?. 2003 , 21, 1787-803	133
1600	Gender-specific implications for cardiovascular medication use in the elderly optimizing therapy for older women. 2003 , 11, 275-98	28
1599	Novel Serum Cardiac Risk Biomarkers: Risk Assessment for Primary Prevention. 2003 , 6, 121-128	
1598	Body mass index, but not physical activity, is associated with C-reactive protein. 2003 , 35, 1160-6	91
1597	Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. 2003 , 23, 1576-82	97
1596	Periodontal Disease and the Cardiovascular System. 2003 , 179-200	1
1595	The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. 2003 , 163, 1323-8	87
1594	Cardiac Involvement in Rheumatoid Arthritis. 2003 , 121-143	
1593	Association between depression and elevated C-reactive protein. 2003 , 65, 347-56	245
1592	The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. 2003 , 3, 3-13	59
1591	C-reactive protein is independently associated with fasting insulin in nondiabetic women. 2003 , 23, 650-5	161
1590	Inflammation in uremic patients: what is the link?. 2003 , 26, 65-75	11

1589	Real or apparent ethnic differences in cellular adhesion molecule activity?. 2003 , 104, 559-60	
1588	C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. 2003 , 163, 93-9	242
1587	An association between an antibody against Chlamydia pneumoniae and ischemic stroke in elderly Japanese. 2003 , 42, 571-5	11
1586	Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women. 2003 , 77, 37-42	105
1585	Long-term combined supplementations with alpha-tocopherol and vitamin C have no detectable anti-inflammatory effects in healthy men. 2003 , 133, 1170-3	54
1584	Lipopolysaccharide-Induced Immunostimulation Produces A Dose- and Time-Dependent Decrease in General Activity and Weight Gain in Preweanling Rats. 2003 , 53, 253-267	
1583	Inflammation and vascular endothelial activation in an Aboriginal population: relationships to coronary disease risk factors and nutritional markers. 2003 , 178, 495-500	64
1582	Epidemiology of Cardiac and Respiratory Diseases. 7-23	
1581	High-pressurized orange juice consumption affects plasma vitamin C, antioxidative status and inflammatory markers in healthy humans. 2003 , 133, 2204-9	69
1580	Dose Dependent Changes of Lipid Profiles, IL-6 and CRP in Unstable Angina Patients after Simvastatin Therapy. 2003 , 33, 663	4
1579	C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?. 2003 , 285, R1250-2	29
1578	Estrogen and stroke: a balanced analysis. 2003 , 34, 338-41	117
1577	Atherosclerosis and Inflammation. 2003 , 33-61	1
1576	Plasma levels of soluble thrombomodulin, C-reactive protein, and serum amyloid A protein in the atherosclerotic coronary circulation. 2003 , 44, 601-12	24
1575	Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. 2003 , 26, 691-7	87
1574	Correlation between turbidimetric and nephelometric methods of measuring C-reactive protein in patients with unstable angina or non-ST elevation acute myocardial infarction. 2003 , 81, 133-6, 129-32	8
1573	Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. 2003 , 90, 124-131	76
1572	Investigation and Treatment of Subclinical Coronary Atherosclerosis. 2003 , 3, 97-106	

1571 Effects of Statins on C-Reactive Protein: Are All Statins Similar?. **2004**, 189-201

1570 Statins, Inflammation, and C-Reactive Protein. **2004**, 219-232

1569 Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. **2004**, 96, 143-8 27

1568 Predictors of atherosclerosis. **2004**, 11, 265-70 51

1567 Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway. **2004**, 19, 131-42 41

1566 Effect of insulin therapy on nonglycemic variables during acute illness. **2004**, 10 Suppl 2, 63-70 19

1565 C-reactive protein and peripheral artery disease among Japanese elderly: the Tsurugaya Project. **2004**, 27, 955-61 34

1564 Vasculature, Vascular Disease, and Atherosclerosis. **2004**, 39-55

1563 C-Reactive Protein as a Marker for Cardiovascular Disease. **2004**, 39, 735-744 1

1562 C-reactive protein and atherosclerosis of the thoracic aorta: a population-based transesophageal echocardiographic study. **2004**, 164, 1781-7 21

1561 Low plasma vitamin B-6 concentrations and modulation of coronary artery disease risk. **2004**, 79, 992-8 94

1560 Serum albumin predicts cardiac adverse events in patients with advanced atherosclerosis - interrelation with traditional cardiovascular risk factors. **2004**, 91, 610-8 25

1559 [Vascular risk factors and renal failure]. **2004**, 20, 1100-3 3

1558 Plasma C-reactive protein levels among children with sleep-disordered breathing. **2004**, 113, e564-9 215

1557 Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers. **2004**, 6, C21-C27 5

1556 Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. **2004**, 35, 1625-30 44

1555 Relation between C reactive protein concentrations and coronary microvascular endothelial function. **2004**, 90, 750-4 63

1554 Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. **2004**, 112, 378-82 99

1553	A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. 2004 , 291, 2221-8	197
1552	Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index. 2004 , 89, 5713-7	36
1551	Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. 2004 , 35, 163-8	141
1550	Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. 2004 , 89, 2114-8	78
1549	Durability of glycemic control: a feature of the thiazolidinediones. 2004 , 6, 179-89	4
1548	Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. 2004 , 24, 613-21	37
1547	Estrogen regulation of growth hormone action. 2004 , 25, 693-721	354
1546	Gender difference in C-reactive protein concentrations in individuals with atherothrombotic risk factors and apparently healthy ones. 2004 , 9, 85-92	31
1545	C-reactive protein, cardiovascular disease and stroke: new roles for an old biomarker. 2004 , 4, 507-18	7
1544	Inflammation as a cardiovascular risk factor. 2004 , 109, 112-10	670
1543	Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. 2004 , 63, 31-5	191
1542	Serum amyloid A, C-reactive protein and remnant-like lipoprotein particle cholesterol in type 2 diabetic patients with coronary heart disease. 2004 , 41, 125-9	11
1541	Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. 2004 , 53, 701-10	287
1540	The role of aspirin in cardiovascular diseases--forgotten benefits?. 2004 , 5, 109-15	16
1539	Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. 2004 , 109, 2613-6	62
1538	Are patients with asthma at increased risk of coronary heart disease?. 2004 , 33, 743-8	92
1537	Sudden unexpected death in heart failure may be preceded by short term, intraindividual increases in inflammation and in autonomic dysfunction: a pilot study. 2004 , 90, 1263-8	30
1536	C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. 2004 , 95, 877-83	122

1535	The effect of different doses of micronized 17beta-estradiol on C-reactive protein, interleukin-6, and lipids in older women. 2004 , 59, 827-32	45
1534	New risk factors for atherosclerosis and patient risk assessment. 2004 , 109, III15-9	181
1533	Role of C-reactive protein in cardiovascular disease. 2004 , 38, 110-8	50
1532	Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. 2004 , 43, 947-51	66
1531	Homozygous familial hyperlipidaemia presenting as severe aortic stenosis and unstable angina. 2004 , 90, 1285	2
1530	Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins. 2004 , 24, 577-82	36
1529	The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. 2004 , 27, 2682-8	39
1528	C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. 2004 , 109, 647-55	328
1527	Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. 2004 , 109, 2818-25	508
1526	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. 2004 , 110, e568-71	42
1525	Septicemia in the United States dialysis population, 1991 to 1999. 2004 , 15, 1038-45	125
1524	Plasma cGMP and large artery remodeling in asymptomatic men. 2004 , 44, 919-23	11
1523	Dyslipidemia and the metabolic syndrome. 2004 , 27, 3009-16	16
1522	Chapter 2 Primary Prevention of Stroke by Modification of Selected Risk Factors. 2004 , 29, 5-54	
1521	The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. 2004 , 89, 6061-7	82
1520	Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals. 2004 , 109, 2405-10	19
1519	White blood cell count and C-reactive protein predict short-term prognosis in acute myocardial infarction. 2004 , 32, 646-54	7
1518	Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). 2004 , 109, 726-32	319

1517	Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. 2004 , 43, 731-6	33
1516	Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. 2004 , 43, 297-305	124
1515	The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. 2004 , 62, 105-11	204
1514	Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. 2004 , 109, 2518-23	282
1513	The search for the "holy grail" of clinically significant coronary atherosclerosis. 2004 , 164, 1266-8	1
1512	Insulin resistance and cardiovascular disease: the role of PPARGgamma activators beyond their anti-diabetic action. 2004 , 1, 76-81	16
1511	Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. 2004 , 110, 540-5	140
1510	Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. 2004 , 110, 803-9	151
1509	Prevalence of high C-reactive protein in persons with serum lipid concentrations within recommended values. 2004 , 50, 1618-22	18
1508	Variability of serum soluble intercellular adhesion molecule-1 measurements attributable to a common polymorphism. 2004 , 50, 2185-7	33
1507	C-reactive protein and white blood cell count increases in the first 24 hours after acute stroke. 2004 , 18, 214-9	53
1506	Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. 2004 , 62, 283-7	25
1505	C-reactive protein: structure affects function. 2004 , 109, 1914-7	85
1504	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the population science discussion group. 2004 , 110, e554-9	54
1503	C-reactive protein modifies the relationship between blood pressure and microalbuminuria. 2004 , 43, 791-6	74
1502	Fatty acids and the immune system: from basic science to clinical applications. 2004 , 63, 89-104	92
1501	Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. 2004 , 89, 2160-5	223
1500	CRP and risk of coronary heart disease: can exercise training cool down the flames?. 2004 , 24, 1743-5	7

1499	Addressing cardiovascular disease in women: focus on dyslipidemia. 2004 , 17, 424-37	32
1498	Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. 2004 , 109, 580-6	144
1497	The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. 2004 , 15, 538-48	138
1496	C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. 2004 , 109, 2058-67	460
1495	Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of high-sensitivity C-reactive protein. 2004 , 126, 1032-9	36
1494	Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. 2004 , 27, 2960-5	105
1493	The pro- and anti-inflammatory markers in patients with acute myocardial infarction and chronic stable angina. 2004 , 14, 317	6
1492	Finding vulnerable atherosclerotic plaques: is it worth the effort?. 2004 , 24, 1775-82	67
1491	Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. 2004 , 109, 1955-9	378
1490	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. 2004 , 110, e550-3	86
1489	Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. 2004 , 35, 677-81	76
1488	Leukocyte count as an independent predictor of recurrent ischemic events. 2004 , 35, 1147-52	221
1487	Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. 2004 , 35, 1619-24	165
1486	Prospective study of major dietary patterns and stroke risk in women. 2004 , 35, 2014-9	183
1485	Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. 2004 , 25, 1029-35	30
1484	Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. 2004 , 19, 2810-5	36
1483	High-density lipoproteins neutralize C-reactive protein proinflammatory activity. 2004 , 109, 2116-22	129
1482	Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. 2004 , 109, IV6-19	246

1481	Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with FcγRIIIa. 2004 , 24, 2372-7	41
1480	C-reactive protein increases oxygen radical generation by neutrophils. 2004 , 9, 203-9	46
1479	Results of blood inflammatory markers are associated more strongly with toe-brachial index than with ankle-brachial index in patients with type 2 diabetes. 2004 , 27, 1381-6	24
1478	Inflammation and glucose intolerance: a prospective study of gestational diabetes mellitus. 2004 , 27, 21-7	115
1477	C-reactive protein: risk marker or mediator in atherothrombosis?. 2004 , 44, 6-11	442
1476	Low cardiorespiratory fitness is associated with elevated C-reactive protein levels in women with type 2 diabetes. 2004 , 27, 320-5	46
1475	Inflammation as a possible link between coronary and carotid plaque instability. 2004 , 109, 3158-63	173
1474	Periodontal disease and biomarkers related to cardiovascular disease. 2004 , 83, 151-5	153
1473	Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. 2004 , 110, 2952-67	681
1472	Metabolic syndrome, a cardiovascular disease risk factor: role of adipocytokines and impact of diet and physical activity. 2004 , 29, 808-29	46
1471	Biomarkers of cardiac disease. 2004 , 4, 805-20	21
1470	Total Abdominal Hysterectomy May Be a Risk Factor for Acute Myocardial Infarction in Postmenopausal Women: An Age-Matched, Case-Controlled Retrospective Analysis. 2004 , 20, 75-80	1
1469	Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. 2004 , 110, 1103-7	353
1468	Autoimmune and inflammatory mechanisms in atherosclerosis. 2004 , 22, 361-403	344
1467	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. 2004 , 110, e545-9	186
1466	Asymptotic dental score and prevalent coronary heart disease. 2004 , 109, 1095-100	76
1465	Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation?. 2004 , 24, 628-36	80
1464	IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. 2004 , 24, 1503-8	150

1463	Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in postmenopausal women. 2004 , 24, e164-7	27
1462	Increased high sensitivity C reactive protein concentrations and increased arterial stiffness in children with a history of Kawasaki disease. 2004 , 90, 1281-5	54
1461	CARDIOVASCULAR SYSTEMIC LUPUS ERYTHEMATOSUS. 2004 , 913-942	1
1460	Association between air pollution exposure and exhaled nitric oxide in an elderly population. 2004 , 59, 204-9	81
1459	C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. 2004 , 24, 1509-15	148
1458	Highly sensitive determination of C-reactive protein on the Innotracc Aio! immunoanalyzer. 2004 , 64, 677-85	11
1457	Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. 2004 , 18, 341-8	18
1456	Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. 2004 , 6, 249-58	117
1455	Lack of concordance between plasma markers of cardiovascular risk and intima-media thickness in patients with type 2 diabetes. 2004 , 6, 69-77	20
1454	Higher carotid-radial pulse wave velocity in healthy offspring of patients with Type 2 diabetes. 2004 , 21, 262-6	27
1453	C-reactive protein and risk factors for peripheral vascular disease in subjects with Type 2 diabetes mellitus. 2004 , 21, 336-41	26
1452	Strong association of C-reactive protein with body mass index and 2-h post-challenge glucose in non-diabetic, non-smoker subjects without hypertension. 2004 , 21, 581-5	37
1451	Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk. 2004 , 61, 387-93	28
1450	Correlations of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. 2004 , 61, 753-9	50
1449	Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. 2004 , 61, 760-7	18
1448	Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. 2004 , 256, 119-27	62
1447	Inflammatory markers and heart rate variability in women with coronary heart disease. 2004 , 256, 421-8	72
1446	Rationale, design and methods of the CASHMERE study. 2004 , 18, 131-8	14

1445	Effects of oestrogen replacement therapy on serum C-reactive protein levels in hysterectomised women. 2004 , 44, 131-4	5
1444	Physical activity, exercise, and inflammatory markers in older adults: findings from the Health, Aging and Body Composition Study. 2004 , 52, 1098-104	336
1443	The relationship between tomato intake and congestive heart failure risk in periodontitis subjects. 2004 , 31, 574-80	28
1442	Poor oral health is associated with coronary heart disease and elevated systemic inflammatory and haemostatic factors. 2004 , 31, 25-9	88
1441	Long-term effects of a high-protein, low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects. 2004 , 28, 661-70	177
1440	Elevated sialic acid, but not CRP, predicts features of the metabolic syndrome independently of BMI in women. 2004 , 28, 1004-10	27
1439	Markers of increased cardiovascular risk: are we measuring the most appropriate parameters?. 2004 , 12 Suppl 2, 107S-14S	16
1438	C-reactive protein as a marker for inflammatory bowel disease. 2004 , 10, 661-5	319
1437	The epidemiology of central fat distribution in relation to disease. 2004 , 62, S120-6	98
1436	C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. 2004 , 4, 1148-54	53
1435	Anti-inflammatory nature of exercise. 2004 , 20, 323-6	87
1434	Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. 2004 , 34, 585-92	273
1433	Epidemiology of coronary heart disease in women. 2004 , 46, 287-95	127
1432	Markers of cardiac ischemia, injury, and inflammation. 2004 , 46, 404-16	14
1431	The concomitant presence of polymorphic alleles of interleukin-1beta, interleukin-6 and apolipoprotein E is associated with an increased risk of myocardial infarction in elderly men. Results from a pilot study. 2004 , 125, 575-9	16
1430	Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. 2004 , 43, 61-6	129
1429	Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?. 2004 , 43, 471-8	60
1428	Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. 2004 , 43, 1047-55	85

1427	High-sensitivity C-reactive protein: Clinical importance. 2004 , 29, 439-493	14
1426	Comorbidity assessment in localized prostate cancer: a review of currently available techniques. 2004 , 46, 28-41; discussion 41	23
1425	The IL-6 -174G>C polymorphism is associated with cardiovascular diseases and mortality in 80-year-old humans. 2004 , 39, 255-61	42
1424	Plasma homocysteine and inflammation in elderly patients with cardiovascular disease and dementia. 2004 , 39, 443-50	19
1423	Effect of physical activity on serum C-reactive protein. 2004 , 93, 221-5	135
1422	C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). 2004 , 93, 1238-42	197
1421	Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women. 2004 , 94, 1205-8	11
1420	Vascular disease and inflammation. 2004 , 22, 183-97, v	1
1419	Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women. 2004 , 57, 190-4	114
1418	Evidence for C-reactive protein's role in (CRP) vascular disease: atherothrombosis, immuno-regulation and CRP. 2004 , 17, 95-105	47
1417	Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies. 2004 , 4, 243-60	29
1416	HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure. 2004 , 4, 303-16	31
1415	Postmenopausal hormone replacement and cardiovascular disease: incorporating research into practice. 2004 , 33, 648-56	
1414	The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. 2004 , 14, 589-600	342
1413	Racial disparity in infant and maternal mortality: confluence of infection, and microvascular dysfunction. 2004 , 8, 45-54	35
1412	Assessing coronary heart disease risk with traditional and novel risk factors. 2004 , 27, III7-11	33
1411	The effect of medical treatment on the level of C-Reactive protein and leukocyte count in patients with congestiveheart failure. 2004 , 13, 168-172	
1410	Inflammation and cardiovascular risk: An overview. 2004 , 13, 161-167	2

1409	Serum carotenoids and vitamins in relation to markers of endothelial function and inflammation. 2004 , 19, 915-21	96
1408	Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin. 2004 , 19, 257-62	26
1407	[Atherosclerosis and arteriitis: implications for therapy of cardiovascular disease]. 2004 , 29, 4-11	9
1406	[Rheumatoid arthritis, inflammation, and atherosclerosis]. 2004 , 29, 760-8	25
1405	[Acute coronary syndrome and inflammation. Biomarkers for diagnostics and risk stratification]. 2004 , 29, 769-76	8
1404	Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. 2004 , 6, 243-50	58
1403	Postprandial lipid oxidation and cardiovascular disease risk. 2004 , 6, 477-84	54
1402	Individualizing therapy in acute coronary syndromes: using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy. 2004 , 6, 273-8	12
1401	Cardiovascular risk associated with the metabolic syndrome. 2004 , 4, 63-8	72
1400	Treatment of PCOS with metformin and other insulin-sensitizing agents. 2004 , 4, 69-75	31
1399	Nutrition and the endothelium. 2004 , 4, 253-9	25
1398	Heritability of C-reactive protein and association with apolipoprotein E genotypes in Japanese Americans. 2004 , 68, 179-88	49
1397	Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. 2004 , 51, 451-7	61
1396	Cardiovascular risk factors in women with and without rheumatoid arthritis. 2004 , 50, 3444-9	163
1395	High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. 2004 , 39, 1458-9	48
1394	Long-term outcome of hepatitis C in children. 2004 , 39, 1455; author reply 1455-6	7
1393	Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. 2004 , 39, 1456-7; author reply 1457-8	34
1392	Reply. 2004 , 39, 1457-1458	4

1391	Evolution of intrapulmonary vascular dilatations in cirrhosis. 2004 , 39, 1454	4
1390	Reply. 2004 , 39, 1455-1456	5
1389	Comparative study of cardiovascular markers data by various techniques of multivariate analysis. 2004 , 72, 259-267	6
1388	Th1/Th2 cells in inflammatory disease states: therapeutic implications. 2004 , 4, 1887-96	67
1387	CARDIOVASCULAR SYSTEMIC LUPUS ERYTHEMATOSUS. 2004 , 913-942	1
1386	Diabetes, lipids, and adipocyte secretagogues. 2004 , 82, 170-90	100
1385	Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. 2004 , 159, 882-90	861
1384	Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. 2004 , 109, 118-26	364
1383	Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. 2004 , 24, 2227-36	215
1382	Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation. 2004 , 23, 141-7	63
1381	La inflamaci3n en los s3ndromes coronarios agudos: mecanismos e implicaciones cl3nicas. 2004 , 57, 433-446	19
1380	The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. 2004 , 15, 2792-800	680
1379	Inflamaci3n, disfunci3n endotelial e hipertensi3n arterial. 2004 , 21, 347-354	
1378	Gu3as para el tratamiento de las dislipemias en el adulto: Adult Treatment Panel III (ATP-III). 2004 , 51, 254-265	5
1377	Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. 2004 , 39, 1178-85	148
1376	Management of metabolic syndrome: aspirin. 2004 , 33, 577-93, vii	17
1375	Inflammation in Acute Coronary Syndromes: Mechanisms and Clinical Implications. 2004 , 57, 433-446	3
1374	The acute phase response and atherosclerosis. 2004 , 1, 17-22	9

1373	Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. 2004 , 43, 169-75	78
1372	Reduction in C-reactive protein through cardiac rehabilitation and exercise training. 2004 , 43, 1056-61	241
1371	Heritability and correlates of intercellular adhesion molecule-1 in the Framingham Offspring Study. 2004 , 44, 168-73	44
1370	The Yin and Yang of arterial inflammation. 2004 , 44, 50-2	37
1369	Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. 2004 , 44, 972-9	225
1368	A novel technique to assess flow-mediated vasodilation. 2004 , 44, 1478-80	0
1367	The cardiovascular effects of chronic hypoestrogenism in amenorrhoeic athletes: a critical review. 2004 , 34, 601-27	31
1366	Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. 2004 , 3, 105-15	19
1365	C-reactive protein is a significant predictor of vascular calcification of both aorta and hand arteries. 2004 , 24, 408-12	28
1364	Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. 2004 , 27, 1721-7	142
1363	Inflammatory markers and the risk of coronary heart disease in men and women. <i>New England Journal of Medicine</i> , 2004 , 351, 2599-610	59.2 899
1362	Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. 2004 , 27, 813-23	1001
1361	Immunopathogenesis of atherosclerosis. 2004 , 76, 300-6	19
1360	C-reactive protein and red cell aggregation correlate with late venous function after acute deep venous thrombosis. 2004 , 40, 644-9	21
1359	Quality specifications and the assessment of the biochemical risk of atherosclerosis. 2004 , 346, 55-64	11
1358	Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. 2004 , 346, 119-28	32
1357	The influence of tumor necrosis factor -308 and C-reactive protein G1059C gene variants on serum concentration of C-reactive protein: evidence for an age-dependent association. 2004 , 349, 129-34	28
1356	Inflammatory markers and coronary artery disease. 2004 , 4, 124-31	29

1355	Mild renal insufficiency as a cardiovascular risk factor in non-proteinuric type II diabetes. 2004 , 64, 191-9	8
1354	Acute-phase proteins and microalbuminuria among patients with type 2 diabetes. 2004 , 66, 31-9	25
1353	Serum high sensitivity C-reactive protein is associated with carotid intima-media thickness in type 2 diabetes. 2004 , 66 Suppl 1, S115-20	28
1352	Proinflammatory parameters as CRP and IL-6 do not discriminate between post-PCI cardiac patients with and without exercise-induced ischemia as indicated by Tl-201 myocardial scintigraphy. 2004 , 13, 299-305	
1351	Socioeconomic status and stress-induced increases in interleukin-6. 2004 , 18, 281-90	152
1350	C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemo-cytokines in human endothelial progenitor cells. 2004 , 321, 65-71	69
1349	ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. 2004 , 325, 532-40	63
1348	Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. 2004 , 15, 66-72	46
1347	Cardiovascular risk factors in Mexican-American children at risk for type 2 diabetes mellitus (T2DM). 2004 , 34, 290-9	16
1346	Effect of diet and exercise intervention on inflammatory and adhesion molecules in postmenopausal women on hormone replacement therapy and at risk for coronary artery disease. 2004 , 53, 377-81	99
1345	Body fat is the main predictor of fibrinogen levels in healthy non-obese men. 2004 , 53, 984-8	18
1344	Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. 2004 , 53, 693-9	50
1343	Discrimination ratio analysis of inflammatory markers: implications for the study of inflammation in chronic disease. 2004 , 53, 899-903	33
1342	Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys. 2004 , 53, 1121-5	17
1341	Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. 2004 , 53, 1436-42	70
1340	To what extent are the effects of diet on coronary heart disease lipid-mediated?. 2004 , 95, 35-8	11
1339	Vascular effects of diet and statin in hypercholesterolemic patients. 2004 , 95, 185-91	40
1338	High-sensitivity C-reactive protein concentration in a healthy Brazilian population. 2004 , 97, 433-8	12

1337	Leukocyte count predicts outcome after ischemic stroke: the Northern Manhattan Stroke Study. 2004 , 13, 220-7	72
1336	Effects of progestins on estrogen-induced increase in C-reactive protein in postmenopausal women. 2004 , 49, 315-20	12
1335	C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. 2004 , 62, 499-506	167
1334	Peripheral inflammatory and fibrinolytic markers in adolescents with growth hormone deficiency: relation to postprandial dyslipidemia. 2004 , 145, 657-61	30
1333	Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. 2004 , 147, 931-8	146
1332	Cardiovascular effects of raloxifene: the arterial and venous systems. 2004 , 147, 783-9	36
1331	Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. 2004 , 148, 34-40	120
1330	High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. 2004 , 148, S19-26	188
1329	Glaucoma risk factor assessment and prevention: lessons from coronary heart disease. 2004 , 138, S11-8	21
1328	Correlation between cardiovascular disease and diabetes mellitus: current concepts. 2004 , 116 Suppl 5A, 11S-22S	125
1327	Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. 2004 , 116 Suppl 6A, 9S-16S	428
1326	C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. 2004 , 117, 499-507	122
1325	Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. 2004 , 117, 390-7	73
1324	Hormone replacement therapy in postmenopausal women. 2004 , 188, 136-49	27
1323	Statin-induced immunomodulatory effects on human T cells in vivo. 2004 , 175, 83-90	95
1322	Diet for preventing cardiovascular diseases: light from Ancel Keys, distinguished centenarian scientist. 2004 , 14, 52-7	20
1321	The metabolic syndrome and inflammation: association or causation?. 2004 , 14, 228-32	145
1320	HIV infection, HAART, and endothelial adhesion molecules: current perspectives. 2004 , 4, 213-22	114

1319	Effects of acute stress, relaxation, and a neurogenic inflammatory stimulus on interleukin-6 in humans. 2004 , 18, 55-64	31
1318	C-reactive protein and body mass index in women with pre-eclampsia. 2004 , 84, 75-6	3
1317	Inflammatory gene load is associated with enhanced inflammation and early carotid atherosclerosis in smokers. 2004 , 35, 2438-43	67
1316	Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy. 2004 , 172, 121-5	20
1315	Alcohol consumption and inflammatory markers in older adults: the Cardiovascular Health Study. 2004 , 173, 79-87	53
1314	A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. 2004 , 174, 349-56	63
1313	Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL. 2004 , 176, 37-44	64
1312	Association between leisure time physical activity and markers of chronic inflammation related to coronary heart disease. 2004 , 176, 303-10	66
1311	IL-6 and the acute phase response in murine atherosclerosis. 2004 , 177, 43-51	59
1310	Homocysteine as a risk factor for coronary heart diseases and its association with inflammatory biomarkers, lipids and dietary factors. 2004 , 177, 375-81	69
1309	Do pregnancy complications and CVD share common antecedents?. 2004 , 5, 3-7	57
1308	Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. 2004 , 81, 1624-31	12
1307	Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. 2004 , 134, 1806-11	271
1306	Dietary fiber and C-reactive protein: findings from national health and nutrition examination survey data. 2004 , 134, 1181-5	203
1305	Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. 2004 , 80, 1029-35	594
1304	New clinical markers predictive of cardiovascular disease: the role of inflammatory mediators. 2004 , 12, 151-7	13
1303	Association of fear of terror with low-grade inflammation among apparently healthy employed adults. 2004 , 66, 484-91	36
1302	Substitution of transdermal estradiol during oral estrogen-progestin therapy in postmenopausal women: effects on hypertriglyceridemia. 2004 , 11, 331-6	24

1301	C-reactive protein is associated with psychological risk factors of cardiovascular disease in apparently healthy adults. 2004 , 66, 684-91	116
1300	C-reactive protein for the prediction of cardiovascular risk: ready for prime-time?. 2004 , 170, 1563-5	6
1299	CE Test: Predicting CAD Events. 2004 , 29, 27-29	2
1298	The concomitant presence of polymorphic alleles of interleukin-1 β interleukin-6 and apolipoprotein E is associated with an increased risk of myocardial infarction in elderly menResults from a pilot study. 2004 , 125, 575-579	37
1297	Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. 2004 , 164, 440-6	53
1296	Management of the acute coronary syndrome patient. 2004 , 6, C49-C57	
1295	Is Dressler syndrome dead?. 2004 , 126, 1680-2	32
1294	C-reactive protein: a surrogate marker for atherosclerosis. 2004 , 15, 365-7	2
1293	Markers of myocardial injury and dysfunction. 2004 , 15, 547-57	8
1292	Predicting CAD events: C-reactive protein a marker for atherosclerotic risk. 2004 , 29, 14-5, 19-27; quiz 27-9	1
1291	Paraoxonase, a cardioprotective enzyme: continuing issues. 2004 , 15, 261-7	124
1290	Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. 2004 , 16, 18-24	38
1289	New blood test to measure heart attack risk: C-reactive protein. 2004 , 19, 425-9	5
1288	Metabolic syndrome: the new cardiovascular target. 2004 , 15, 1-3	1
1287	Cardiovascular risk factors in Mexican-American children at risk for type 2 diabetes mellitus (T2DM). 2004 , 34, 290-299	15
1286	Association between C-reactive protein and hypertension in healthy middle-aged men and women. 2004 , 15, 331-6	45
1285	Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. 2004 , 125, 1610-5	38
1284	Religious participation, interleukin-6, and mortality in older adults. 2004 , 23, 465-75	103

1283	Effects of oxidative stress on endothelial function after a high-fat meal. 2004 , 106, 315-9	147
1282	Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes. 2004 , 68, 628-33	11
1281	High-sensitivity C-reactive protein: Clinical importance. 2004 , 29, 439-493	30
1280	The use of very-low-calorie diets (VLCDs) and meal replacements for weight control. 2005 , 379-411	
1279	Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. 2005 , 135, 562-6	389
1278	Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production. 2005 , 82, 1260-8; quiz 1365-6	104
1277	Are a Single Measurement of Troponin-I and C-Reactive Protein of Clinical Significance in Patients with Acute Coronary Syndromes?. 2005 , 11-16	
1276	Estrogen, the Cerebrovascular System, and Dementia. 2005 , 99-112	
1275	Autonomic dysfunction in children with sleep-disordered breathing. 2005 , 28, 747-52	114
1274	Pretransplant pregnancy-associated plasma protein-a as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events. 2005 , 80, 1441-6	25
1273	Endothelial dysfunction in trauma patients: a preliminary communication. 2005 , 24, 210-3	12
1272	Association between C-reactive protein and insulin resistance in a Japanese population: the Minoh Study. 2005 , 44, 542-7	29
1271	Subclinical hypothyroidism may be associated with elevated high-sensitive c-reactive protein (low grade inflammation) and fasting hyperinsulinemia. 2005 , 52, 89-94	113
1270	C-reactive protein levels in non-obese pregnant women with gestational diabetes. 2005 , 206, 341-5	20
1269	Stroke: background, epidemiology, etiology and avoiding recurrence. 2005 , 1-46	
1268	Production of modified C-reactive protein in U937-derived macrophages. 2005 , 230, 762-70	48
1267	Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. 2005 , 2, 423-30	49
1266	Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. 2005 , 14, 33-7	110

1265	Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine. 2005 , 12, 92-8	14
1264	Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering. 2005 , 16, 415-22	9
1263	Putting cardiovascular disease and vitamin D insufficiency into perspective. 2005 , 94, 483-92	306
1262	Cross-sectional study of complement C3 as a coronary risk factor among men and women. 2005 , 108, 129-35	53
1261	Serum concentrations of high-sensitivity C-reactive protein predict progressively obstructive lesions rather than late restenosis in patients with unstable angina undergoing coronary artery stenting. 2005 , 69, 1202-7	15
1260	Association of inflammatory marker and highly sensitive C-reactive protein with aerobic exercise capacity, maximum oxygen uptake and insulin resistance in healthy middle-aged volunteers. 2005 , 69, 452-7	49
1259	Cardiovascular risk factors in hemodialysis patients: results from baseline data of kaleidoscopic approaches to patients with end-stage renal disease study. 2005 , 15, 96-105	15
1258	Quels critères le rhumatologue doit-il connaître et utiliser pour suivre une polyarthrite rhumatoïde?. 2005 , 72, 207-212	
1257	Comparative study of two automated high-sensitivity C-reactive protein methods in a large population. 2005 , 38, 31-5	20
1256	Relationship of beta2-microglobulin to arterial stiffness in Japanese subjects. 2005 , 28, 505-11	43
1255	[Cardiovascular manifestations in inflammatory rheumatic diseases]. 2005 , 64, 12-7	1
1254	Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. 2005 , 97, e53-9	278
1253	Inflammation, atherosclerosis, and coronary artery disease. <i>New England Journal of Medicine</i> , 2005 , 352, 1685-95	59.2 6348
1252	Associations between C-reactive protein and circulating cell adhesion molecules in patients with unstable angina undergoing coronary intervention and their clinical implication. 2005 , 28, 47-51	11
1251	High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. 2005 , 28, 408-12	59
1250	The effect of weight loss on a stable biomarker of inflammation, C-reactive protein. 2005 , 63, 22-8	80
1249	Systemic associations of retinal microvascular signs: a review of recent population-based studies. 2005 , 25, 195-204	78
1248	Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions. 2005 , 3, 897-908	46

1247	Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. 2005 , 3, 1618-27	149
1246	Management of dyslipidemia in women in the post-hormone therapy era. 2005 , 20, 297-305	7
1245	Interleukin-6 modulates plasma cholesterol and C-reactive protein concentrations in nonagenarians. 2005 , 53, 1552-8	15
1244	Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. 2005 , 68, 2787-93	43
1243	Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects. 2005 , 7, 729-36	42
1242	Usefulness of total cholesterol/HDL-cholesterol ratio in the management of diabetic dyslipidaemia. 2005 , 22, 26-31	28
1241	Association of C-reactive protein with body fat, diabetes and coronary artery disease in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-6). 2005 , 22, 863-70	47
1240	Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. 2005 , 22, 999-1004	92
1239	Should we quantify insulin resistance in patients with renal disease?. 2005 , 10, 599-605	24
1238	Elevated serum interleukin-18 levels might reflect the high risk of hospitalization in patients on peritoneal dialysis. 2005 , 10, 576-82	19
1237	Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. 2005 , 35, 331-5	72
1236	Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. 2005 , 257, 100-9	173
1235	Prognostic value of erythrocyte sedimentation rate in ST segment elevation myocardial infarction: interaction with hyperglycaemia. 2005 , 257, 423-9	13
1234	SLE, atherosclerosis and cardiovascular disease. 2005 , 257, 485-95	95
1233	Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. 2005 , 258, 145-52	39
1232	Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: The Cardiovascular Risk in Young Finns Study. 2005 , 258, 428-34	60
1231	Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. 2005 , 62, 228-35	33
1230	The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. 2005 , 63, 203-6	55

1229	Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. 2005 , 63, 428-36	54
1228	Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. 2005 , 63, 493-8	49
1227	Gestational diabetes mellitus is associated with increased C-reactive protein concentrations in the third but not second trimester. 2005 , 35, 752-7	25
1226	High-sensitivity C-reactive protein in Japanese patients with type 2 diabetes. 2005 , 13, 1810-6	21
1225	Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. 2005 , 4, 977-87	619
1224	Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. 2005 , 29, 766-71	133
1223	Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. 2005 , 29, 1452-6	105
1222	Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. 2005 , 19, 149-54	375
1221	Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. 2005 , 19, 429-37	43
1220	Gender-specific association between pulse pressure and C-reactive protein in a Chinese population. 2005 , 19, 293-9	9
1219	C-reactive protein, atherosclerosis and kidney function in hypertensive patients. 2005 , 19, 521-6	19
1218	Relationships of C-reactive protein, uric acid, and glomerular filtration rate to arterial stiffness in Japanese subjects. 2005 , 19, 907-13	27
1217	A network-based analysis of systemic inflammation in humans. 2005 , 437, 1032-7	1236
1216	Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. 2005 , 59, 1276-82	108
1215	Biological foundation for periodontitis as a potential risk factor for atherosclerosis. 2005 , 40, 87-95	69
1214	Periodontal health improves systemic inflammatory and haemostatic status in subjects with coronary heart disease. 2005 , 32, 188-92	95
1213	Serum antibodies to periodontal pathogens and markers of systemic inflammation. 2005 , 32, 1189-99	71
1212	Comprehensive endovascular therapy for femoropopliteal arterial atherosclerotic occlusive disease. 2005 , 201, 275-96	32

1211	Selecting criteria for monitoring patients with rheumatoid arthritis. 2005 , 72, 129-34	10
1210	Immunologic influences on emotion regulation. 2005 , 4, 325-333	17
1209	Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. 2005 , 19, 823-38	48
1208	Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. 2005 , 95, 317-21	104
1207	Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. 2005 , 96, 92-7	137
1206	Role of depression and inflammation in incident coronary heart disease events. 2005 , 96, 1016-21	82
1205	Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. 2005 , 96, 24F-33F	200
1204	Relation of low socioeconomic status to C-reactive protein in patients with coronary heart disease (from the heart and soul study). 2005 , 96, 1506-11	33
1203	Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III). 2005 , 46, 577-86	74
1202	Diet and lifestyle are associated with serum C-reactive protein concentrations in a population-based study. 2005 , 145, 41-6	54
1201	Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in Type 2 diabetic patients. 2005 , 19, 123-7	13
1200	Role of inflammation in cardiopulmonary health effects of PM. 2005 , 207, 483-8	112
1199	Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. 2005 , 25, 1365-77	7
1198	LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. 2005 , 20, 239-43	42
1197	The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern-European population-based cohort. 2005 , 21, 515-24	59
1196	Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. 2005 , 52, 2293-9	223
1195	C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. 2005 , 20, 45-9	84
1194	-717A>G polymorphism of human C-reactive protein gene associated with coronary heart disease in ethnic Han Chinese: the Beijing atherosclerosis study. 2005 , 83, 72-8	58

1193	Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study. 2005 , 48, 370-8	209
1192	The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. 2005 , 48, 1684-99	307
1191	Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis -- comparison with stable and unstable angina. 2005 , 54, 187-93	25
1190	[Obesity and osteoporosis]. 2005 , 34, 645-51	
1189	The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease. 2005 , 38, 1138-40	29
1188	The impact of laparoscopy on bariatric surgery. 2005 , 19, 621-7	24
1187	CPAP does not reduce high-sensitivity c-reactive protein in patients with coronary artery disease and obstructive sleep apnea. 2005 , 14, 129-132	4
1186	Urinary excretion of liver fatty acid-binding protein in health-check participants. 2005 , 9, 34-9	23
1185	Nonlipid-lowering effects of statins. 2005 , 7, 459-66	21
1184	Effects of the individual isomers cis-9,trans-11 vs. trans-10,cis-12 of conjugated linoleic acid (CLA) on inflammation parameters in moderately overweight subjects with LDL-phenotype B. 2005 , 40, 909-18	47
1183	Treatment of the metabolic syndrome: the impact of lifestyle modification. 2005 , 7, 95-102	36
1182	Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. 2005 , 7, 389-95	33
1181	Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. 2005 , 7, 22-8	7
1180	New benefits of statin treatment. 2005 , 5, 165; discussion 165-6	
1179	Innate immunity and inflammation in ageing: a key for understanding age-related diseases. 2005 , 2, 8	323
1178	Comparative proteome analyses of human plasma following in vivo lipopolysaccharide administration using multidimensional separations coupled with tandem mass spectrometry. 2005 , 5, 572-84	120
1177	Preexisting morbidity as an independent risk factor for perioperative acute thromboembolism syndrome. 2005 , 140, 1210-7; discussion 1218	35
1176	The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. 2005 , 81, 1257-66	84

1175	Relationship of C-reactive protein to adverse cardiovascular events in patients treated by percutaneous coronary intervention for stable angina pectoris. 2005 , 46, 195-204	9
1174	TNF-alpha, but not IL-6, stimulates plasminogen activator inhibitor-1 expression in human subcutaneous adipose tissue. 2005 , 98, 2019-23	33
1173	Analysis of Trigger Mechanisms for Inflammation in Cardiovascular Disease: Application to Shock and Multiorgan Failure. 2005 , 193-202	
1172	. 2005 ,	9
1171	Relations of plasma high-sensitivity C-reactive protein to various cardiovascular risk factors. 2005 , 20, 379-83	12
1170	Repolarization changes induced by air pollution in ischemic heart disease patients. 2005 , 113, 440-6	101
1169	The relation between hypoalbuminemia and compliance and intima-media thickness of carotid artery in continuous ambulatory peritoneal dialysis patients. 2005 , 20, 70-4	5
1168	Septicemia, Access, Cardiovascular Disease, and Death in Dialysis Patients. 2005 , 25, 534-540	17
1167	RHEUMATOID ARTHRITIS AND CARDIOVASCULAR RISK: PERSPECTIVES OF TREATMENT WITH STATINS. 2005 , 1, 47-53	1
1166	. 2005 ,	17
1165	References. 312-370	
1164	Intracellular signaling mechanisms of sex hormones in acute myocardial inflammation and injury. 2005 , 10, 1835-67	33
1163	Lipid response to a low-fat diet with or without soy is modified by C-reactive protein status in moderately hypercholesterolemic adults. 2005 , 135, 1075-9	43
1162	Potential role of ultrafine particles in associations between airborne particle mass and cardiovascular health. 2005 , 113, 934-46	654
1161	Coronary heart disease in patients with chronic kidney disease. 2005 , 16 Suppl 2, S103-6	16
1160	HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol. 2005 , 5, 441-53	37
1159	Air pollution and the heart. 2005 , 55, 439-47	30
1158	Accelerated atherosclerosis in patients with Wegener's granulomatosis. 2005 , 64, 753-9	104

1157	Evidence of age-dependent genetic influences on plasma total cholesterol. 2005 , 12, 380-6	3
1156	Air pollution and ST-segment depression in elderly subjects. 2005 , 113, 883-7	98
1155	C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. 2005 , 68, 47-55	106
1154	Fatty acids and atherosclerotic risk. 2005 , 165-94	19
1153	Complete aspiration of thrombi from an occluded coronary artery. 2005 , 91, 530	2
1152	CRP is or is not a reliable marker of ischaemic heart disease?. 2005 , 14, 752-5	1
1151	A mutation in NFkB interacting protein 1 results in cardiomyopathy and abnormal skin development in wa3 mice. 2005 , 14, 667-77	32
1150	Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers. 2005 , 2, 34-43	34
1149	Inflammation and Carotid Artery--Risk for Atherosclerosis Study (ICARAS). 2005 , 111, 2203-9	178
1148	Atherogenesis and autoimmune disease: the model of lupus. 2005 , 14, 687-90	35
1147	Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans. 2005 , 91, 526-30	82
1146	C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. 2005 , 112, 25-31	289
1145	New developments in lung cancer screening. 2005 , 23, 3198-202	13
1144	Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. 2005 , 112, 651-7	322
1143	Inflammation, atherosclerosis, and aspects of insulin action. 2005 , 28, 2312-9	43
1142	Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. 2005 , 111, 2446-53	79
1141	Disease modification and cardiovascular risk reduction: two sides of the same coin?. 2005 , 44, 1473-82	59
1140	C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. 2005 , 112, 976-83	328

1139	Autoimmune mechanisms of atherosclerosis. 2005 , 723-43	16
1138	Obesity and the Metabolic Syndrome. 2005 , 57-74	
1137	Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. 2005 , 10, 1-6	97
1136	Genomics of in-stent restenosis: early insights into a complex disease. 2005 , 112, 2378-9	5
1135	C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. 2005 , 112, 900-5	265
1134	Association between 5-lipoxygenase expression and plaque instability in humans. 2005 , 25, 1665-70	131
1133	Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. 2005 , 46, 389-403	172
1132	Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. 2005 , 26, 241-9	81
1131	N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. 2005 , 293, 1609-16	386
1130	Coronary heart disease in women: what do we know now?. 2005 , 1, 617-28	2
1129	Adipokine dysregulation in turner syndrome: comparison of circulating interleukin-6 and leptin concentrations with measures of adiposity and C-reactive protein. 2005 , 90, 2948-53	38
1128	Circulating endothelial progenitor cells. <i>New England Journal of Medicine</i> , 2005 , 353, 2613-6; author reply 2613-6	59.2 14
1127	C-reactive protein in end-stage renal disease: are there reasons to measure it?. 2005 , 23, 72-8	49
1126	Maternal serum C-reactive protein concentration early in pregnancy and subsequent pregnancy loss. 2005 , 22, 299-304	16
1125	Cost implications of new evidence on prevention of cardiovascular disease. 2005 , 5, 183-92	1
1124	Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. 2005 , 3, 743-59	8
1123	Acute-Phase Proteins and Inflammation: Immunological and Clinical Implications. 2005 , 131-143	2
1122	Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. 2005 , 25, 785-90	96

1121	New biochemical insights into the pathogenesis of osteoarthritis and the role of laboratory investigations in clinical assessment. 2005 , 42, 279-309	33
1120	Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation. 2005 , 6, 2169-80	3
1119	Ambient particulate matter, C-reactive protein, and coronary artery disease. 2005 , 17, 409-13	27
1118	Is high-sensitivity C-reactive protein associated with carotid atherosclerosis in healthy Koreans?. 2005 , 12, 548-554	3
1117	Antiatherogenic potential of red wine: clinician update. 2005 , 288, H2023-30	41
1116	Association of periodontitis with increased white blood cell count and blood pressure. 2005 , 14, 53-8	25
1115	Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. 2005 , 280, 26714-9	174
1114	C-reactive protein in heart failure: prognostic value and the effect of valsartan. 2005 , 112, 1428-34	329
1113	Plasma C reactive protein concentration indicates a direct relation between systemic inflammation and social deprivation. 2006 , 92, 533-5	25
1112	Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. 2005 , 28, 2472-9	45
1111	Contribution of abdominal visceral obesity and insulin resistance to the cardiovascular risk profile of postmenopausal women. 2005 , 54, 770-7	57
1110	Protein kinase C pathway is involved in transcriptional regulation of C-reactive protein synthesis in human hepatocytes. 2005 , 25, 186-92	31
1109	Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. 2005 , 25, 839-46	85
1108	Effect of celecoxib, a cyclooxygenase-2-specific inhibitor, on insulin sensitivity, C-reactive protein, homocysteine, and metabolic profile in overweight or obese subjects. 2005 , 3, 95-101	13
1107	Inflammatory, atherothrombotic aspects of type 2 diabetes. 2005 , 21 Suppl 1, S5-12	16
1106	The effects of green tea ingestion over four weeks on atherosclerotic markers. 2005 , 42, 292-7	28
1105	Inflammatory markers and cardiovascular risk in healthy polish women across the menopausal transition. 2005 , 51, 1893-5	12
1104	Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease--a follow-up study. 2005 , 101, c18-24	28

1103	C-reactive protein induces NF-kappaB activation through intracellular calcium and ROS in human mesangial cells. 2005 , 101, e165-72	20
1102	Predictive value of soluble intercellular adhesion molecule-1 for risk of ischemic events in individuals with cerebrovascular disease. 2005 , 20, 456-62	16
1101	Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. 2005 , 97, 135-43	70
1100	Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. 2005 , 36, 1316-29	226
1099	Quantitative proteome analysis of human plasma following in vivo lipopolysaccharide administration using 16O/18O labeling and the accurate mass and time tag approach. 2005 , 4, 700-9	144
1098	Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists. 2005 , 5, 126-132	2
1097	C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. 2005 , 165, 2473-8	168
1096	Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension. 2005 , 42, 393-452	4
1095	Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. 2005 , 5, 127-34	32
1094	A systematic comparison of the quality and volume of published data available on novel risk factors for stroke versus coronary heart disease. 2005 , 20, 180-6	17
1093	Atherosclerosis and vascular calcification in chronic renal failure. 2005 , 28, 280-9	51
1092	'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. 2005 , 44, 1492-502	217
1091	Cardiovascular risk stratification in older patients: role of brain natriuretic peptide, C-reactive protein, and urinary albumin levels. 2005 , 293, 1667-9	5
1090	Respiratory disease and cardiovascular morbidity. 2005 , 62, 650-5	14
1089	Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. <i>New England Journal of Medicine</i> , 2005 , 352, 29-38	59.2 1048
1088	Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. 2005 , 240, 30-40	25
1087	New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in smokers. 2005 , 12, 542-547	13
1086	Evaluation of a high-sensitivity turbidimetric immunoassay for serum C-reactive protein: application to the study of longitudinal changes throughout normal pregnancy. 2005 , 43, 308-13	10

1085	Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. 2005 , 127, 803-8	50
1084	Enhanced coronary calcification determined by electron beam CT is strongly related to endothelial dysfunction in patients with suspected coronary artery disease. 2005 , 128, 810-5	44
1083	Cerebral ischemic events in patients with advanced lung or prostate cancer. 2005 , 24, 230-6	5
1082	The functional role of C-reactive protein in aortic wall calcification. 2005 , 104, 57-64	14
1081	C-reactive protein predicts death in patients with non-ischemic cardiomyopathy. 2005 , 104, 196-201	10
1080	Levels of, and factors associated with, C-reactive protein in employees attending a company-sponsored cardiac screening program. 2005 , 103, 180-4	5
1079	Associations of serum IL-18 levels with carotid intima-media thickness. 2005 , 25, 1458-62	97
1078	Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. 2005 , 45, 69-74	38
1077	Early carotid atherosclerosis in subjects with periodontal diseases. 2005 , 36, 1195-200	88
1076	Compromised LCAT function is associated with increased atherosclerosis. 2005 , 112, 879-84	135
1075	One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. 2005 , 26, 1379-84	41
1074	Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?. 2005 , 26, 1633-9	37
1073	Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. 2005 , 26, 2114-9	24
1072	Biochemical risk markers: a novel area for better prediction of renal risk?. 2005 , 20, 497-508	17
1071	Levels of serum C-reactive protein during oral and transdermal estradiol in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. 2005 , 90, 142-6	14
1070	Evolution of C-Reactive Protein as a Cardiac Risk Factor. 2005 , 36, 234-238	3
1069	Increased cardiovascular disease risk indices in HIV-infected women. 2005 , 39, 44-54	140
1068	Factores de riesgo cardiovascular. 2005 , 9, 2506-2513	

1067	Utilidad de la medici3n de la apolipoprote3na B en la pr3ctica cl3nica. 2005 , 17, 142-146	0
1066	El paradigma inmune Th1-Th2: un v3nculo entre obesidad, aterosclerosis y diabetes mellitus. 2005 , 17, 232-248	
1065	Diet-induced weight loss is associated with decreases in plasma serum amyloid a and C-reactive protein independent of dietary macronutrient composition in obese subjects. 2005 , 90, 2244-9	92
1064	Utilizing human blood plasma for proteomic biomarker discovery. 2005 , 4, 1073-85	240
1063	Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. 2005 , 31, 55-62	159
1062	[Increase in C-reactive protein plasma levels during diabetes in infants and young adults]. 2005 , 34, 89-93	11
1061	Serum levels of soluble vascular cell adhesion molecule-1 are decreased in women receiving oral contraceptives compared with normally menstruating women: implications in atherosclerosis. 2005 , 83, 1480-8	11
1060	Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. 2005 , 178, 139-45	117
1059	Lovastatin compromises C-reactive protein induced endothelial dysfunction including altered expression of cell adhesion molecules and increased monocyte recruitment. 2005 , 178, 399-401	1
1058	Associations of soluble intercellular adhesion molecule-1 with carotid atherosclerosis progression. 2005 , 179, 155-60	30
1057	Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. 2005 , 179, 361-7	62
1056	C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. 2005 , 179, 413-7	59
1055	Interleukin-2 levels are associated with carotid artery intima-media thickness. 2005 , 180, 181-7	47
1054	Plasma homocysteine predicts progression of atherosclerosis. 2005 , 181, 159-65	68
1053	Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. 2005 , 182, 315-21	58
1052	Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. 2005 , 4, 371-80	281
1051	Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. 2005 , 77, 64-77	258
1050	Traditional and emerging risk factors for cardiovascular disease. 2005 , 32, 963-76, vii	13

1049	Advances in cardiac biomarkers. 2005 , 23, 959-75	3
1048	Premature atherosclerosis in systemic lupus erythematosus. 2005 , 31, 329-54, vii-viii	75
1047	Advances in stroke neuroprotection: hyperoxia and beyond. 2005 , 15, 697-720, xii-xiii	19
1046	Effects of inflammation on plasma composition and endothelial structure and function. 2005 , 15, 94-8	13
1045	Biochemical cardiac risk markers in the general population, hypertension and coronary artery disease. 2005 , 240, 138-42	4
1044	Estrogen replacement raises rat CRP without evidence of complement activation. 2005 , 31, 121-32	8
1043	Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids. 2005 , 21, 207-14	
1042	A patient with cerebral Whipple's disease and a stroke-like syndrome. 2005 , 40, 607-9	16
1041	Correlations between white blood cell count and metabolic syndrome in middle-age Taiwanese. 2005 , 31, 39-50	12
1040	Serum C-reactive protein and plasma homocysteine levels are associated with hormone therapy use and other factors: a population-based study of middle-aged Australian-born women. 2005 , 8, 263-70	7
1039	CYP450, COX-2 and Obesity Related Renal Damage. 2005 , 15, 125-36	9
1038	Lone mothers are at higher risk for cardiovascular disease compared with partnered mothers. Data from the National Health and Nutrition Examination Survey III (NHANES III). 2005 , 26, 604-21	48
1037	Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease?. 2005 , 28, 145-50	35
1036	Inflammatory markers in women with a recent history of gestational diabetes mellitus. 2005 , 28, 34-8	86
1035	Thyroid disease and increased cardiovascular risk. 2005 , 15, 718-24	69
1034	The anti-inflammatory effect of exercise. 2005 , 98, 1154-62	1873
1033	C-reactive protein comes of age. 2005 , 2, 29-36; quiz 58	150
1032	Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women?. 2005 , 54, 72-8	23

1031	Carotid artery intima-media thickness and lipid profile in adults with growth hormone deficiency after long-term growth hormone replacement. 2005 , 54, 321-9	18
1030	Exercise training is not associated with improved levels of C-reactive protein or adiponectin. 2005 , 54, 533-41	167
1029	High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. 2005 , 54, 552-8	46
1028	Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. 2005 , 54, 809-14	25
1027	High-sensitive C-reactive protein, tumor necrosis factor alpha, and cardiovascular risk factors before and after weight loss in obese children. 2005 , 54, 1155-61	93
1026	Immunology of ischemic vascular disease: plaque to attack. 2005 , 26, 550-6	56
1025	Reciprocal association between visceral obesity and adiponectin: in healthy premenopausal women. 2005 , 101, 385-90	41
1024	Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. 2005 , 101, 65-70	33
1023	Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. 2005 , 98, 199-206	61
1022	Rheumatoid disease and ischaemic heart disease: insights from pathophysiology and vascular biology. 2005 , 105, 1-10	9
1021	Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. 2005 , 50, 305-11	27
1020	The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. 2005 , 52, 111-8	48
1019	High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. 2005 , 1736, 136-43	31
1018	Self-rated health and vital exhaustion, but not depression, is related to inflammation in women with coronary heart disease. 2005 , 19, 555-63	117
1017	Evaluation of an enzymatic homocysteine assay for the Hitachi series chemistry analyzer. 2005 , 354, 117-22	8
1016	Brief review and critical examination of the use of hs-CRP for cardiac risk assessment with the conclusion that it is premature to use this test. 2005 , 356, 1-8	14
1015	Role of hs-CRP measurements in the current cardiovascular risk assessment. 2005 , 356, 225-6	1
1014	Role of hs-CRP measurements in the current cardiovascular risk assessment. 2005 , 355, 215-8	5

1013	Leptin as a new diagnostic tool in chronic heart failure. 2005 , 362, 1-11	51
1012	Variability of serum levels of tumor necrosis factor-alpha, interleukin 6, and soluble interleukin 6 receptor over 2 years in young women. 2005 , 30, 1-6	26
1011	Association between fasting glucose and C-reactive protein in a Japanese population: the Minoh study. 2005 , 69, 88-98	17
1010	Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. 2005 , 51, 227-30	51
1009	C-reactive protein and atherogenesis: new insights from established animal models. 2005 , 167, 923-5	28
1008	CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. 2005 , 41, 651-6	86
1007	HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration?. 2005 , 50, 194-206	45
1006	Leptin and immune function: integrating the evidence. 2005 , 25, 791-803	7
1005	Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. 2005 , 112, 2076-80	132
1004	Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease. 2005 , 150, 109-15	26
1003	An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. 2005 , 149, 619-26	49
1002	Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). 2005 , 149, 1066-73	112
1001	Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). 2005 , 149, 512-9	146
1000	Obesity and clinical restenosis after coronary stent placement. 2005 , 150, 821-6	23
999	Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial. 2005 , 150, 907-11	28
998	The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part I. 2005 , 149, 971-6	11
997	The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II. 2005 , 149, 977-83	20
996	The relationship between C-reactive protein and subclinical cardiovascular disease in the Diabetes Heart Study (DHS). 2005 , 150, 1032-8	30

995	The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention. 2005 , 150, 1190-7	15
994	Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. 2005 , 150, 900-6	51
993	Low HDL-C: a secondary target of dyslipidemia therapy. 2005 , 118, 1067-77	58
992	Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. 2005 , 65, 137-52	12
991	Role of Estrogens in Vascular Disease in Diabetes. 2005 , 129-165	
990	The metabolic consequences of childhood obesity. 2005 , 19, 405-19	171
989	Multiple plaque rupture and C-reactive protein in acute myocardial infarction. 2005 , 45, 1594-9	160
988	C-reactive protein and electrocardiographic ST-segment depression additively predict mortality: the Strong Heart Study. 2005 , 45, 1787-93	13
987	Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. 2005 , 45, 1925-31	240
986	Race and gender differences in C-reactive protein levels. 2005 , 46, 464-9	514
985	Prospects for personalized cardiovascular medicine: the impact of genomics. 2005 , 46, 1615-27	56
984	Pathogenic role of TNF α in rheumatoid arthritis. 2005 , 2, 367-375	4
983	Inflammatory response after acute ischemic stroke. 2005 , 236, 65-71	40
982	Pleiotropic effects of statins. 2005 , 45, 89-118	1303
981	Markers of cardiac ischemia and inflammation. 2005 , 23, 491-501, vi	4
980	The association between burnout, depression, anxiety, and inflammation biomarkers: C-reactive protein and fibrinogen in men and women. 2005 , 10, 344-62	208
979	Atherosclerosis: Diet and Drugs. 2005 ,	2
978	The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. 2005 , 28, 2289-304	1574

977	Novel Digital-Style Rapid Test Simultaneously Detecting Heart Attack and Predicting Cardiovascular Disease Risk. 2005 , 38, 423-439	23
976	Therapeutic roles of peroxisome proliferator-activated receptor agonists. 2005 , 54, 2460-70	514
975	Circulating endothelial progenitor cells and cardiovascular outcomes. <i>New England Journal of Medicine</i> , 2005 , 353, 999-1007	59.2 1760
974	Inflammation causes tissue-specific depletion of vitamin B6. 2005 , 7, R1254-62	84
973	Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. 2005 , 7, R984-91	103
972	Accumulation of low density lipoprotein associated cholesterol in calcifying vesicle fractions correlates with intimal thickening in thoracic aortas of juvenile rabbits fed a supplemental cholesterol diet. 2006 , 5, 25	4
971	Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. 2007 , 29, 156-78	556
970	Cardiovascular Biomarkers. 2006 ,	2
969	Does treating subclinical hypothyroidism improve markers of cardiovascular risk?. 2006 , 5, 65-81	26
968	Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. 2006 , 5, 37-51	27
967	Angiographically confirmed coronary heart disease and periodontal disease in middle-aged males. 2006 , 77, 95-102	39
966	Plasma Proteins and Protein Catabolism. 2006 , 81-92	
965	Invited commentary. 2006 , 43, 977	
964	Inflammatory markers and type 2 diabetes. 2006 , 8, 1-6	12
963	Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. 2006 , 4, 445-59	34
962	Combining serum biomarkers: the association of C-reactive protein, insulin sensitivity, and homocysteine with cardiovascular disease history in the general US population. 2006 , 13, 180-5	23
961	Short-term lifestyle modification alters circulating biomarkers of endothelial health in sedentary, overweight adults. 2006 , 31, 512-7	11
960	Present and future biochemical markers for detection of acute coronary syndrome. 2006 , 43, 427-95	14

959	Systemic markers of inflammation--are they useful predictive tools in coronary artery disease?. 2006 , 40, 262-6	3
958	Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control. 2006 , 22 Suppl 2, S15-26	7
957	Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. 2006 , 66, 45-54	56
956	The endothelium and inflammation. 2006 , 13, 423-9	73
955	Cellular adhesion molecules and peripheral arterial disease. 2006 , 11, 39-47	33
954	Experimental exposure to wood-smoke particles in healthy humans: effects on markers of inflammation, coagulation, and lipid peroxidation. 2006 , 18, 845-53	211
953	Hematological and biochemical factors predicting SARS fatality in Taiwan. 2006 , 105, 439-50	34
952	Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD40 ligand. 2006 , 22, 691-6	13
951	Relaci3n entre la prote3na C reactiva ultrasensible y el s3ndrome metab3lico en una poblaci3n semiurbana espa3ola. 2006 , 18, 75-81	
950	S3ndrome metab3lico e inflamaci3n. 2006 , 18, 89-95	
949	Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. 2006 , 30, 400-18	493
948	Ischemic Stroke: Basic Pathophysiology and Neuroprotective Strategies. 2006 , 1-26	
947	Oily fish reduces plasma triacylglycerols: a primary prevention study in overweight men and women. 2006 , 22, 1012-24	59
946	C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells. 2006 , 185, 39-46	50
945	Sex differences in the relation of body composition to markers of inflammation. 2006 , 184, 216-24	191
944	Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. 2006 , 184, 431-7	132
943	The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. 2006 , 185, 347-52	58
942	Plasma cystatin-C and development of coronary heart disease: The PRIME Study. 2006 , 185, 375-80	86

941	Association of C-reactive protein and myocardial perfusion in patients with ST-elevation acute myocardial infarction. 2006 , 186, 177-83	26
940	High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. 2006 , 186, 396-401	45
939	C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. 2006 , 187, 415-22	134
938	Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. 2006 , 187, 18-25	67
937	C-reactive protein and alcohol consumption: Is there a U-shaped association? Results from a population-based study in Russia. The Arkhangelsk study. 2006 , 188, 309-15	18
936	A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. 2006 , 7, 21-9	4
935	Trans fatty acids - effects on systemic inflammation and endothelial function. 2006 , 7, 29-32	148
934	Serum markers of vascular inflammation in dyslipemia. 2006 , 369, 1-16	44
933	Role of adhesion molecules in the induction of restenosis after angioplasty in the lower limb. 2006 , 43, 969-77; discussion 977	12
932	Inflammatory and long-term risk markers. 2006 , 26, 553-70, v	8
931	Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. 2006 , 35, 561-74, ix	22
930	Infections and cardiovascular disease in patients with chronic kidney disease. 2006 , 13, 205-8	13
929	Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?. 2006 , 59, 247-258	4
928	Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. 2006 , 66, 191-221	43
927	Inflamaci3n, aterosclerosis y riesgo cardiovascular: PAPP-A, Lp-PLA2 y cistatina C. ¿Nuevas aportaciones o informaci3n redundante?. 2006 , 59, 247-258	19
926	Chocolate and prevention of cardiovascular disease: a systematic review. 2006 , 3, 2	167
925	Trans fatty acids and cardiovascular disease. <i>New England Journal of Medicine</i> , 2006 , 354, 1601-13	59.2 1171
924	Metabolic syndrome, C-reactive protein and increased arterial stiffness in Japanese subjects. 2006 , 29, 589-96	26

923	The metabolic syndrome and cardiovascular disease. 2006 , 38, 64-80	139
922	Antiatherogenic small, dense HDL--guardian angel of the arterial wall?. 2006 , 3, 144-53	245
921	High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. 2006 , 8, 28-36	134
920	Physical activity and high-sensitivity C-reactive protein. 2006 , 36, 443-58	161
919	Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. 2006 , 47, 962-8	202
918	The number of endothelial progenitor cell colonies in the blood is increased in patients with angiographically significant coronary artery disease. 2006 , 48, 1579-87	167
917	Intima media thickness in childhood obesity: relations to inflammatory marker, glucose metabolism, and blood pressure. 2006 , 55, 113-8	200
916	Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. 2006 , 55, 67-71	14
915	Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. 2006 , 55, 439-44	16
914	Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type 2 diabetes mellitus. 2006 , 55, 461-6	33
913	Association of C-reactive protein with the metabolic risk factors among young and middle-aged Koreans. 2006 , 55, 415-21	21
912	Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. 2006 , 55, 928-34	245
911	High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. 2006 , 55, 1014-21	30
910	Effect of periodontal treatment on serum C-reactive protein levels: a systematic review and meta-analysis. 2006 , 77, 1635-42	82
909	The association between cumulative periodontal disease and stroke history in older adults. 2006 , 77, 1744-54	37
908	Relation between C-reactive protein and serum and dietary antioxidants in older adults at increased risk for cardiovascular disease. 2005 , 24, 23-37	2
907	Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis. 2006 , 2, 320-9	37
906	C-reactive protein in atherosclerosis: A causal factor?. 2006 , 71, 30-9	142

905	Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men. 2006 , 19, 1025-31	13
904	Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. 2006 , 119, 167.e1-8	17
903	Tumor necrosis factor alpha influences the inflammatory response after coronary surgery. 2006 , 81, 132-7	34
902	Understanding omega-3's. 2006 , 151, 564-70	110
901	Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS). 2006 , 151, 412-8	284
900	Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. 2006 , 152, 94-101	74
899	Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. 2006 , 152, 593-8	225
898	Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. 2006 , 580, 2788-96	29
897	Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women. 2006 , 85, 667-73	12
896	Long-term effects of tibolone on circulating levels of vascular cell adhesion molecules and E-selectin in postmenopausal women. 2006 , 86, 899-904	9
895	High cardiovascular risk in young Saudi males: cardiovascular risk factors, diet and inflammatory markers. 2006 , 365, 288-96	9
894	Genomic variants in polycystic ovary syndrome. 2006 , 366, 14-26	37
893	The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. 2006 , 368, 183-7	13
892	Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. 2006 , 28, 849-59	15
891	Hostility and pain are related to inflammation in older adults. 2006 , 20, 389-400	105
890	Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. 2006 , 72, 244-50	56
889	Effect of a diet and exercise intervention on oxidative stress, inflammation and monocyte adhesion in diabetic men. 2006 , 73, 249-59	68
888	Coexistence of insulin resistance and inflammation effectively predicts cardiac disease but not stroke in Japanese patients with type 2 diabetes mellitus. 2006 , 74, 316-21	8

887	Metabolic syndrome and prediabetes. 2006 , 52, 55-144	15
886	C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. 2006 , 42, 704-7	51
885	Risk factors for atherosclerosis in healthy employees-a multidisciplinary approach. 2006 , 17, 247-53	9
884	Severity of periodontal disease and number of remaining teeth are related to the prevalence of myocardial infarction and hypertension in a study based on 4,254 subjects. 2006 , 77, 1173-8	140
883	Inflammation and atherosclerosis. 2006 , 1, 297-329	718
882	Interleukin-6 is associated with cognitive function: the Northern Manhattan Study. 2006 , 15, 34-8	100
881	C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. 2006 , 78, 1021-8	41
880	Decreased risk for myocardial infarction and lower tumor necrosis factor-alpha levels in carriers of variants of the PDCD1 gene. 2006 , 67, 700-5	10
879	The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. 2006 , 106, 291-7	150
878	Enhanced expression of platelet CD40-ligand by in vitro lipopolysaccharide-challenge in patients with ventricular fibrillation complicating acute myocardial infarction. 2006 , 107, 350-5	13
877	CD40 ligand and risk of ischemic stroke or coronary events in patients with chronic coronary heart disease. 2006 , 107, 322-6	20
876	CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. 2006 , 108, 55-62	50
875	C-reactive protein and atrial fibrillation: "evidence for the presence of inflammation in the perpetuation of the arrhythmia". 2006 , 108, 326-31	41
874	All teas are not created equal: the Chinese green tea and cardiovascular health. 2006 , 108, 301-8	142
873	Increased high sensitivity C-reactive protein and neutrophil count are related to increased standard cardiovascular risk factors in healthy Chinese men. 2006 , 110, 191-8	21
872	Coagulation activation and expression of CD40 ligand on platelets upon in vitro lipopolysaccharide-challenge in patients with unstable angina. 2006 , 111, 217-23	19
871	Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women. 2006 , 113, 66-75	4
870	Does the pre-existing inflammation play a role in the increased C-reactive protein levels in acute myocardial infarction?. 2006 , 112, 134-5; author reply 136-8	3

869	C-reactive protein activates the nuclear factor-kappaB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. 2006 , 40, 412-20	52
868	Elevated circulating levels of markers of oxidative-nitrative stress and inflammation in a genetic rat model of metabolic syndrome. 2006 , 15, 380-6	51
867	Endothelial dysfunction and oxidative stress in arterial hypertension. 2006 , 16, 222-33	83
866	The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor. 2006 , 117, 343-9	24
865	Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. 2006 , 27, 498-502	13
864	C-reactive protein diagnostic and prognostic value in patients presenting at the emergency room with chest pain. 2006 , 87, 275-80	8
863	Complications of Chronic Obstructive Pulmonary Disease. 2006 , 49, 321	
862	The Association Between Inflammatory Markers and Hypertension. A Call for Anti-Inflammatory Strategies?. 2006 , 6, 1262-1273	
861	[Menstrual cycle irregularity as a marker of cardiovascular risk factors at postmenopausal years]. 2006 , 50, 876-83	13
860	New frontiers for cardiac risk assessment: C-reactive protein. 2006 , 21, 188-91, 195-6, 205-6	1
859	[Analysis on the association of physical activity with metabolic syndrome in a population-based study of Japanese-Brazilians]. 2006 , 50, 1066-74	9
858	Baseline plasma C-reactive protein concentrations influence lipid and lipoprotein responses to low-fat and high monounsaturated fatty acid diets in healthy men. 2006 , 136, 1005-11	14
857	Association between dietary fiber and serum C-reactive protein. 2006 , 83, 760-6	255
856	Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects. 2006 , 84, 1324-9	50
855	Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. 2006 , 3, e287	249
854	Obesity as an inflammatory condition. 2006 , 11,	0
853	Obesity and Cancer Risk. 2006 , 185-197	1
852	Depression and the development of coronary heart disease. 53-86	8

851	Body mass index and C-reactive protein in the healthy Korean aged men. 2006 , 21, 811-5	2
850	Relationship between hs-CRP, proMMP-1, TIMP-1 and coronary plaque morphology: intravascular ultrasound study. 2006 , 119, 1689-1694	8
849	Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. 2006 , 119, 32-36	34
848	Inflammation, Cardiovascular Disease and the Metabolic Syndrome. 2006 , 207-238	
847	Effects of etanercept in patients with the metabolic syndrome. 2006 , 166, 902-8	190
846	Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. 2006 , 70, 1437-42	221
845	Relationship between the serum concentrations of C-reactive protein and parameters of adiposity and insulin resistance in patients with type 2 diabetes mellitus. 2006 , 53, 345-56	22
844	Association of C-reactive protein with early-stage carotid atherosclerosis in Japanese patients with early-state type 2 diabetes mellitus. 2006 , 53, 693-8	21
843	Burnout and risk of cardiovascular disease: evidence, possible causal paths, and promising research directions. 2006 , 132, 327-53	545
842	Sex differences in the relation of depressive symptoms, hostility, and anger expression to indices of glucose metabolism in nondiabetic adults. 2006 , 25, 484-92	50
841	Inflammation and cardiovascular disease mechanisms. 2006 , 83, 456S-460S	720
840	Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. 2006 , 83, 475S-483S	88
839	The Relationship Between Sleep-Disordered Breathing and High-Sensitivity C-Reactive Protein in Japanese Men. 2006 ,	
838	Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. 2006 , 83, 774-9	65
837	Effect of soy protein varying in isoflavone content on serum lipids in healthy young men. 2006 , 83, 244-51	60
836	Corrections to Effects of Riboflavin and Folic Acid Supplementation on Plasma Homocysteine Levels in Healthy Subjects [Cherng Zee Chuang, PhD, Adrienne Boyles, BA, Barbara LeGardeur, MPH, Joseph Su, PhD, Shanker Japa, PhD, Alfredo Lopez-S, MD, PhD Am J Med Sci 2006;331(2):657-1. 2006 , 331, 269	
835	C-reactive protein levels in subjects with Prader-Willi syndrome and obesity. 2006 , 8, 243-8	17
834	C-reactive protein in predicting coronary artery disease in subjects with aortic valve sclerosis before diagnostic coronary angiography. 2006 , 331, 264-9	7

833	Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. 2006 , 332, 186-97	33
832	Full Length Article. 2006 , 48, 1579-1587	150
831	Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. 2006 , 24, 1083-8	52
830	Role of adipokines in the obesity-inflammation relationship: the effect of fat removal. 2006 , 118, 1048-1057	63
829	Influence of an algal triacylglycerol containing docosahexaenoic acid (22 : 6n-3) and docosapentaenoic acid (22 : 5n-6) on cardiovascular risk factors in healthy men and women. 2006 , 95, 525-31	82
828	C-reactive protein and cardiovascular disease in people with diabetes: high-sensitivity CRP testing can help assess risk for future cardiovascular disease events in this population. 2006 , 106, 66-72	10
827	Missed targets: gender differences in the identification and management of dyslipidemia. 2006 , 21, 342-6	9
826	A Review of Macronutrient Considerations for Persons With Prediabetes. 2006 , 21, 64-75	
825	Cyclooxygenase-2 and nitric oxide. 2006 , 47 Suppl 1, S21-5	11
824	Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. 2006 , 47, 508-12	7
823	Does genotype and equol-production status affect response to isoflavones? Data from a pan-European study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women. 2006 , 65, 106-15	18
822	Plasma adhesion molecules in children with sleep-disordered breathing. 2006 , 129, 947-53	92
821	Identification of the metabolic syndrome and imaging of subclinical coronary artery disease: early markers of cardiovascular risk. 2006 , 21, 291-7	5
820	Strategies for Controlling Glucose in the Intensive Care Unit. 2006 , 13, 332-347	3
819	Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. 2006 , 13, 840-5	215
818	Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. 2006 , 68, 187-200	143
817	Direct detection of C-reactive proteins in human serum using nanoparticle-enhanced surface plasmon resonance biosensing. 2006 ,	
816	Vascular failure or sick vessel syndrome: The cardiovascular continuum is a useful concept for clinical research. 2006 , 24, 2147-8	4

815	Biomarkers of outcome from cardiovascular disease. 2006 , 12, 412-9	32
814	The selective estrogen receptor-beta agonist biochanin A shows vasculoprotective effects without uterotrophic activity. 2006 , 13, 489-99	25
813	The obesity epidemic and its cardiovascular consequences. 2006 , 21, 353-60	72
812	Contemporary scientific insights: role of biomarkers of inflammation in cardiovascular disease/atherosclerosis. 2006 , 5, 191-210	3
811	Assessment of metabolic profile in a clinical setting. 2006 , 9, 589-95	9
810	Inflammation, atherosclerosis, and stroke. 2006 , 12, 140-8	83
809	Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. 2006 , 68, 895-903	123
808	Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. 2006 , 1, 129-47	42
807	Antidepressant therapy and C-reactive protein levels. 2006 , 188, 449-52	121
806	Strong correlation between serum levels of inflammatory mediators and their distribution in infarct-related coronary artery. 2006 , 70, 838-45	23
805	Which thyroid-stimulating hormone level should be sought in hypothyroid patients under L-thyroxine replacement therapy?. 2006 , 60, 655-9	6
804	Hormone replacement therapy is associated with increased C-reactive protein in women with Type 2 diabetes in the Diabetes Heart Study. 2006 , 23, 763-7	11
803	Obstructive sleep apnoea syndrome: translating science to clinical practice. 2006 , 11, 136-44	40
802	Quantitative analysis of carotid atherosclerotic lesions and high-sensitivity C-reactive protein in community-dwelling elderly 80 years or older. 2006 , 6, 186-193	0
801	Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and in hypercholesterolemic men. 2001 , 949, 168-74	14
800	Infliximab (Remicade®): from bench to clinical practice. A paradigm shift in rheumatology practice. 2006 , 9, 107-118	3
799	Investigating the genetic determinants of cardiovascular disease using candidate genes and meta-analysis of association studies. 2006 , 70, 145-69	44
798	Lack of association between genetic variation in 9 innate immunity genes and baseline CRP levels. 2006 , 70, 574-86	7

797	Heritability and expression of C-reactive protein in type 2 diabetes in the Diabetes Heart Study. 2006 , 70, 717-25	31
796	Soluble intracellular adhesion molecule-1 is associated with cardiovascular disease risk and mortality in older adults. 2006 , 4, 107-13	32
795	Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. 2006 , 4, 77-82	69
794	Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. 2006 , 4, 114-20	53
793	The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. 2006 , 4, 2308-16	19
792	Inflammatory biomarkers and cardiovascular risk: association or cause and effect?. 2006 , 19, 129-35	24
791	C-reactive protein (CRP)-lowering agents. 2006 , 24, 33-50	193
790	Low serum bilirubin concentrations are associated with impaired aortic elastic properties, but not impaired left ventricular diastolic function. 2007 , 61, 218-24	11
789	LDL-apheresis reduces P-Selectin, CRP and fibrinogen -- possible important implications for improving atherosclerosis. 2006 , 10, 219-23	33
788	Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism. 2006 , 65, 530-5	40
787	Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. 2006 , 62, 391-402	23
786	Consequences of and strategies to deal with residual post-treatment root canal infection. 2006 , 39, 343-56	138
785	The immune response in atherosclerosis: a double-edged sword. 2006 , 6, 508-19	1682
784	Soluble intercellular adhesion molecules, soluble vascular cell adhesion molecules, and risk of coronary heart disease. 2006 , 14, 2099-106	52
783	The effects of the dietary glycemic load on type 2 diabetes risk factors during weight loss. 2006 , 14, 2200-9	65
782	Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. 2006 , 14 Suppl 3, 135S-142S	20
781	Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. 2006 , 60, 802-9	110
780	Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels--a study in twins. 2006 , 7, 600-5	63

779	Obesity, inflammatory markers and cardiovascular disease: distinguishing causality from confounding. 2006 , 20, 837-40	17
778	Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. 2006 , 70, 1142-8	36
777	Immunodetection of pentamer and modified C-reactive protein using surface plasmon resonance biosensing. 2006 , 21, 1631-7	63
776	Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. 2006 , 80, 275-81	45
775	The course of high-sensitive C-reactive protein in correlation with pain and clinical function in patients with acute lumbosciatic pain and chronic low back pain - a 6 months prospective longitudinal study. 2006 , 10, 711-9	33
774	Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?. 2006 , 30, 1217-25	25
773	Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. 2006 , 30, 1535-44	166
772	Ankle-Brachial Index as the Best Predictor of First Acute Coronary Syndrome in Patients with Treated Systemic Hypertension. 2020 , 2020, 6471098	3
771	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. 2020 , 159, 4-33	23
770	Frequency of daily tooth brushing and subsequent cardiovascular events. 2020 , 31, 545-549	1
769	Particle characterization and toxicity in C57BL/6 mice following instillation of five different diesel exhaust particles designed to differ in physicochemical properties. 2020 , 17, 38	14
768	Use of an Exposome Approach to Understand the Effects of Exposures From the Natural, Built, and Social Environments on Cardio-Vascular Disease Onset, Progression, and Outcomes. 2020 , 8, 379	12
767	Cardiovascular Risk Assessment in Children With Chronic Cholestatic Liver Diseases. 2020 , 71, 647-654	1
766	Marine-derived Potential Anti-inflammatory Agents. 2020 , 2585-2605	1
765	Postpartum metabolic syndrome and high-sensitivity C-reactive protein after gestational hypertension and pre-eclampsia. 2020 , 151, 443-449	2
764	Helminth Mediated Attenuation of Systemic Inflammation and Microbial Translocation in Helminth-Diabetes Comorbidity. 2020 , 10, 431	
763	The myeloid type I interferon response to myocardial infarction begins in bone marrow and is regulated by Nrf2-activated macrophages. 2020 , 5,	10
762	A conceptual model for understanding the rapid COVID-19-related increase in food insecurity and its impact on health and healthcare. 2020 , 112, 1162-1169	84

761	Association Between IL-6 and Seizure Recurrence in Patients with the First Post-Ischemic Stroke Seizure. 2020 , 16, 1955-1963	3
760	Lactobacillus fermentum promotes adipose tissue oxidative phosphorylation to protect against diet-induced obesity. 2020 , 52, 1574-1586	4
759	Single-Cell Transcriptomics Reveals That Metabolites Produced by sp. nov. BD3526 Ameliorate Type 2 Diabetes in GK Rats by Downregulating the Inflammatory Response. 2020 , 11, 568805	1
758	Metabolic comparison of polycystic ovarian syndrome and control women in Middle Eastern and UK Caucasian populations. 2020 , 10, 18895	2
757	The effect of acute stress on salivary markers of inflammation: A systematic review and meta-analysis. 2020 , 88, 887-900	16
756	GlycA: A New Biomarker for Systemic Inflammation and Cardiovascular Disease (CVD) Risk Assessment. 2020 , 5,	14
755	Association of Childhood Trauma Exposure with Inflammatory Biomarkers Among Midlife Women. 2020 , 29, 1540-1546	7
754	Volunteering, Subjective Sleep Quality, and Chronic Inflammation: A 5-Year Follow-Up of the National Social Life, Health, and Aging Project. 2020 , 42, 291-299	2
753	Serum homocysteine levels and their association with clinical characteristics of inflammatory arthritis. 2020 , 39, 3295-3302	6
752	Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. 2020 , 75, 2602-2618	56
751	Effect of Sodium Bicarbonate Mouth Wash on Salivary pH and Interleukin-1 β Levels among Smokers. 2020 , 14, 260-267	6
750	Changes in Soluble TWEAK Concentrations, but Not Those in Amyloid- β (1-40), Are Associated with a Decrease in Carotid Intima-Media Thickness after Bariatric Surgery in Obese Women. 2020 , 13, 321-330	0
749	Cardiovascular risk assessment: The foundation of preventive cardiology. 2020 , 1, 100008	2
748	Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale. 2020 , 17, 16	68
747	Organomodified nanoclays induce less inflammation, acute phase response, and genotoxicity than pristine nanoclays in mice lungs. 2020 , 14, 869-892	4
746	Future of preventing and managing common chronic inflammatory diseases. 2020 , 91 Suppl 1, S12-S18	2
745	High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. 2020 , 4, 2430-2438	22
744	Polycyclic aromatic hydrocarbon exposure and atherosclerotic cardiovascular disease risk in urban adults: The mediating role of oxidatively damaged DNA. 2020 , 265, 114860	17

743	Ibuprofen use is associated with reduced C-reactive protein and interleukin-6 levels in chronic spinal cord injury. 2020 , 1-9	2
742	Association of pulse pressure, pulse pressure index, and ambulatory arterial stiffness index with kidney function in a cross-sectional pediatric chronic kidney disease cohort from the CKiD study. 2020 , 22, 1059-1069	3
741	The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease. 2020 , 20, 295	5
740	Inflammation and Oral Contraceptive Use in Female Athletes Before the Rio Olympic Games. 2020 , 11, 497	7
739	Activated Clotting Time as a Marker of Inflammation in Hospitalized Patients. 2020 , 26, 1076029620929090	1
738	Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects. 2020 , 10, 4750	30
737	Associations of Inflammation, Physical Activity, and Sleep in a Diverse Population of Women. 2020 , 29, 1007-1016	3
736	Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. 2020 , 7, 22	228
735	Non-Systematic Review of Diet and Nutritional Risk Factors of Cardiovascular Disease in Obesity. 2020 , 12,	12
734	Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. 2020 , 41, 2952-2961	32
733	Acute Phase Response as a Biological Mechanism-of-Action of (Nano)particle-Induced Cardiovascular Disease. 2020 , 16, e1907476	21
732	Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease. 2020 , 26, 583-596	17
731	Double Trouble: The Burden of Child-rearing and Working on Maternal Mortality. 2020 , 57, 559-576	2
730	A Comprehensive Multidisciplinary Management Plan Is Effective in Reducing the Prevalence of Overweight and Obesity in Childhood and Adolescence. 2020 , 93, 94-107	3
729	Title: Human Serum/Plasma Glycoprotein Analysis by H-NMR, an Emerging Method of Inflammatory Assessment. 2020 , 9,	29
728	Depression and cardiovascular disease: Shared molecular mechanisms and clinical implications. 2020 , 285, 112802	16
727	Maternal Cardiovascular Disease 3 Decades After Preterm Birth: Longitudinal Cohort Study of Pregnancy Vascular Disorders. 2020 , 75, 788-795	8
726	Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac). 2020 , 9,	8

725	Immune biomarkers alterations in post-traumatic stress disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2020 , 268, 39-46	6.6	28
724	Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. 2020 , 209, 107511		36
723	Elevated neutrophil-lymphocyte ratio predicts mortality following elective endovascular aneurysm repair. 2020 , 72, 129-137		15
722	Effects of dairy products consumption on inflammatory biomarkers among adults: A systematic review and meta-analysis of randomized controlled trials. 2020 , 30, 872-888		14
721	Obesity and cardiovascular disease in women. 2020 , 44, 1210-1226		20
720	Risk of Cardiometabolic Disease and All-Cause Mortality in Female Survivors of Domestic Abuse. 2020 , 9, e014580		25
719	2019 Plenary Lecture: Interleukin-2 Therapy in Cardiovascular Disease: The Potential to Regulate Innate and Adaptive Immunity. 2020 , 40, 853-864		12
718	Association between serum amyloid A levels and coronary heart disease: a systematic review and meta-analysis of 26 studies. 2020 , 69, 331-345		9
717	The effect of the systemic folic acid intake as an adjunct to scaling and root planing on clinical parameters and homocysteine and C-reactive protein levels in gingival crevicular fluid of periodontitis patients: A randomized placebo-controlled clinical trial. 2020 , 47, 602-613		7
716	Daily watermelon consumption decreases plasma sVCAM-1 levels in overweight and obese postmenopausal women. 2020 , 76, 9-19		10
715	Intracranial Atherosclerosis Treatment: Past, Present, and Future. 2020 , 51, e49-e53		10
714	Adrenal incidentaloma: cardiovascular and metabolic effects of mild cortisol excess. 2020 , 9, 94-104		4
713	The Aging Cochlea. 2020 , 871-883		
712	Intravascular Molecular Imaging to Detect High-Risk Vulnerable Plaques: Current Knowledge and Future Perspectives. 2020 , 13, 1		1
711	Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. 2020 , 41, 2974-2982		82
710	Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis. 2020 , 22, 7		19
709	Association of Childhood Psychosocial Environment With 30-Year Cardiovascular Disease Incidence and Mortality in Middle Age. 2020 , 9, e015326		18
708	Evidence for skin-deep resilience using a co-twin control design: Effects on low-grade inflammation in a longitudinal study of youth. 2020 , 88, 661-667		8

707	Plaque vulnerability and adverse outcomes: The long road to fight atherosclerosis. 2020 , 50, e13253	3
706	Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety. 2020 , 11, 422	80
705	Sex as a Biological Variable in Atherosclerosis. 2020 , 126, 1297-1319	66
704	Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention. 2020 , 9,	0
703	Why Do South Asians Have High Risk for CAD?. 2012 , 7, 307-14	28
702	Coronary artery disease in women: a 2013 update. 2013 , 8, 105-12	56
701	The effect of dried Ziziphus vulgaris on glycemic control, lipid profile, Apo-proteins and hs-CRP in patients with type 2 diabetes mellitus: A randomized controlled clinical trial. 2021 , 45, e13193	1
700	Preoperative C-reactive protein predicts early postoperative outcomes after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. 2021 , 161, 1532-1542.e5	3
699	Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. 2021 , 7, 97-106	6
698	Syndemics and salivary inflammation in people living with HIV/AIDS. 2021 , 36, 496-510	
697	Role of Periodontal Infection, Inflammation and Immunity in Atherosclerosis. 2021 , 46, 100638	2
696	Cardiovascular Disease in Women: From Pathophysiology to Novel and Emerging Risk Factors. 2021 , 30, 9-17	15
695	Effect of garlic intake on inflammatory mediators: a systematic review and meta-analysis of randomised controlled trials. 2021 , 97, 156-163	4
694	Effects of eight weeks of aerobic exercise and taking caraway supplement on C-reactive protein and sleep quality in obese women. 2021 , 52, 218-226	6
693	Differences Between Morbid Obesity With Metabolic Syndrome and Overweight Turkish Adult Participants in Multiple Atherosclerotic Cardiovascular Disease Risk Factors. 2021 , 72, 131-137	0
692	Genistein supplementation improves some cardiovascular risk factors in postmenopausal women with Type 2 diabetes mellitus. 2021 , 51, 125-136	
691	Sex Differences in the Inflammatory Response: Pharmacological Opportunities for Therapeutics for Coronary Artery Disease. 2021 , 61, 333-359	9
690	Combating Inflammation in Cardiovascular Disease. 2021 , 30, 197-206	13

689	A cohort study of cucumber greenhouse workers' exposure to microorganisms as measured using NGS and MALDI-TOF MS and biomarkers of systemic inflammation. 2021 , 192, 110325	5
688	Effects of aerobic training and licorice extract consumption on inflammation and antioxidant states in overweight women. 2021 , 21, 100271	0
687	Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention. 2021 , 97, E936-E944	0
686	C-Reactive Protein Levels Are Higher in Patients With Fusiform Intracranial Aneurysms: A Case-Control Study. 2021 , 146, e896-e901	3
685	Impact of root canal treatment on high-sensitivity C-reactive protein levels in systemically healthy adults with apical periodontitis - a preliminary prospective, longitudinal interventional study. 2021 , 54, 501-508	3
684	Subchronic exposure to concentrated ambient PM2.5 perturbs gut and lung microbiota as well as metabolic profiles in mice. 2021 , 272, 115987	17
683	Associations between short term exposure to ambient particulate matter from dust storm and anthropogenic sources and inflammatory biomarkers in healthy young adults. 2021 , 761, 144503	10
682	Sex- and age-related differences in the predictive capability of circulating biomarkers: from the MONICA 10 cohort. 2021 , 55, 65-72	0
681	Obesity as a risk factor for unfavourable outcomes in critically ill patients affected by Covid 19. 2021 , 31, 762-768	8
680	Effect of Sleep Surgery on C-Reactive Protein Levels in Adults With Obstructive Sleep Apnea: A Meta-Analysis. 2021 , 131, 1180-1187	1
679	The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. 2021 , 133, 28-41	4
678	Anti-Inflammatory Effects of Exercise on Metabolic Syndrome Patients: A Systematic Review and Meta-Analysis. 2021 , 23, 280-292	17
677	The effect of grape products containing polyphenols on C-reactive protein levels: a systematic review and meta-analysis of randomised controlled trials. 2021 , 125, 1230-1245	2
676	Elevated preoperative C-reactive protein is associated with renal functional decline and non-cancer mortality in surgically treated renal cell carcinoma: analysis from the INternational Marker Consortium for Renal Cancer (INMARC). 2021 , 127, 311-317	3
675	NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. 2021 , 10,	11
674	Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome. 2021 , 1, 37	
673	Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome. 2021 , 1, 37	0
672	Evaluation on blood coagulation and C-reactive protein level among children with mycoplasma pneumoniae pneumonia by different chest imaging findings. 2021 , 100, e23926	0

- 671 Suprainguinal and infrainguinal peripheral artery diseaseDo women present differently than men. **2021**, 167-180
- 670 [Analysis of the causes of repeat stenosis of the coronary arteries after elective stenting in patients with stable angina pectoris]. **2021**, 93, 59-65
- 669 Effect of a nut-enriched low-calorie diet on body weight and selected markers of inflammation in overweight and obese stable coronary artery disease patients: a randomized controlled study. **2021**, 75, 1099-1108 4
- 668 The Effects of a Nutrition Education Program on Dietary Intake and Biomarkers in HIV+ Adults. 155982762098679
- 667 The challenges and possibilities of earthquake predictions using non-seismic precursors. **2021**, 230, 367-380 4
- 666 Outcomes of open treatment of infrainguinal peripheral artery disease in women. **2021**, 223-231
- 665 Periodontitis is associated with cardiovascular diseases: A 13-year study. **2021**, 48, 348-356 6
- 664 Risk of Medication Exposures in Pregnancy and Lactation. **2021**, 55-97 0
- 663 Mitochondria and traffic-related air pollution linked coronary artery calcification: exploring the missing link. **2021**, 36, 545-563 1
- 662 Role of Serum High-Sensitivity C-Reactive Protein Level as Risk Factor in the Prediction of Coronary Artery Disease in Hyperglycemic Subjects. **2021**, 123-134
- 661 An evaluation of lipid profile and pro-inflammatory cytokines as determinants of cardiovascular disease in those with diabetes: a study on a Mexican American cohort. **2021**, 11, 2435 3
- 660 Biomarkers. **2021**, 31-64
- 659 Effects of daidzein and genistein on markers of cardiovascular disease risk among women with impaired glucose regulation: a double-blind, randomized, placebo-controlled trial. **2021**, 12, 7997-8006 1
- 658 Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy.
- 657 Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy.
- 656 New Biomarkers of Cardiovascular Diseases (Literature Review). Part 1. **2021**, 7, 130-151
- 655 Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. **2020**, 11, 634409 8
- 654 Pharmacological Therapy Determines the Gut Microbiota Modulation by a Pomegranate Extract Nutraceutical in Metabolic Syndrome: A Randomized Clinical Trial. **2021**, 65, e2001048 8

- 653 The prediction of Metabolic Syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone. **2021**, 20, 68 3
- 652 Cardiovascular Risk Factors from Another Point of View. **2021**, 6, 27-31
- 651 Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. **2021**, 42, 1742-1756 20
- 650 Cardiovascular risk factors in extended family members and birthweight in offspring. **2021**, 1-7 0
- 649 Cardiovascular Outcomes With Anti-Inflammatory Therapies: Review of Literature. **2021**, 47, 100840
- 648 MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation. **2021**, 10, 5
- 647 Emerging optofluidic technologies for biondiagnostic applications. **2021**, 2, 20200035 5
- 646 Usefulness of ischemia-modified albumin for assessment of the effects of small ventricular septal defects on the pulmonary vascular bed. **2021**, 31, 1207-1212 0
- 645 Intracerebral Hemorrhage in Patients with Neuromyelitis Optica: Case Report with Literature Review for Possible Pathological Association. **2021**, 13, 157-165
- 644 Role of Inflammation in Coronary Epicardial and Microvascular Dysfunction. **2021**, 16, e13 5
- 643 Factors Associated With Being Overweight and Obesity in People Living With Human Immunodeficiency Virus on Antiretroviral Therapy: Socioclinical, Inflammation, and Metabolic Markers. **2021**, 224, 1570-1580 0
- 642 Atherosclerosis: Cholesterol Management. 1-36
- 641 Potential Impact of Exercise-Associated Amenorrhea and Subsequent Estrogen Therapy on Cardiovascular Disease Risk Factors in Pre-Menopausal Athletes: A Research Protocol. **2021**, 5, 1-13
- 640 Biomarkers of Inflammation and Risk of Hospitalization for Heart Failure in Patients With Atrial Fibrillation. **2021**, 10, e019168 3
- 639 Inflammation and Cardiovascular Disease: The Future. **2021**, 16, e20 10
- 638 Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. **2021**, 128, 1728-1746 46
- 637 Association between serum level of C-reactive protein and risk of cardiovascular events based on cohort studies. **2021**, 35, 1149-1158 1
- 636 Assessment of mesalamine in the alterations of metabolic parameters in comorbid ulcerative colitis and metabolic syndrome patients: A retrospective study.

635	Urolithiasis Develops Endothelial Dysfunction as a Clinical Feature. 2021 , 10,	0
634	IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. 2021 , 397, 2060-2069	80
633	Periodontal Disease, Atrial Fibrillation and Stroke. 2021 , 235, 36-43	8
632	The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review. 2021 , 6, 247-258	5
631	High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events. 2021 , 143, 1935-1945	11
630	Crosslinking of human plasma C-reactive protein to human serum albumin via disulfide bond oxidation. 2021 , 41, 101925	5
629	Effect of garlic powder supplementation on blood pressure and hs-C-reactive protein among nonalcoholic fatty liver disease patients: A randomized, double-blind, placebo-controlled trial. 2021 , 9, 3556-3562	3
628	Atherosclerosis. 2021 , 13, 2063-2070	
627	Temporal changes in blood oxidative stress biomarkers across the menstrual cycle and with oral contraceptive use in active women. 2021 , 121, 2607-2620	3
626	Quantification of glycoproteins by nuclear magnetic resonance associated with preclinical carotid atherosclerosis in patients with type 1 diabetes. 2021 , 31, 2099-2108	2
625	Single-cell dissection of live human hearts in ischemic heart disease and heart failure reveals cell-type-specific driver genes and pathways.	2
624	Association between Carbonated Beverage Intake and High-Sensitivity C-Reactive Protein in Korean Adults. 2021 , 11, 197-203	
623	Associations between high-sensitivity C-reactive protein and non-communicable diseases in an Asian population: findings from the IFLS study. 2021 , 26, 548-556	1
622	Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. 2021 , 161, 105776	2
621	An Oily Fish Diet Improves Subclinical Inflammation in People at High Cardiovascular Risk: A Randomized Controlled Study. 2021 , 26,	1
620	Targeting Parenting Quality to Reduce Early Life Adversity Impacts on Lifespan Cardiometabolic Risk. 2021 , 12, 678946	
619	Cardiovascular risk assessment by coronary artery calcium score in subjects with maturity-onset diabetes of the young caused by glucokinase mutations. 2021 , 176, 108867	2
618	Legumes as Functional Food for Cardiovascular Disease. 2021 , 11, 5475	4

617	Biochemical markers of coronary atherosclerosis: building models and assessing their prognostic value regarding the lesion severity. 2021 , 26, 4559	2
616	Possible Gender Difference in the Association Between Abdominal Obesity, Chronic Inflammation, and Preclinical Atherosclerosis in the General Population. 2021 , 62, 837-842	0
615	Association between serum secretory phospholipase A2 and risk of ischaemic stroke. 2021 , 28, 3650-3655	1
614	Biological anti-psoriatic therapy profoundly affects high-density lipoprotein function. 2021 , 1866, 158943	1
613	Early Detection of Cardiotoxicity from Systemic and Radiation Therapy in Breast Cancer Patients (CardioTox Breast): Protocol Design of a Multi-Institutional Prospective Study (Preprint).	
612	Descriptive modification of inflammatory markers in HIV patients after cART initiation according to gender, smoking habit, CMV infection, BMI and serum lipids. 2021 , 143, 155547	
611	High-Sensitivity C-Reactive Protein Relationship with Metabolic Disorders and Cardiovascular Diseases Risk Factors. 2021 , 11,	0
610	Effects of the Great Recession on Educational Disparities in Cardiometabolic Health. 2021 ,	
609	High Sensitivity C-reactive Protein in Patients with Coronary Artery in-stent Restenosis: A Case-control Study. 2021 , 15, 29-37	
608	A Comprehensive, Multidisciplinary, Personalized, Lifestyle Intervention Program Is Associated with Increased Leukocyte Telomere Length in Children and Adolescents with Overweight and Obesity. 2021 , 13,	1
607	Effects of social support in an academic context on low-grade inflammation in high school students. 2021 , 44, 803-810	2
606	Age, sex, and inflammatory markers predict chronic conditions, cardiac disease, and mortality among captive western lowland gorillas (<i>Gorilla gorilla gorilla</i>). 2021 , 62, 931-943	1
605	The Link Between Positive and Negative Parenting Behaviors and Child Inflammation: A Systematic Review. 2021 , 1	0
604	Fabrication of a surface-enhanced Raman spectroscopy-based analytical method consisting of multifunctional DNA three-way junction-conjugated porous gold nanoparticles and Au-Te nanoworm for C-reactive protein detection. 2021 , 1	0
603	Vitamin D levels and C-reactive protein/albumin ratio in pregnant women with cerebral venous sinus thrombosis. 2021 , 1	1
602	Effects of Oats (L.) on Inflammation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2021 , 8, 722866	2
601	Inflammation and ischemic heart disease: The next therapeutic target?. 2021 , 40, 785-785	3
600	Influences of the menopause transition and adverse childhood experiences on peripheral basal inflammatory markers. 2021 , 15, 100280	3

599	The Predictive Value of Carotid Ultrasonography With Cardiovascular Risk Factors-A "SPIDER" Promoting Atherosclerosis. 2021 , 8, 706490	2
598	Study of emotional distress in a comparative effectiveness trial of diabetes treatments: Rationale and design. 2021 , 107, 106366	0
597	Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers. 2021 , 12, 681455	0
596	Mitogen and Stress-Activated Kinases 1 and 2 Mediate Endothelial Dysfunction. 2021 , 22,	1
595	Effects of Combined High-Protein Diet and Exercise Intervention on Cardiometabolic Health in Middle-Aged Obese Adults: A Randomized Controlled Trial. 2021 , 8, 705282	1
594	Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy: what is next?. 2021 , 36, 776-783	
593	Sortilin and Homocysteine as Potential Biomarkers for Coronary Artery Diseases. 2021 , 14, 6167-6176	0
592	Interleukin-1 β s a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. 2021 , 144, 893-908	8
591	Association between histological severity of Helicobacter pylori infection and cardiovascular risk scores in the Korean population. 2021 , 333, 124-130	1
590	Gestational hyperglycemia and the risk of cardiovascular diseases among elderly Chinese women: Findings from the REACTION study. 2021 , 13, 949-959	1
589	Cardiovascular Health Trajectories and Elevated C-Reactive Protein: The CARDIA Study. 2021 , 10, e019725	1
588	Inflammation and Comorbidity. Are There any Chances to Improve the Prognosis in Patients with Extremely High Cardiovascular Risk?. 2021 , 17, 606-611	1
587	HIV and Antiretroviral Therapy Are Independently Associated with Cardiometabolic Variables and Cardiac Electrical Activity in Adults from the Western Cape Region of South Africa. 2021 , 10,	1
586	Sex-Related Differences in Cardiovascular Disease Risk Profile in Children and Adolescents with Type 1 Diabetes. 2021 , 22,	1
585	Inflammatory cardiovascular risk markers and silent myocardial ischemia in type 2 diabetic patients. 2021 , 10-10	
584	Increased Omega-3 Fatty Acid Intake Is Inversely Associated with Subclinical Inflammation in Healthy Elderly Men, Based on the 2015-2018 Korean National Health and Nutrition Examination Survey. 2021 , 13,	1
583	Assessment of female sex in preclinical vascular models. 2021 , 349-385	
582	Obesity, Metabolic Syndrome and Disorders of Energy Balance. 2021 , 939-1003	0

581	The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. 2021 , 42, 896-903	48
580	Dried Pears: Phytochemicals and Potential Health Effects. 325-356	1
579	Inflammation and Metabolic Syndrome. 210-228	4
578	Role of inflammation in atrial fibrillation: A comprehensive review of current knowledge. 2021 , 37, 1-10	5
577	Inflammation is a crucial feature of atherosclerosis and a potential target to reduce cardiovascular events. 2005 , 697-722	11
576	The Relationship Between Periodontal Disease and Systemic Disease in the Elderly. 2008 , 247-271	2
575	The Genetics of Innate Immunity and Inflammation in Ageing, Age-Related Diseases and Longevity. 2007 , 154-173	1
574	Cytokine-Induced Sickness Behavior and Depression. 2009 , 145-181	1
573	Interactions of Dietary Patterns, Systemic Inflammation, and Bone Health. 2013 , 19-30	1
572	Inflammation Through a Psychoneuroimmunological Lens. 2013 , 279-299	11
571	Cytokine Regulation in Major Depression. 2003 , 259-280	1
570	Identification of diseases that may be targets for complementary and alternative medicine (CAM). 2004 , 546, 75-104	3
569	Menopausal Hormone Therapy. 2004 , 321-348	0
568	Lipid Metabolism and Coronary Artery Disease. 2006 , 130-137	4
567	Endothelial Dysfunction, Inflammation, and Exercise. 2009 , 131-147	1
566	Lipoprotein(a) as an Emerging Risk Factor for Atherothrombosis. 2007 , 241-266	2
565	Cardiovascular Disease in Women. 2007 , 349-368	2
564	C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease. 2007 , 69-112	1

563	From Vulnerable Plaque to Vulnerable Patient. 2011 , 13-38	4
562	Comprehensive Non-contrast CT Imaging of the Vulnerable Patient. 2011 , 375-391	1
561	Dietary Mg Intake and Biomarkers of Inflammation and Endothelial Dysfunction. 2013 , 35-50	2
560	Inflammation, C-Reactive Protein, and Vulnerable Plaques. 2007 , 611-620	2
559	Risk Factors for Frailty and Cardiovascular Diseases: Are They the Same?. 2020 , 1216, 39-50	12
558	Inflammation, 'Frailty' and 'Cardiovascular' Disease. 2020 , 1216, 55-64	49
557	Kardiologie. 2008 , 343-387	2
556	Depression and Cardiovascular Disease in Women: Behavioral and Biological Mechanisms Involved in this Association. 2015 , 41-61	1
555	Epidemiology of Atherosclerotic Vascular Disease. 2002 , 3-16	1
554	Immunological Aspects of Moyamoya Disease. 2010 , 82-86	1
553	Links Between Biomarkers and Mortality. 2011 , 381-398	15
552	Sudden Cardiac Death. 2004 , 720-731	9
551	The Effects of Hormone Therapy on Inflammatory, Hemostatic, and Fibrinolytic Markers in Postmenopausal Women. 2007 , 471-480	3
550	Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors. 2012 , 731-805	4
549	Specific Proteins. 2011 , 259-272	3
548	Lipoprotein(a). 2009 , 130-143	11
547	Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review. 2020 , 75, 2726-2737	18
546	Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin:cholesterol acyltransferase. 2001 , 42, 967-975	42

545	Childhood socioeconomic status and inflammation: Psychological moderators among Black and White Americans. 2020 , 39, 497-508	9
544	Air pollution. 2005 , 480-494	1
543	Acute Coronary Syndromes. 2009 , 535-596	9
542	New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in smokers. 2005 , 12, 542-7	13
541	Is high-sensitivity C-reactive protein associated with carotid atherosclerosis in healthy Koreans?. 2005 , 12, 548-54	11
540	Physical performance is associated with markers of vascular inflammation in patients with coronary heart disease. 2006 , 13, 356-362	6
539	Treatment of patients with lipid disorders in the primary care setting: new treatment guidelines and their implications. 2003 , 96, 266-75	5
538	Correlation of high-sensitivity C-reactive protein and plasma fibrinogen with individual complications in patients with type 2 diabetes. 2006 , 99, 23-7	14
537	Gender Differences in Mortality After Left Ventricular Assist Device Implant: A Causal Mediation Analysis Approach. 2021 , 67, 614-621	6
536	C-reactive protein: the harbinger of cardiovascular diseases. 2008 , 101, 525-33	4
535	Assessing 42 inflammatory markers in 321 control subjects and 887 major depressive disorder cases: BMI and other confounders and overall predictive ability for current depression.	2
534	Venous and arterial disease in inflammatory bowel disease. 2013 , 28, 1095-113	49
533	Innate immunity, local inflammation, and degenerative disease. 2002 , 2002, re3	43
532	Gut permeability, inflammation, and bone density across the menopause transition. 2020 , 5,	14
531	Serum amyloid A-containing HDL binds adipocyte-derived versican and macrophage-derived biglycan, reducing its antiinflammatory properties. 2020 , 5,	1
530	Hepatic JAK2 protects against atherosclerosis through circulating IGF-1. 2017 , 2,	9
529	C-reactive protein: a critical update. 2003 , 111, 1805-12	1134
528	C-reactive protein: a critical update. 2003 , 111, 1805-1812	2388

527	Serum amyloid A impairs the antiinflammatory properties of HDL. 2016 , 126, 266-81	88
526	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. 2000 , 2000, 394-408	1
525	Current understanding of the bi-directional relationship of major depression with inflammation. 2012 , 2, 4	11
524	Novel biomarkers for cardiovascular risk prediction. 2017 , 14, 135-150	109
523	Atherosclerosis. 2006 , 363-378	1
522	Rheumatoid Arthritis. 2007 ,	1
521	Lycopene and Risk of Cardiovascular Disease. 2005 ,	3
520	CMR plaque characterization. 2005 , 116-127	1
519	Health Effects of Urban Air Pollution in India. 2010 , 165-201	1
518	Influence of hypertension, obesity and nicotine abuse on quantitative and qualitative changes in acute-phase proteins in patients with essential hypertension. 2012 , 18, CR330-6	4
517	Cholesterol ester transfer protein (CETP) gene polymorphism and selected parameters of lipid metabolism in children from families with history of cardiovascular system diseases. 2013 , 19, 818-25	8
516	Oxidative Stress and C-Reactive Protein in Patients with Cerebrovascular Accident (Ischaemic Stroke): The role of Ginkgo biloba extract. 2012 , 12, 197-205	13
515	Nonfasting Lipemia and Inflammation as Cardiovascular Disease Risks After SCI. 2009 , 14, 15-31	5
514	Cardiometabolic Risk Clustering and Atherosclerosis: Is There a Link in Spinal Cord Injury?. 2011 , 16, 1-13	6
513	Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers. 2018 , 24, 379-423	41
512	Anti-inflammatory properties of antidiabetic agents. 2019 , 7, 129-141	2
511	C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies. 2008 , 3, e1395	64
510	Glucokinase regulatory protein genetic variant interacts with omega-3 PUFA to influence insulin resistance and inflammation in metabolic syndrome. 2011 , 6, e20555	22

509	Levels and determinants of inflammatory biomarkers in a Swiss population-based sample (CoLaus study). 2011 , 6, e21002	48
508	Multiple inflammatory biomarker detection in a prospective cohort study: a cross-validation between well-established single-biomarker techniques and an electrochemiluminescence-based multi-array platform. 2013 , 8, e58576	22
507	Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis--a population-based longitudinal follow-up study. 2013 , 8, e64155	32
506	Eosinophil inversely associates with type 2 diabetes and insulin resistance in Chinese adults. 2013 , 8, e67613	16
505	Glycosylation of immunoglobulin g: role of genetic and epigenetic influences. 2013 , 8, e82558	70
504	Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. 2014 , 9, e94073	12
503	Adipose tissue-derived human serum amyloid a does not affect atherosclerotic lesion area in hSAA1+/-/ApoE-/- mice. 2014 , 9, e95468	7
502	Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability. 2014 , 9, e100045	60
501	Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients. 2014 , 9, e105442	18
500	Endoplasmic reticulum stress mediates the anti-inflammatory effect of ethyl pyruvate in endothelial cells. 2014 , 9, e113983	12
499	Peripheral Endothelial (Dys)Function, Arterial Stiffness and Carotid Intima-Media Thickness in Patients after Kawasaki Disease: A Systematic Review and Meta-Analyses. 2015 , 10, e0130913	21
498	Effect of Vitamin D3 Supplementation on Inflammatory Markers and Glycemic Measures among Overweight or Obese Adults: A Systematic Review of Randomized Controlled Trials. 2016 , 11, e0154215	22
497	Changes in Cardiovascular Health Status and the Risk of New-Onset Hypertension in Kailuan Cohort Study. 2016 , 11, e0158869	1
496	Serum amyloid A, protein Z, and C4b-binding protein β chain as new potential biomarkers for pulmonary tuberculosis. 2017 , 12, e0173304	20
495	Multi-walled carbon nanotube-physicochemical properties predict the systemic acute phase response following pulmonary exposure in mice. 2017 , 12, e0174167	50
494	Serum biomarkers in patients with ossification of the posterior longitudinal ligament (OPLL): Inflammation in OPLL. 2017 , 12, e0174881	22
493	Diagnostic Value of C-Reactive Protein in Patients with Angiographically Documented Coronary Heart Disease. 2002 , 45, 155-160	1
492	Effects of coenzyme Q10 supplementation on C-reactive protein and homocysteine as the inflammatory markers in hemodialysis patients; a randomized clinical trial. 2016 , 5, 38-43	10

491	Interleukin 6 G-174C polymorphism influences outcome following coronary revascularization surgery. 2005 , 8, E140-5; discussion E145	17
490	Repercussions of adjuvant-induced arthritis on body composition, soleus muscle, and heart muscle of rats. 2020 , 53, e8969	2
489	[The influence of estrogen and progestogen replacement on growth hormone activity in women with hypopituitarism]. 2008 , 52, 901-16	3
488	Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis. 2010 , 10, 19-25	9
487	The impact of the cumulative burden of LDL-c and hs-CRP on cardiovascular risk: a prospective, population-based study. 2020 , 12, 11990-12001	4
486	Ongoing clinical trials of the pleiotropic effects of statins. 2005 , 1, 29-40	35
485	Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. 2006 , 2, 221-37	55
484	Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events. 2012 , 26, 217	2
483	Role of C reactive protein (CRP) in leptin resistance. 2014 , 20, 609-15	45
482	Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment. 2020 , 18, 431-446	10
481	Expanded Network of Inflammatory Markers of Atherogenesis: Where Are We Now?. 2010 , 4, 38-44	3
480	Expanded network of inflammatory markers of atherogenesis: where are we now?. 2010 , 4, 38-44	5
479	[The influence of age and the beginning of menopause on the lipid status, LDL oxidation, and CRP in healthy women]. 2007 , 135, 280-5	4
478	[Gender difference in lipopemic and anti-inflammatory effects of statins in diabetics with coronary artery disease]. 2009 , 66, 966-72	3
477	Evaluation of Neutrophil-lymphocyte and Platelet-lymphocyte Ratios as Predictors of 30-day Mortality in Patients Hospitalized for an Episode of Acute Decompensated Heart Failure. 2019 , 38, 452-460	8
476	C-Reactive Protein/Albumin and Neutrophil/Albumin Ratios as Novel Inflammatory Markers in Patients with Schizophrenia. 2020 , 17, 902-910	11
475	Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency. 2013 , 36, 28-32	21
474	Endogenous sex hormones and their associations with cardiovascular risk factors in post-menopausal women. 2013 , 36, 588-92	7

473	Serum HMGB1 levels and its association with endothelial dysfunction in patients with polycystic ovary syndrome. 2018 , 67, 911-919	10
472	The effect of shift work on high sensitivity C-reactive protein level among female workers. 2019 , 31, e5	6
471	Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease. 2010 , 16, 2604-8	16
470	Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. 2010 , 16, 4773-83	130
469	Disease monitoring in inflammatory bowel disease. 2015 , 21, 11246-59	86
468	Atherosclerosis Prediction with High Sensitivity C-Reactive Protein (hs-CRP) and Related Risk Factor in Patient with Dyslipidemia. 2019 , 7, 3887-3890	8
467	Significance of inflammatory markers in diabetic patients with stable coronary artery disease. 2009 , 24, 212-9	6
466	Relation of anti- to pro-inflammatory cytokine ratios with acute myocardial infarction. 2010 , 25, 44-50	40
465	Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. 2009 , 76, 37-44	7
464	[C-reactive protein and carotid intima-media thickness in a population of middle-aged Koreans]. 2009 , 42, 29-34	5
463	Epicardial adipose tissue: far more than a fat depot. 2014 , 4, 416-29	115
462	[Inflammation and C-reactive protein in cardiovascular disease]. 2009 , 129, 1221-4	4
461	Interleukin-4, Oxidative Stress, Vascular Inflammation and Atherosclerosis. 2010 , 18, 135-144	36
460	Association of Serum Total Bilirubin with Serum High Sensitivity C-reactive Protein in Middle-aged Men. 2011 , 32, 327-33	12
459	Alterations in Lipid Metabolism and Antioxidant Status in Lichen Planus. 2015 , 60, 439-44	21
458	Association of periodontal and cardiovascular diseases: South-Asian studies 2001-2012. 2015 , 19, 495-500	10
457	The effect of sub-antimicrobial dose-doxycycline periodontal therapy on serum inflammatory biomarker C-reactive protein levels in post-menopausal Women: A 2-year, double-blinded, randomized clinical trial. 2013 , 4, 71-3	2
456	Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome. 2015 , 6, 130-5	32

455	Association between dietary iron, iron stores, and serum lipid profile in reproductive age women. 2014 , 3, 15	9
454	Association of Elevated C-Reactive Protein with Severe Periodontitis in Hypertensive Patients in Lagos, Nigeria: A Pilot Study. 2018 , 9, S95-S99	1
453	Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. 2007 , 13, 363-72	43
452	Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?. 2015 , 7, 633-44	30
451	Associations between Periodontal Disease Parameters and Coronary Heart Disease in Greek Adults: A Cross-sectional Study. 2015 , 4, 4-10	1
450	Mean platelet volume is associated with aortic intima-media thickness in patients without clinical manifestation of atherosclerotic cardiovascular disease. 2015 , 15, 753-8	8
449	Neutrophil-to-lymphocyte ratio predicts hemodynamic significance of coronary artery stenosis. 2015 , 15, 1002-7	17
448	Testing lipid markers as predictors of all-cause morbidity, cardiac disease, and mortality risk in captive western lowland gorillas (). 2020 , 7, 41-59	1
447	Relationship between periodontitis and cardiovascular diseases: A literature review. 2014 , 3, 1	2
446	Acute phase reactants as novel predictors of cardiovascular disease. 2012 , 2012, 953461	49
445	SOLUBLE CELL ADHESION MOLECULES S-VCAM-1 AND S-ICAM-1 IN SUBJECTS WITH FAMILIAL COMBINED HYPERLIPIDEMIA. 2005 , 149, 101-108	15
444	Inflammation and cardiovascular disease. 2019 , 8, 1-8	19
443	Pravastatin improves insulin resistance in dyslipidemic patients. 2005 , 12, 322-9	20
442	Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. 2010 , 17, 37-44	31
441	Usefulness of C-reactive protein to high-molecular-weight adiponectin ratio to predict insulin resistance and metabolic syndrome in Japanese men. 2010 , 17, 944-52	5
440	Derivatives of reactive oxygen metabolites correlates with high-sensitivity C-reactive protein. 2008 , 15, 206-12	38
439	Effect of a Probiotic Preparation (VSL#3) on CardiovascularRisk Parameters in Critically-Ill Patients. 2013 , 5, 67-70	13
438	Effects of Whole Body Vibration Training on Inflammatory Markers in Young Healthy Males. 2019 , 17,	1

437	Changes of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention. 2016 , 5, e28997	8
436	Green Tea Supplementation During Resistance Training Minimally Affects Systemic Inflammation and Oxidative Stress Indices in Obese Men. 2019 , In Press,	3
435	Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. 2002 , 126, 1281-95	55
434	Hypercoagulation testing in ischemic stroke. 2007 , 131, 890-901	38
433	Correlation between C-reactive protein in peripheral vein and coronary sinus in stable and unstable angina. 2015 , 104, 202-8	3
432	Increased P-wave dispersion in patients with newly diagnosed lichen planus. 2013 , 68, 846-50	14
431	The Association between Monocyte HDL-C Ratio and SYNTAX Score and SYNTAX Score II in STEMI Patients Treated with Primary PCI. 2018 , 34, 23-30	13
430	Research progress of gut microbiota and frailty syndrome. 2021 , 16, 1525-1536	1
429	Moderating effect of ppar- γ on the association of c-reactive protein and ischemic stroke in patients younger than 60. 2022 , 809, 146029	1
428	Association between coronary artery vitamin D receptor expression and select systemic risks factors for coronary artery atherosclerosis. 2021 , 1-7	
427	Study of Some Inflammatory Mediators in the Serum of Patients With Atherosclerosis and Acute Myocardial Infarction. 2021 , 13, e18450	0
426	[Correlation between insufficiency or deficiency of vitamin D levels and interleukins 1 β and 6]. 2021 , 68, 180-184	
425	Infectious Myocarditis. 2001 , 259-269	
424	APPENDIX VI. 2002 , 949-955	
423	C-Reactive Protein.	
422	Metabolic Syndrome X and low-grade systemic inflammation. 2002 , 61-93	
421	Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall. 2002 , 81-98	
420	Kardiovaskuläre Risikofaktoren und deren Bedeutung für die Entstehung der koronaren Herzkrankheit bei der Frau. 2002 , 15-37	

419 Effects of Estrogen Replacement in Women with Coronary Disease. **2002**, 131-138

418 ????????LDL??? (5.????????????????????) (66????????????). **2002**, 10, 287-291

417 References. **2002**, 106, 3373-3421

1

416 Inflammation and Cardiovascular Disease. **2003**, 3-18

415 Rationale for the Early Clinical Application of Markers of Ischemia in Patients with Suspected Acute Coronary Syndromes. **2003**, 245-257

414 Cardiovascular Risk Factors and the Development of Coronary Heart Disease in Women. **2003**, 13-33

413 The Newer Coronary Risk Factors. **2003**, 193-211

412 Association between coronary endothelial dysfunction and local inflammation of atherosclerotic coronary arteries. **2003**, 67-73

411 C-Reactive Protein for Primary Risk Assessment. **2003**, 279-290

410 [Statins and cerebral ischemia]. **2003**, 60, 461-70

409 Preanalytic and Analytic Sources of Variations in C-Reactive Protein Measurement. **2003**, 305-317

408 Nutritional Issues of Cardiovascular Disease in Women. **2003**, 257-293

407 Risk Assessment in Patients with Non-ST Elevation Acute Coronary Syndromes. **2003**, 97-108

406 Novel Atherosclerotic Risk Factors and Management. **2003**, 41-58

405 Diet, Atherosclerosis, and Endothelial Dysfunction. **2003**,

404 Guidelines for clinical use of the statins. **2003**, 200-212

403 Endothelial Cell Biology: Inflammatory Biomarkers and Risk of Transplant Atherosclerosis. **2004**, 591-605

402 Serum Biomarkers in Prediction of Stroke Risk and Outcome. **2004**, 257-278

- 401 Markers of myocardial damage and inflammation in patients with coronary artery disease. **2004**, 23, 249-253
- 400 Genes That Modify Susceptibility to Atherosclerosis: Targets for Drug Action. **2004**, 79-105
- 399 Infection and Atherosclerosis. **2004**, 701-709 0
- 398 Kardiologie. **2004**, 313-356
- 397 Angiologie. **2004**, 389-418
- 396 State-of-the-Art Diagnostic Testing in Women. **2004**, 173-194
- 395 B-Type Natriuretic Peptides in Acute Coronary Syndromes. **2004**, 323-338
- 394 Statins and Plaque Stabilization. **2004**, 521-562
- 393 [Cardiovascular diseases mortality in the population of Belgrade aged 30-69 years for 1990-2002 period]. **2005**, 62, 343-8 0
- 392 Determination of high sensitivity C-reactive protein: Clinical and analytical quality. **2005**, 24, 85-93 1
- 391 Vascular Inflammation as a Cardiovascular Risk Factor. **2005**, 577-604
- 390 Air Pollutants, Epithelial Surfaces, and Lung Disease. **2005**, 185-222 2
- 389 Gene-Environment interaction in coronary artery disease: apolipoprotein E and smoking and the interleukin-6 gene and inflammation as examples. **2005**, 528-544
- 388 Coagulation, thrombosis, and coronary heart disease. **2005**, 466-479
- 387 Antihypertensive Drugs. **2005**, 165-200
- 386 Obesity, Cytokines, and Other Inflammatory Markers. **2005**, 317-327 1
- 385 Lack of Association Between Genetic Variation in 9 Innate Immunity Genes and Baseline CRP Levels. **2006**, 060721082338045
- 384 Cognitive Function in the Elderly with Diabetes Mellitus. **2006**, 38, 19-24

383 Analytic Issues for Clinical Use of C-Reactive Protein. **2006**, 223-235

382 Statins, Inflammation, and Cardiomyopathy: Old Pathways, New Targets. **2006**, 155-166

381 Vascular Dysfunction and Obesity. **2006**, 93-120

380 The Metabolic Syndrome: Time for a Critical Appraisal. **2006**, 12, 99-116

3

379 The Metabolic Syndrome: Identification and Management of the Patient at High Risk for Cardiovascular Disease. **2006**, 409-440

378 Risk Factors for Cardiovascular Disease and the Framingham Study Equation. **2006**, 1-18

377 Stroke Prevention. **2006**, 545-584

376 Metabolic Syndrome and Type 2 Diabetes Mellitus. **2006**, 41-78

375 Effects of Particles on the Cardiovascular System. **2006**, 259-273

374 Sleep apnea and stroke. **2006**, 209-224

373 Preventive Cardiology: The Effects of Exercise. **2007**, 2631-2648

372 Effect of Low-Dose Theophylline on Airway Resistance, Respiratory Muscle Strength, and High-Sensitivity C-reactive Protein in Patients with Chronic Obstructive Pulmonary Disease. **2007**, 33, 141-144

2

371 Prediction of Global Cardiovascular Risk in Hypertension. **2007**, 190-198

370 Mechanisms of Action of Estrogen on the Cardiovascular System. **2007**, 453-459

369 Biomarkers of Inflammation as Surrogate Markers in Detection of Vulnerable Plaques and Vulnerable Patients. **2007**, 641-651

1

368 Management of Lipids in the Elderly. **2007**, 369-387

367 Risk Factors for Cardiovascular Disease and Arterial Thrombosis. **2007**, 371-378

366 Coronary Risk Factors: An Overview. **2007**, 2609-2630

365 Atherosclerotic Vulnerable Plaques: Pathophysiology, Detection, and Treatment. **2007**, 621-639

364 Depression and the inflammatory state. **2007**, 49, 143-146

1

363 Heart disease and stroke. **2007**, 45-59

362 Carotid vulnerable plaque. **2007**, 75-86

361 Risk Factors for Cardiovascular Disease and the Framingham Study Equation. **2007**, 1-18

360 Nutritional Modulation of Inflammation in Metabolic Syndrome. **2007**, 227-242

359 Impact of hypertension, smoking and liver affection on endothelial dysfunction and subsequent vascular damage in Saudi middle aged males. **2007**, 5, 179-188

358 Women and Coronary Heart Disease. **2008**, 71-96

357 High-Sensitivity C-Reactive Protein and the Metabolic Syndrome. **2008**, 167-188

356 Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. **2008**, 1009-1033 ¹

355 Biochemical Aspects, Laboratory Diagnosis and Follow-Up of High Blood Cholesterol: NCEP ATP III Guidelines. **2008**, 27, 64-85

354 Obesity and C-reactive Protein Levels Among White, Black, and Hispanic US Adults.

353 The effect of 12 week combined exercise on cardiovascular risk factors and inflammation markers in obese middle school girls. **2008**, 17, 173-182

2

352 The Effect of Weight Reduction Diet on C-Reactive Protein Level in Obese-Adult Subjects. **2008**, 9, 17-23

3

351 Composizione corporea con tecnica DXA. **2009**, 401-418

350 Lipid Disorders. **2009**, 65-75

349 3.???CRP????????? ??????????????????(N Engl J Med 2006)?????????. **2009**, 40, 171S-172S

348 Diet and Exercise in the Prevention and Management of the Metabolic Syndrome. **2009**, 149-160

- 347 Thyroid and Cardiovascular Risk. **2009**, 151-165 1
- 346 Cardiovascular Issues. **2009**, 397-413
- 345 The Association between Serum GGT within Normal Range and Cardiovascular Risk Factors, Metabolic Syndrome of Premenopausal and Postmenopausal Women. **2009**, 13, 171-181
- 344 Inflammatory and Anti-Inflammatory Mediators Secreted by Adipose Tissue. **2009**, 65-81
- 343 [Are de novo acute heart failure and acutely worsened chronic heart failure two subgroups of the same syndrome?]. **2010**, 138, 162-9
- 342 Hypercoagulable States. **2010**, 588-598
- 341 Atherosclerosis. **2010**, 53-67
- 340 1.?????????????????. **2010**, 41, 90-94
- 339 Relationship between complex plaques detected by vascular ultrasound and plaque destabilization. **2010**, 37, 455-462
- 338 Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood. **2011**, 53-66
- 337 Implications of genetic polymorphisms in inflammation-induced atherosclerosis. **2010**, 4, 30-7 8
- 336 Atherothrombosis in South asians: implications of atherosclerotic and inflammatory markers. **2010**, 4, 45-50 1
- 335 The Metabolic Syndrome: 2009. **2011**, 137-163
- 334 Anemia and Cardiovascular Disease. 229-251
- 333 Newer Coronary Risk Factors. **2011**, 113-139
- 332 Metabolic Syndrome and Inflammation. **2011**, 69-92 1
- 331 Collagen Vascular and Infectious Diseases. **2011**, 687-702
- 330 -174G>C Interleukin-6 Gene Polymorphism in Tunisian Patients with Coronary Artery Disease. **2011**, 31, 40-44 1

- 329 Effect of *Helicobacter pylori* Eradication on High Density Lipoprotein Cholesterol and Prevalence of Metabolic Syndrome. **2011**, 11, 176
- 328 Extra-articular features of rheumatoid arthritis and systemic involvement. **2011**, 839-848.e1 0
- 327 A Study on Blood Lipid Levels, Nutrient Intakes, and Oxidation and Inflammation Markers of Overweight and Obese Adults according to Blood Cholesterol Levels in Korea. **2011**, 24, 1-11 6
- 326 Empirical Evaluation of Ensemble Approach for Diagnostic Knowledge Management. **2011**, 20, 237-255 1
- 325 Other cardiovascular consequences of sleep apnea. **2011**, 251-285
- 324 Approach to the Patient with Chest Pain. **2012**, 349-371
- 323 Inflammatory Biomarkers. **2012**, 481-495
- 322 Imaging of Atherosclerosis. **2012**, 583-611
- 321 Future Directions of Atherosclerosis Research and Translation into Clinical Application. **2012**, 613-623
- 320 Cardiovascular Implications. **2012**, 475-491
- 319 Cardiovascular Disease. **2012**, 478-549
- 318 Stroke-Related Inflammation and Infection. **2012**, 14, 6
- 317 Sleep-Disordered Breathing and Cardiac Arrhythmias: Role of Intermittent Hypoxia. **2012**, 3-14
- 316 The Pathophysiology of Coronary Artery Disease. **2012**, 1-28 1
- 315 Preoperative Cardiovascular Risk Assessment. **2013**, 57-69
- 314 Childhood Obesity. **2012**, 863-888
- 313 Medical Management of Carotid Artery Disease. 389-404
- 312 Novel Biomarkers of Cardiovascular Disease. **2013**, 27-43

311 Pentraxins.

310 Inflammatory Markers and Mortality in Critical Lower Limb Ischemia. **2013**, 91-96

309 Dried Cherries: Phytochemicals and Health Perspectives. 243-257

308 Benefits and Risks of Exercise for the Coronary Patient. **2013**, 1037-1051

307 C-Reactive Protein in Cardiovascular Disease. **2013**, 3-18

306 Antithrombotic Issues in Women. **2014**, 321-357

305 ASSOCIATION OF MENOPAUSE WITH INFLAMMATION-SENSITIVE PROTEIN THE C-REACTIVE PROTEIN AMONG THE INDIAN WOMEN. **2013**, 2, 10144-10153

o

304 Lipid Nephrotoxicity: New Concept for an Old Disease. **2014**, 9-25

303 Sudden Cardiac Death in Adults. **2014**, 981-991

302 Integration of Biomarkers with Plaque Imaging. **2014**, 203-214

301 Obesity and Cancer: Clinical Epidemiology. **2014**, 583-594

300 New Biomarkers of Cardiovascular Disease in Diabetes. 30-57

299 [What pathomechanisms can lead to stroke in obstructive sleep apnea?]. **2014**, 155, 615-9

o

298 [Beneficial effect of continuous positive airway pressure therapy in obstructive sleep apnea syndrome]. **2014**, 155, 1855-9

297 Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles. **2015**, 1-24

1

296 Trans Fatty Acids: A Summary of the Evidence Relating Consumption to Cardiovascular Outcomes and the Efficacy of Prevention Policy to Reduce Levels in the Food Supply. **2015**, 273-296

295 Extraarticular features of rheumatoid arthritis and systemic involvement. **2015**, 712-719

1

294 Lipid and Inflammation in Atherosclerosis. **2015**, 37-63

- 293 Cardiovascular and Metabolic Syndrome Impact on Uristatin. **2015**, 157-170
- 292 Inflammation Biomarkers and Cardiometabolic Risk. **2015**, 1-24
- 291 Berries in the Nutritional Management of Metabolic Syndrome. **2015**, 364-371
- 290 Inflammation and Insufficient or Disordered Sleep. **2015**, 47, 97-104 4
- 289 ASSESSMENT OF INFLAMMATORY MARKERS AND LIPID PROFILE LEVELS IN NORMOTENSIVE, PRIMARY HYPERTENSIVE AND SECONDARY HYPERTENSIVE MALE OBESE INDIVIDUALS. **2015**, 4, 16337-16340
- 288 Postmenopausal Hypertension and Coronary Artery Disease Risk. **2016**, 329-350
- 287 C-Reactive Protein Decrease After Postbariatric Abdominoplasty. **2016**, 407-411
- 286 Sulforaphane and Atherosclerosis. **2016**, 1-19
- 285 High Sensitive C - Reactive Protein Levels in Pre and Post Menopausal Healthy Women in Kirkuk City-Iraq. **2016**, 2,
- 284 The Role of High-sensitivity C-reactive Protein as a Cardiovascular Risk Marker in Essential Hypertension. **2016**, 02, 23-28
- 283 Is a Potential Therapeutic Strategy of Periodontal Intervention on Cardiovascular Disease, Yes or No?. **2017**, 08, 52-64
- 282 Sulforaphane and Atherosclerosis. **2017**, 319-337
- 281 Echocardiographic epicardial fat thickness measurement: A new screening test for subclinic atherosclerosis in patients with inflammatory bowel diseases. **2017**, 4, 4-12 1
- 280 Gesamtliteraturverzeichnis. **2017**, 1-153
- 279 Cardiovascular Diseases among Women. **2017**, 62, 18-23
- 278 Effects of 8 weeks of circuit training on blood lipids, insulin resistance, cardiovascular function, and metabolic syndrome risk factors in bus drivers. **2017**, 28, 11-25 0
- 277 Periodontal Diseases and Possible Future Cardiovascular Events, Are they Related? An Overview. **2017**, 6,
- 276 Gestasyonel diabetes mellitusta osteopontin seviyeleri artmaz. **2017**, 56, 173-177

- 275 TO STUDY THE RELATIONSHIP BETWEEN MICROALBUMINURIA AND ISCHAEMIC HEART DISEASE IN NON-DIABETIC SUBJECTS. **2018**, 7, 2562-2565
- 274 Serum Level of Endothelial Cell-Specific Molecule -1 (ESM -1) as a New Potential Biomarker for Rheumatoid Arthritis Disease Activity. **2018**, 12, 189-196 ○
- 273 Targeting C-Reactive Protein in Inflammatory Disease. **2019**, 173-186
- 272 Effect of ultramarathon race on liver and skeletal muscle biomarkers in recovery period. **2019**, 178,
- 271 Nutraceuticals and Metabolic Syndrome. **2019**, 167-195
- 270 The Effects of Menopausal Hormone Therapy on Serum Level of C-reactive Protein in Postmenopausal Korean Women. **2019**, 25, 49-54 ○
- 269 Atherosclerosis Risk Factors. **2019**, 9-45
- 268 Maternal biomarker patterns for metabolism and inflammation in pregnancy are influenced by multiple micronutrient supplementation and associated with childrens biomarker patterns and nutritional status at 9-12 years of age in Lombok, Indonesia.
- 267 A COMPARATIVE STUDY OF hsCRP AND LDL-C/HDL-C RATIO IN ACUTE CORONARY SYNDROME. **2019**, 6, 1567-1569
- 266 The Impact of Very Low-Calorie Diet-Induced Weight Loss on Changes in the Serum Vitamin D Levels, Insulin Resistance, and Inflammatory Biomarkers in Overweight Korean Women. **2019**, 29, 238-252 ○
- 265 Type I interferon responses to ischemic injury begin in the bone marrow of mice and humans and depend on Tet2, Nrf2, and Irf3. 1
- 264 Treatments. **2020**, 35-83
- 263 Clinical outcome of intracoronary versus intravenous high-dose bolus administration of tirofiban in diabetic patients undergoing primary percutaneous coronary intervention. **2019**, 30, 285-289 1
- 262 Other Important Differences in Clinical Care. **2020**, 153-175
- 261 Pathophysiology of Atherosclerosis. **2020**, 19-45 1
- 260 Serum levels of Total Sialic Acid and Lipid Profile with the Severity of the Vessel in patients with non-smoker and diabetic Coronary Artery Disease. **2020**, 42, 152-159
- 259 The Relationship Between Antioxidants and Inflammation in Children With Attention Deficit Hyperactivity Disorder. **2020**, 11, 313-321 2
- 258 Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections. **2020**, 212-228

- 257 C-reactive protein and cardiovascular disease: From animal studies to the clinic (Review). **2020**, 20, 1211-1219 3
- 256 Prevention and/or recovery from corona virus infections. **2020**, 022-024
- 255 Effectiveness of vitamin D2 supplementation on high-sensitivity C-reactive protein and other metabolic indices in menopausal Thai women: a randomized-controlled trial. **2021**, 1-7 0
- 254 Nanomaterial- and shape-dependency of TLR2 and TLR4 mediated signaling following pulmonary exposure to carbonaceous nanomaterials in mice. **2021**, 18, 40 1
- 253 Effects of Lifestyle Intervention on Inflammatory Markers and Waist Circumference in Overweight/Obese Adults With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2022**, 24, 94-105 3
- 252 Association between Biomarkers of Oxidative Stress and Inflammation with Cardiac Necrosis and Heart Failure in Non-ST Segment Elevation Myocardial Infarction Patients and Various Degrees of Kidney Function. **2021**, 2021, 3090120 1
- 251 Variability of C-reactive protein in first-generation Ecuadorian immigrants living in the United States. **2020**, 33, e23547 1
- 250 Inflammation and Atherosclerotic Cardiovascular Disease. **2021**, 289-333
- 249 Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. **2021**, 19, 323-342 8
- 248 Mitogen and Stress-Activated Kinases 1 and 2 Mediate Endothelial Dysfunction.
- 247 Association of high sensitivity C-reactive protein and metabolic syndrome components in middle-aged subjects without overt cardiovascular disease in LitHiR primary prevention programme. **2020**, 26, 14-19
- 246 Multiple Faces of C-Reactive Protein: StructureFunction Relationships. **2020**, 1-34
- 245 The Process of Acute and Chronic Inflammation. **2020**, 1-23 0
- 244 Uric acid-lymphocyte ratios and myocardial damage parameters in ST elevated myocardial infarction. 108-113
- 243 Plasma extracellular vesicles in people living with HIV and type 2 diabetes are related to microbial translocation and cardiovascular risk. **2021**, 11, 21936 0
- 242 Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment. **2021**, 12, 703279
- 241 Plaque Rupture, Compared With Plaque Erosion, Is Associated With a Higher Level of Pancoronary Inflammation. **2021**, 0
- 240 Risk Factors. **2005**, 475-516

239	The Relation between Serum Cytokine Levels and Common Laboratory Tests in Healthy Japanese Males. 2003 , 8, 6-12	
238	Angiologie. 2008 , 421-450	
237	Influence of Antihypertensive Therapy depending on the Classes of Drugs on the Level of New Biomarkers of Inflammation GDF-15, P-Selectin and Galectin-3 in Patients with Hypertension in Combination with Type 2 Diabetes. 2020 , 5, 82-89	
236	Statins and the prevention of dementia. 2001 , 165, 908-9	6
235	Plasma C-reactive protein in nonobese children with obstructive sleep apnea before and after adenotonsillectomy. 2006 , 2, 301-4	54
234	Role of leptin in atherogenesis. 2006 , 11, 269-75	39
233	Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus. 2007 , 3, 417-23	2
232	Coronary Heart Disease (CHD) Risk Factors and Metabolic Syndrome in HIV-Positive Drug Users in Miami. 2006 , 2, 173-179	10
231	Role of plaque inflammation in acute and recurrent coronary syndromes. 2004 , 12, 106-109	6
230	Imaging of coronary atherosclerosis and identification of the vulnerable plaque. 2003 , 11, 347-358	
229	Nonobese, exercising children diagnosed with dyslipidemia have normal C-reactive protein. 2009 , 5, 65-9; quiz 70-2	1
228	Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future. 2008 , 3, 293-302	1
227	Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. 2009 , 5, 757-65	358
226	PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. 2009 , 36, 530-9	9
225	Variation in high-sensitivity C-reactive protein levels over 24 hours in patients with stable coronary artery disease. 2010 , 37, 42-8	20
224	Relationship between C-reactive protein and physical fitness, physical activity, obesity and selected cardiovascular risk factors in schoolchildren. 2010 , 1, 242-6	1
223	C-Reactive Protein: How Has JUPITER Impacted Clinical Practice?. 2009 , 9, 204-10	6
222	Modulatory Effect of Inflammation on Blood Pressure Reduction via Therapeutic Lifestyle Change. 2009 , 9, 175-80	

221	Systemic inflammation and early atheroma formation: are they related?. 2010 , 5, 292-301	8
220	Role of Oxytocin in deceleration of early atherosclerotic inflammatory processes in adult male rats. 2011 , 4, 169-78	13
219	Maintaining brain health by monitoring inflammatory processes: a mechanism to promote successful aging. 2012 , 3, 16-33	44
218	Periodontitis as a risk factor in non-diabetic patients with coronary artery disease. 2010 , 6, 106-11	5
217	Effect of metformin on serum ferritin level in women with polycystic ovary syndrome. 2011 , 13, 487-92	1
216	Correlation of oxidative stress parameters and inflammatory markers in tunisian coronary artery disease patients. 2011 , 7, 6-13	3
215	Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?. 2013 , 124, 174-90	56
214	Possible relationship of folic Acid supplementation and improved flow-mediated dilation in premenopausal, eumenorrheic athletic women. 2009 , 8, 123-9	8
213	Evaluating health and disease in Sub-Saharan Africa: minimally invasive collection of plasma in the Malawi Longitudinal Study of Families and Health (MLSFH). 2012 , 68, 1-27	10
212	Focus on the heart: alcohol consumption, HIV infection, and cardiovascular disease. 2010 , 33, 237-46	17
211	Assessment of C-reactive Protein and C3 as Inflammatory Markers of Insulin Resistance in Women with Polycystic Ovary Syndrome: A Case-Control Study. 2013 , 14, 197-201	10
210	Association between periodontal disease and plasma levels of cholesterol and triglycerides. 2013 , 44, 80-6	9
209	Effect of Brown Rice Consumption on Inflammatory Marker and Cardiovascular Risk Factors among Overweight and Obese Non-menopausal Female Adults. 2014 , 5, 478-88	9
208	Rheumatoid factor, anti-nuclear antibody in ischemic heart disease: Acute versus chronic patients. 2014 , 10, 305-10	1
207	Comparison of Biomedical Variables in PCOS Patients with Normal Iranian Women. 2015 , 9, 5-11	5
206	Relationship of inflammation and endothelial dysfunction with risks to cardiovascular disease among people in Inner Mongolia of China. 2013 , 26, 792-800	7
205	Anticoagulants and Statins As Pharmacological Agents in Free Flap Surgery: Current Rationale. 2015 , 15, e51	6
204	The Role of IL-33 in the Inflammation Process of Asthma and Atherosclerosis. 2011 , 22, 79-91	3

203	Mid-term Risk Stratification of Patients with a Myocardial Infarction and Atrial Fibrillation: Beyond GRACE and CHADS. 2013 , 6, 897	
202	Transcriptional activity of tumor necrosis factor-alpha gene in peripheral blood mononuclear cells in patients with coronary slow flow. 2017 , 13, 196-201	2
201	Immune Response in Women during Exercise in the Heat: A Spotlight on Oral Contraception. 2018 , 17, 229-236	5
200	Chemokine RANTES is increased at early stages of coronary artery disease. 2016 , 67, 321-8	20
199	Inflammation beyond the Joints: Rheumatoid Arthritis and Cardiovascular Disease. 2018 , 2,	18
198	[Expression of connexin 43 in peripheral blood monocytes from patients with acute coronary syndrome]. 2019 , 39, 471-476	
197	Associations of severity of fatty liver with oxidative stress, SAA, CRP and degree of cerebral arteriosclerosis in cerebral arteriosclerosis patients who have fatty liver. 2019 , 12, 3022-3026	2
196	Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Patients With Breast Cancer: Protocol for a Multi-Institutional Prospective Study.. 2022 , 11, e31887	
195	Inflammation and ischemic heart disease: The next therapeutic target?. 2021 , 40, 785-796	1
194	Anthropometric Measurements, Metabolic Profile and Physical Fitness in a Sample of Spanish Women with Type 2 Diabetes. 2021 , 18,	2
193	The Usefulness of C-Reactive Protein to Albumin Ratio in the Prediction of Adverse Cardiovascular Events in Coronary Chronic Total Occlusion Undergoing Percutaneous Coronary Intervention. 2021 , 8, 731261	0
192	Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: State-of-the-Art Review.. 2021 , 3, 619-634	5
191	Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study.. 2022 , 15, 681-692	0
190	How Families Make Their Way Into Your Heart: Exploring the Associations Between Daily Experiences Involving Family Members and Cardiovascular Health. 2021 ,	
189	Combined impact of residual inflammatory risk and chronic kidney disease on long-term clinical outcomes in patients undergoing percutaneous coronary intervention. 2021 ,	0
188	Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. 2021 ,	1
187	Nanoparticle theranostics in cardiovascular inflammation. 2021 , 56, 101536	0
186	The relationship between IL-6 levels and the angiographic severity of coronary artery disease following percutaneous coronary intervention in acute coronary syndrome patients. 2021 , 21, 578	0

185	Cardiovascular Protection Effect. 2021 , 397-422	
184	Glycosylation and Cardiovascular Diseases. 2021 , 1325, 307-319	1
183	A Novel Method for Quantitative Analysis of C-Reactive Protein Lateral Flow Immunoassays Images via CMOS Sensor and Recurrent Neural Networks. 2021 , 9, 1900415	1
182	Les variabilit��s ��m��taboliques��: fluctuations aigu��s et ondulations lentes, causes et cons��quences. 2022 , 16, 6-6	
181	Gesundheit am Arbeitsplatz: Wie Stress im Beruf das Herz sch��digt.	0
180	Characteristic Frequencies and Times, Signal-to-Noise Ratio and Light Illumination Studies in Nanowire FET Biosensors : Invited paper. 2020 ,	2
179	Serum Cholinesterase Level as a Marker of Systemic Low-Grade Inflammation in Isolated Systolic Hypertension: A Cross-Sectional Study. 2020 , 2,	
178	Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis. 2021 , 359	0
177	Circulating serum amyloid A levels but not SAA1 variants predict long-term outcomes of angiographically confirmed coronary artery disease. 2022 ,	0
176	TNF-��IL-1��MMP-8 Crevicular Profile in Patients with Chronic Kidney Disease and Periodontitis. 2022 , 12, 736	0
175	Modification of associations between indoor particulate matter and systemic inflammation in individuals with COPD.. 2022 , 112802	0
174	A Clinical Perspective on Arsenic Exposure and Development of Atherosclerotic Cardiovascular Disease.. 2022 , 1	
173	Metabolic Syndrome: Updates on Pathophysiology and Management in 2021.. 2022 , 23,	24
172	Defining the effects of traffic-related air pollution on the human plasma proteome using an aptamer proteomic array: A dose-dependent increase in atherosclerosis-related proteins.. 2022 , 209, 112803	0
171	Inflammation as a mechanism and therapeutic target in peripheral artery disease.. 2022 ,	0
170	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.. 2022 ,	6
169	Serial cardiac biomarker assessment in adults with congenital heart disease hospitalized for decompensated heart failure.. 2022 , 7,	2
168	Marqueurs biologiques de souffrance cardiaque. 2004 , 10, 30-32	

167	High Incidence of Metabolic Syndrome Components in Lichen Planus Patients: A Prospective Cross-Sectional Study. 2022 , 2022, 1-6	1
166	Sex Difference in the Association Between Neutrophil to Lymphocyte Ratio and Severity of Coronary Artery Disease.. 2022 , 33197211070884	1
165	Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.. 2022 , 11,	0
164	Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease.. 2022 , 9, 731325	0
163	Impulsive and aggressive traits and increased peripheral inflammatory status as psychobiological substrates of homicide behavior in schizophrenia. 2022 ,	2
162	Sedentary behaviour and physical activity are associated with biomarkers of endothelial dysfunction and low-grade inflammation-relevance for (pre)diabetes: The Maastricht Study.. 2022 , 65, 777	1
161	Interaction between CETP Taq1B polymorphism and HEI, DQI and DPI on metabolic biomarkers in patients with type 2 diabetes.. 2021 ,	0
160	Association between coronary endothelial dysfunction and local inflammation of atherosclerotic coronary arteries. 2003 , 249, 67-73	5
159	Chronic inflammatory diseases, subclinical atherosclerosis, and cardiovascular diseases: Design, objectives, and baseline characteristics of a prospective case-cohort study - ELSA-Brasil.. 2022 , 77, 100013	1
158	Cardiovascular Implications of Immune Disorders in Women.. 2022 , 130, 593-610	0
157	Greenspace, Inflammation, Cardiovascular Health, and Cancer: A Review and Conceptual Framework for Greenspace in Cardio-Oncology Research.. 2022 , 19,	2
156	Mechanisms of Arsenic Exposure-Induced Hypertension and Atherosclerosis: an Updated Overview.. 2022 , 1	0
155	The Association Between White Blood Cell Count and Insulin Resistance in Community-Dwelling Middle-Aged and Older Populations in Taiwan: A Community-Based Cross-Sectional Study.. 2022 , 9, 813222	0
154	Monocyte to high-density lipoprotein ratio at hospital admission predicts intrahospital mortality in patients with Stanford type-A dissection.. 2022 ,	1
153	The Inflammatory Pattern of Chronic Limb-Threatening Ischemia in Muscles: The TNF- α Hypothesis.. 2022 , 10,	
152	Metabolic derangement in patients with vitiligo: a cross-sectional study.. 2022 ,	2
151	Gut microbiota from Mexican patients with metabolic syndrome and HIV infection: an inflammatory profile.. 2022 ,	2
150	Interleukin 6 in diabetes, chronic kidney disease and cardiovascular disease: mechanisms and therapeutic perspectives.. 2022 ,	2

- 149 Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.. **2022**, 23, 0
- 148 Discrimination and Inflammation in Adolescents of Color. **2022**, 0
- 147 Plasma Calcium and Phosphorus Levels and Cardiovascular Disease Risks in Egyptian Type 2 Diabetic Patients. **2022**, 10, 502-513
- 146 Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies.. **2022**, 17, e0264437 0
- 145 Trust, inflammatory biomarkers and adversity: a novel investigation and clinical implications. 1-18
- 144 Effects of periodontitis and periodontal treatment on systemic inflammatory markers and metabolic profile in obese and non-obese rats.. **2022**, 1
- 143 Pharmacological role of Vitamin C in stress-induced cardiac dysfunction via alteration in Gut microbiota.. **2022**, e22986 0
- 142 Is the systemic immune-inflammation index a predictive marker of carotid artery stenosis?. **2022**, 5, 652-658 0
- 141 A Multimarker Model for Aberrant Cardiac Geometry after Preeclampsia.. **2022**, 11,
- 140 Systematic review and meta-analysis of the correlation between plasma homocysteine levels and coronary heart disease.. **2022**, 14, 646-653 0
- 139 Endometriosis Promotes Atherosclerosis in a Murine Model.. **2022**, 1
- 138 Effects of thymoquinone against angiotensin II-induced cardiac damage in apolipoprotein E-deficient mice.. **2022**, 49, 2
- 137 Update on risk factors and biomarkers of sudden unexplained cardiac death.. **2022**, 87, 102332 0
- 136 Associations between fibrinogen levels and the risk of cardiovascular disease and all-cause death: a cohort study from the Chin-Shan community in Taiwan.. **2022**, 12, e054638
- 135 Association of chronic inflammation with cardiovascular risk in chronic obstructive pulmonary disease-A cross-sectional study.. **2022**, 5, e586 1
- 134 Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality, and Systematic Review and Updated Meta-Analysis.. **2022**, 4
- 133 The Immunomodulatory Effects of Statins on Macrophages. **2022**, 2, 317-343 2
- 132 Cardiometabolic Risk Factors and Endogenous Sex Hormones in Postmenopausal Women: A Cross-Sectional Study.. **2022**, 6, bvac050 1

131	Depression duration and risk of incident cardiovascular disease: A population-based six-year cohort study.. <i>Journal of Affective Disorders</i> , 2022 , 305, 188-195	6.6	2
130	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. 2022 , 348, 25-35		2
129	ROLE OF HS CRP AND LIPID ABNORMALITIES AS RISK FACTOR IN CORONARY ARTERY DISEASE. 2021 , 37-39		
128	The Role of Exercise Training on Low-Grade Systemic Inflammation in Adults with Overweight and Obesity: A Systematic Review.. 2021 , 18,		3
127	Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig.. 2021 , 11,		0
126	Obesity, Obstructive Sleep Apnea, and Metabolic Dysfunction. 2021 , 53, 285-295		0
125	The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus.. 2021 , 10,		4
124	Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and high-sensitivity C-reactive protein in CANTOS. 2021 ,		0
123	The Role of the Association Between Serum C-Reactive Protein Levels and Coronary Plaque Macrophage Accumulation in Predicting Clinical Events - Results from the CLIMA Registry.. 2022 , 1		0
122	Visceral Adipose Tissue Influence on Health Problem Development and Its Relationship with Serum Biochemical Parameters in Middle-Aged and Older Adults: A Literature Review.. 2022 , 2022, 8350527		
121	Acute coronary syndrome in patients with cancer.. 2022 ,		
120	Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk.. 2022 ,		1
119	Sex-differential downregulation of methotrexate on plasma viscosity and whole blood viscosity in psoriasis.. 2022 ,		
118	Gender, Hyperlipidemia, and Coronary Artery Disease. 2003 , 29, 07-17		
117	Table_1.DOCX. 2019 ,		
116	Table_2.PDF. 2019 ,		
115	Image_1.TIFF. 2020 ,		
114	Image_1.TIF. 2020 ,		

113 Image_2.TIF. **2020**,

112 Image_3.TIF. **2020**,

111 Image_4.TIF. **2020**,

110 Table_1.XLSX. **2020**,

109 Table_2.XLSX. **2020**,

108 Table_3.XLSX. **2020**,

107 DataSheet_1.docx. **2019**,

106 Adipocyte-Derived Serum Amyloid A Promotes Angiotensin II-Induced Abdominal Aortic Aneurysms in Obese C57BL/6J Mice.. **2022**, ATVBAHA121317225 0

105 Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study.. **2022**, 19, e1003911 3

104 The Association between Nutritional Status and Length of Hospital Stay among Patients with Hypertension. **2022**, 19, 5827 3

103 Characterization of coronary atherosclerotic plaques and the significance of vessel calcification. 40-46

102 Elevated C-reactive protein among symptomatic youth with bipolar disorder.. **2022**, 36, 645-652 0

101 Cardiovascular Risk Assessment in Primary Prevention. **2022**, 3-19

100 High-Sensitivity C-Reactive Protein. **2022**, 347-375

99 Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus on Prevention. **2022**, 247-270 1

98 Reduction in Ferritin Levels Among Patients Consuming a Dark Green Leafy Vegetable Rich, Low Inflammatory Foods Everyday (LIFE) Diet. 1

97 High-sensitivity C-reactive protein and low-density lipoprotein cholesterol association with incident of cardiovascular events: Isfahan cohort study. **2022**, 22, 1

96 Associations between pericarotid fat density and image-based risk characteristics of carotid plaque. **2022**, 153, 110364 0

- 95 The relation between red blood cell distribution width and coronary atherosclerotic plaque vulnerability detected by intracoronary optical coherence tomography. **2022**, 20,
- 94 A SNP in the 5'flanking region of the SAA1 gene is associated with serum levels of serum amyloid A and cardiovascular risk factors. **2022**, 7,
- 93 Rethinking minority stress: A social safety perspective on the health effects of stigma in sexually-diverse and gender-diverse population. **2022**, 104720 4
- 92 Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer. 2
- 91 The usefulness of C-reactive protein to predict improving left ventricular function after aortic valve replacement in patients with aortic regurgitation. **2022**, 17, 100169
- 90 Blood oxidative stress biomarkers in women: influence of oral contraception, exercise, and N-acetylcysteine. **2022**, 122, 1949-1964
- 89 Magnesium Intake, C-Reactive Protein, and Muscle Mass in Adolescents. **2022**, 14, 2882 1
- 88 C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis. **2022**, 2
- 87 Comparison of Inflammatory Markers in the Diagnosis of Metabolic Syndrome in Hemodialysis Patients: A Multicenter Observational Study. Volume 15, 1995-2002
- 86 Psychiatric symptoms are not associated with circulating CRP concentrations after controlling for medical, social, and demographic factors. **2022**, 12,
- 85 Cardiovascular Risk Predictors High Sensitivity C-Reactive Protein and Plasminogen Activator Inhibitor-1 in Women with Lean Phenotype of Polycystic Ovarian Syndrome: A Prospective Case-Control Study.
- 84 The role of solar and geomagnetic activity in endothelial activation and inflammation in the NAS cohort. **2022**, 17, e0268700 0
- 83 Interleukin-8 and depressive responses to an inflammatory challenge: secondary analysis of a randomized controlled trial. **2022**, 12, 0
- 82 The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis. 9,
- 81 Lithium exposure and chronic inflammation with activated macrophages and monocytes associated with atherosclerosis in bipolar disorder. *Journal of Affective Disorders*, **2022**, 314, 233-240 6.6
- 80 Cardiovascular Disease in Myeloproliferative Neoplasms. **2022**, 4, 166-182 1
- 79 New markers in metabolic syndrome. **2022**, 0
- 78 Portable air cleaner use and biomarkers of inflammation: A systematic review and meta-analysis. **2022**, 18, 100182

- 77 Firefighters with higher cardiorespiratory fitness demonstrate lower markers of cardiovascular disease risk. Publish Ahead of Print, 1
- 76 Association of obstructive sleep apnea with endothelial function and heart remodeling in hypertension: A cross-sectional study. **2022**, 0
- 75 Gut immune cellsA novel therapeutical target for cardiovascular disease?. 9,
- 74 The Use of Human Biomonitoring to Assess Occupational Exposure to PAHs in Europe: A Comprehensive Review. **2022**, 10, 480
- 73 The relationship between dyslipidemia and inflammation among adults in east coast China: A cross-sectional study. 13, 1
- 72 ST-segment Yİselmeli Miyokart Enfarktİnde Kronik Total Oklİyonu İlgİmede Nİtrofil/Lenfosit ve Trombosit/Lenfosit Oranİ-277-283
- 71 Causal Association of Thyroid Signaling with C-Reactive Protein: A Bidirectional Mendelian Randomization. **2022**, 2022, 1-8
- 70 Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art review. 0
- 69 Depression: As a Risk Factor for Coronary Heart Disease. **2022**, 139-145
- 68 Cardiovascular Disease in Adults with Type 1 Diabetes: Looking Beyond Glycemic Control. 0
- 67 Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. **2022**, 70, 102863 2
- 66 GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis. **2022**, 12, 100373 2
- 65 Trauma, psychological distress and markers of systemic inflammation among US women: A longitudinal study. **2022**, 145, 105915 0
- 64 Biomarkers in metabolic syndrome. **2022**, 0
- 63 High inflammatory burden predicts cardiovascular events in patients with axial spondyloarthritis: a long-term follow-up study. **2022**, 14, 1759720X2211224 0
- 62 Effect of COVID-19 on food security, hunger, and food crisis. **2022**, 3-29 1
- 61 Examining the Potential Direct Cardiovascular Benefit of Tumor-Necrosis Factor Inhibitor in Rheumatoid Arthritis: Natural and Controlled Direct Effect Analyses. 0
- 60 Targeting autonomic nervous system as a biomarker of well-ageing in the prevention of stroke. 14, 0

59	WISER Survivor Trial: Combined Effect of Exercise and Weight Loss Interventions on Inflammation in Breast Cancer Survivors. Publish Ahead of Print,	2
58	Association between parity and markers of inflammation: The multi-ethnic study of atherosclerosis. 9,	0
57	Targeting innate immunity-driven inflammation in CKD and cardiovascular disease.	2
56	The Gut Microbiome and Obstructive Sleep Apnea Syndrome in Children. 2022 ,	0
55	Biomarkers associated with coronary high-risk plaques.	0
54	HIV-1 Spectrum Disease, Psychological Distress, and Cardiometabolic Risk. 2022 , 1415-1441	0
53	Classification of Cardiovascular Diseases: Epidemiology, Diagnosis, and Treatment. 2022 , 45-80	0
52	Cardiovascular Behavioral Medicine: Past, Present, and Future. 2022 , 3-22	0
51	The Effects of Rhythmic Yoga on Body Composition and Inflammatory Cytokine in Postpartum Depression Women. 2022 , 36, 227-243	0
50	Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis. 9,	0
49	Accelerated Atherosclerosis in SLE: Mechanisms, Consequences, and Future Directions.	0
48	The influence of inflammation on cardiovascular disease in women. 3,	1
47	Prognostic Impact of Statins on Patients With Peripheral Artery Disease With Elevated C-Reactive Protein Levels. 2022 ,	0
46	Role of Sex in Atherosclerosis: Does Sex Matter?.	1
45	Bioactive Yoghurt Containing Curcumin and Chlorogenic Acid Reduces Inflammation in Postmenopausal Women. 2022 , 14, 4619	0
44	Inflammation in heart failure: causal determinant or bystander?. 2022 , 23, 736-737	0
43	Ultrasensitive Detection of C-Reactive Protein by a Novel Nanoplasmonic Immunoturbidimetry Assay. 2022 , 12, 958	0
42	Level of Vascular Inflammation Is Higher in Acute Coronary Syndromes Compared with Chronic Coronary Disease.	0

- 41 Illnesses in Technologically Advanced Societies Due to Lack of Grounding (Earthing). **2022**, 0
- 40 Association between Serum Amyloid A Level and White Matter Hyperintensity Burden: a Cross-Sectional Analysis in Patients with Acute Ischemic Stroke. 0
- 39 The Role of Parenthood for Life Satisfaction of Older Women and Men in Europe. 0
- 38 Depression and cardiovascular diseases. **2022**, 0
- 37 Menopause, Hormone Therapy and Cardiovascular and Cerebrovascular Disease. **2008**, 37, 54-62 1
- 36 Peripheral high levels of CRP predict progression from normal cognition to dementia: A systematic review and meta-analysis. **2023**, 107, 54-63 0
- 35 The benefits of physical activity in middle-aged individuals for cardiovascular disease outcomes. **2023**, 168, 49-52 1
- 34 Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. ar-2022-223302 0
- 33 Persistent Asthma Is Associated With Carotid Plaque in MESA. **2022**, 11, 1
- 32 Sex disparities in left ventricular assist device implantation outcomes: A systematic review and meta-analysis of over 50 000 patients. 0
- 31 Recent research progress on metabolic syndrome and risk of Parkinson's disease. **2022**, 1
- 30 Tracking peripheral vascular function for six months in young adults following SARS-CoV -2 infection. **2022**, 10, 0
- 29 Unchanged pulmonary toxicity of ZnO nanoparticles formulated in a liquid matrix for glass coating. 1-16 0
- 28 Acute phase response following pulmonary exposure to soluble and insoluble metal oxide nanomaterials in mice. **2023**, 20, 0
- 27 The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes. 0
- 26 A cohort study of wastewater treatment plant workers: association between levels of biomarkers of systemic inflammation and exposure to bacteria and fungi, and endotoxin as measured using two methods. **2023**, 119625 0
- 25 Acute Ischemic Stroke in the Patients with Inflammatory Arthritis: An Analysis of Data from National Health Insurance Service. **2022**, 23, 96-114 0
- 24 What may be the best menopausal hormone treatment?. 0

23	A Hidden Organism, Chlamydia in the Age of Atherosclerosis.	o
22	Associations among cardiorespiratory fitness, C-reactive protein, and all-cause mortality in men and women. 108155892211491	o
21	Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives. 2023 , 24, 2079	o
20	Cardiovascular Disease Causes Proinflammatory Microvascular Changes in the Human Right Atrium.	o
19	Humoral Innate Immunity and Acute-Phase Proteins. 2023 , 388, 439-452	1
18	ANGPTL4 stabilizes atherosclerotic plaques and modulates the phenotypic transition of vascular smooth muscle cells through KLF4 downregulation. 2023 , 55, 426-442	o
17	Implementation of risk enhancers in ASCVD risk estimation and hypolipidemic treatment eligibility: a sex-specific analysis. 2023 ,	1
16	Cardiovascular disease and bone health in aging female rheumatic disease populations: A review. 2023 , 19, 174550572311552	o
15	Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. 2023 , 401, 1293-1301	1
14	Baseline inflammatory status affects the prognostic impact of statins in patients with peripheral arterial disease.	o
13	Prognostic impact of white blood cell counts on clinical outcomes in patients with chronic renal insufficiency undergoing percutaneous coronary intervention. 10,	o
12	Inflammation in Chronic Periodontitis and Significant Systemic Diseases. 2010 , 38, 247-257	o
11	Coronary artery restenosis and target lesion revascularisation in women by pregnancy history. 2023 , 10, e002130	o
10	A review of research on the intersection between breast cancer and cardiovascular research in the Women's Health Initiative (WHI). 12,	o
9	Comparative safety of gout treatment strategies on cardiovascular outcomes using observational data: Clone-censor-weight target trial emulation approach.. Publish Ahead of Print,	o
8	Association of mercury exposure with the serum high-sensitivity C-reactive protein level in Korean adults. 11,	o
7	Awareness and Knowledge of Pneumococcal Vaccination in Cardiology Outpatient Clinics and the Impact of Physicians' Recommendations on Vaccination Rates. 2023 , 11, 772	o
6	Contribution of serum lipids and cholesterol cellular metabolism in lung cancer development and progression. 2023 , 13,	o

- 5 POLLUTION FROM FINE PARTICULATE MATTER AND ATHEROSCLEROSIS: A NARRATIVE REVIEW.
2023, 107923 ○
- 4 C-reactive protein and high-sensitivity C-reactive protein levels in asymptomatic intestinal parasite carriers from urban and rural areas of Gabon. ○
- 3 Network analysis of the associations between personality traits, cognitive functioning, and inflammatory markers in elderly individuals without dementia. 15, ○
- 2 The bidirectional association between atrial fibrillation and myocardial infarction. ○
- 1 Coronary Revascularization in Patients With Cancer. ○